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1.  The (malfunctioning) immune system 
 
Throughout evolution, humans have been colonized and infected by microorganisms. To safe-
guard ourselves, we have evolved a series of defense mechanisms which are collectively referred 
to as the immune system. The immune system is equipped to recognize and eliminate pathogens, 
such as bacteria and viruses, through an intruiging arsenal of effector mechanisms. Central to the 
success of the immune system is the capability of mounting strong responses to foreign 
(pathogen-derived) molecules while maintaining tolerance toward the molecules of our own 
body. In other words, our immune system is trained to recognize and respond to non-self 
structures but not to self structures. Autoimmunity implicates that the immune system fails to 
discriminate between non-self and self and consequently starts to attack the cells and tissues of 
our own body (Figure 1). Many different types of  autoimmune diseases  have been identified  and 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Regular immune responses versus autoimmune responses. A prototype ‘normal’ immune re-
sponse starts with (1) the recognition and uptake of a foreign non-self structure by phagocytic cells, 
such as dendritic cells, which are present in the soft tissue. Dendritic cells then (2) migrate to secondary 
lymphoid organs, such as the lymph nodes, where they present the non-self structure to T cells. Finally, 
T cells (3) activate B cells to produce antibodies directed against the non-self structure. During an 
autoimmune response, the same pathway is traversed (4-6) but this time the immune system responds 
to self structures via autoreactive T and B cells, which leads to the production of autoantibodies. 
 
 
 
 
these diseases are not uncommon: an estimated 5% of the population of developed countries has 
one or more of these conditions (1). Both genetic and environmental factors (such as trauma, 
infection, chemicals, irradiation or certain foods) are implicated in predisposing people to auto-
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immune disease, but the pathogenic events that result in autoimmunity are in general poorly 
defined for most conditions (2). Well-known examples of autoimmune diseases include rheuma-
toid arthritis, multiple sclerosis, psoriasis and type 1 diabetes.  
 
2.  Systemic lupus erythematosus 
 
Systemic lupus erythematosus (SLE) is a typical systemic autoimmune disease in which auto-
antibodies can lead to inflammation and damage in multiple organs and tissues. In Europe, 
approximately 1 in every 2500 individuals is diagnosed with SLE (3). Like many autoimmune 
diseases, SLE affects females more frequently than males, at a ratio of about 9 to 1. Symptoms in 
SLE can greatly vary between individuals and may be mild to severe. The most common symptoms 
include painful and swollen joints, fever, hair loss, mouth ulcers, fatigue, chest pain, swollen lymph 
nodes and skin rashes (Figure 2) (4). Most typical for SLE is a butterfly-shaped skin rash (erythema) 
that can occur on the face and gives the face an appearance like a wolf’s head (lupus is Latin for 
wolf). The disease commonly follows a course in which outbreaks of intense inflammation (flares) 
alternate with periods of relative calm. Many patients with SLE eventually die of the disease 
because of overwhelming infections or failure of vital organs, such as the kidneys. Inflammation 
of the kidneys (referred to as lupus nephritis) occurs in up to 60% of the patients and is perceived 
as one of the most serious clinical manifestations of the disease (5).  
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Prevalent symptoms of SLE. SLE can cause a butterfly-shaped erythema in the face (image 1), 
result in hair loss (alopecia; image 2), or cause swelling and redness of joints (arthritis; image 3). 
 
 
 
 
 
 
3.  Apoptotic cell death and lupus 
 
 
After decades of intensive research, the pathogenic events that lead to the development of SLE 
still remain poorly understood. Autoantibodies present in SLE patients mainly target autoantigens 
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that are originally present within cell nuclei, such as DNA and histones (6). As these autoantigens 
are normally shielded from the extracellular space by the nuclear membrane and the plasma 
membrane, research has predominantly focused on the processes by which these autoantigens 
are released and exposed to the immune system and thereby evoke an autoimmune response. 
Aberrant apoptosis and an insufficient removal of apoptotic material are considered responsible 
for the presence of nuclear autoantigens in the extracellular space which drives the autoimmune 
response in SLE (7-9). 
 
 
3.1.  Apoptosis in tissue homeostasis 
 
Apoptosis is a physiological mechanism of programmed cell death that leads to the removal of 
cells from our body without exposing their dying contents to the immune system (10). In every 
individual, billions of cells die through apoptosis on a daily basis. In processes characterized by a 
high-rate of tissue turnover, such as embryogenesis in human development, apoptosis is a crucial 
mechanism that allows tissues to remodel without triggering inflammation. Many cellular path-
ways and signals can activate processes that break down the cell in a strictly controlled and fine-
tuned manner, which distinguishes apoptosis from any other form of cell death. During apoptosis, 
constituents of the apoptotic cell are degraded and modified to facilitate a series of distinct 
morphological changes, including cell shrinkage, DNA fragmentation and plasma membrane 
blebbing (11, 12). Apoptotic cells express ‘eat me’ signals on their surface, i.e. proteins or sugars 
that ‘mark’ the cell as being dead, thereby facilitating their rapid removal by phagocytic cells of 
the immune system, such as dendritic cells (13). The clearance of apoptotic cells usually occurs in 
an immunologically silent and anti-inflammatory manner (Figure 3) (14). 
 
 
 
3.2.  Disturbed apoptosis in the pathogenesis of SLE 
 
There is evidence that apoptosis is more abundant in SLE patients as lymphocytes, neutrophils, 
macrophages and monocytes from SLE patients have all been shown to be more susceptible to go 
into apoptosis (15-18). Additionally, the clearance of apoptotic material by phagocytic cells 
appears to be disturbed (7). Together, the increased rate of apoptosis and the decreased removal 
of apoptotic cells results in an excessive load of apoptotic material in the extracellular space, partly 
present within the circulation. As time progresses, these apoptotic cells are no longer able to 
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maintain the integrity of their plasma membranes and thereby start to fully disintegrate in a 
process known as secondary necrosis (19). Secondary necrosis is characterized by the formation 
of apoptotic blebs (often referred to as apoptotic microparticles, i.e. small vesicles ≤ 1 µm in size) 
and the leakage of apoptotic cell-derived constituents into the extacellular space (20). These 
leaked constituents have been degraded and/or highly modified during apoptosis, and due to 
these modifications the immune system may perceive them no longer as self and even as ‘danger 
signals’. The recognition of modified apoptotic cell-derived constituents by immune cells may 
therefore evoke an autoimmune response characterized by the generation of autoantibodies. 
Such autoantibodies can bind their targets and form immune complexes, which deposit in blood 
vessels, joints and kidneys, and thereby initiate inflammatory tissue destruction (21). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Apoptosis and apoptotic cell clearance in healthy individuals and SLE patients. Viable cells die 
through apoptosis on a daily basis. In healthy individuals, apoptotic cells are recognized and ingested by 
phagocytic cells, such as dendritic cells, in an immunological silent manner. In patients with SLE, there 
is an increased rate of apoptosis and an insufficient clearance of apoptotic cells by phagocytic cells. As 
a result, apoptotic cells may go into secondary necrosis, thereby shedding apoptotic blebs and leaking 
modified constituents into the extracellular space, which may evoke an autoimmune response. 
 
 
 
4. The role of neutrophils in lupus 
 
Neutrophils are important effector cells of the innate immune system. Neutrophils represent the 
most abundant leukocyte population in the blood and about 60% of the hematopoetic activity of 
the bone marrow is devoted to the production of neutrophils (22). Neutrophils are short-lived and 
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circulate in the blood awaiting a call from an infected or inflamed tissue. Neutrophils are excluded 
from healthy tissue, but the release of inflammatory mediators in inflamed tissues attracts neutro-
phils to leave the blood and enter the inflamed/injured area.  
 
4.1. Antimicrobial defense: phagocytosis versus NETosis 
 
Once arrived at the site of inflammation, neutrophils execute their arsenal of effector mechanisms 
to eradicate the intruding pathogens. The main effector mechanism through which neutrophils 
kill pathogens is phagocytosis (23). In addition to phagocytosis, neutrophils can kill pathogens 
through the formation of so-called neutrophil extracellular traps (NETs) (24). NETs are web-like 
structures consisting of the neutrophil’s nuclear contents (i.e. its chromatin) and its antimicrobial 
enzymes (25). NETs are released extracellularly upon challenge with (specific) pathogens or (their) 
inflammatory components (Figure 4). The release of NETs occurs during a unique cell death 
pathway  termed NETosis, which  is fundamentally  different  from the  aformentioned  process of  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Neutrophils release NETs. NETs consist of a backbone of modified chromatin (DNA and his-
tones) which is decorated with granule-derived antimicrobial enzymes, such as myeloperoxidase (MPO), 
neutrophil elastase and cathepsin G.  
 
 
 
 
 
 
apoptosis (26). The sticky chromatin fibers of NETs are able to bind pathogens, thereby preventing 
them from further spreading across the body. Moreover, the locally high concentrations of anti-
microbial enzymes that cluster along the chromatin fibers of NETs have the capacity to directly 
damage or fully degrade the pathogen that has been captured. 
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4.2. Neutrophil extracellular traps in the pathogenesis of SLE 
 
Although NETosis is an important strategy of neutrophils to combat pathogens, there is growing 
evidence that this innate immune strategy can also be deleterious to the host (27). As their 
backbone is made of (modified) chromatin, NETs are thought to be able to drive or aggravate the 
autoimmune response in diseases where chromatin components are being targeted, as occurs in 
SLE (28-30). Thus, NETs may be an additional source of autoantigens in SLE next to the previously 
described disturbances in apoptosis (30-32). In addition to providing autoantigens, NETs may also 
be involved in the development of tissue damage as the antimicrobial enzymes within NETs are 
not only toxic to pathogens but also cause injury to host cells (33-35). Thus, if the balance between 
the formation and degradation of NETs is shifted, either due to an excessive formation of NETs or 
due to their impaired degradation, NETs may become rather harmful than beneficial to the host.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.3. Molecular mechanisms of NETosis 
 
The observation that neutrophils are able to release NETs was first described in 2004 (24). In the 
following years, significant advances have been made in the understanding of the molecular 
mechanisms that facilitate NETosis. When neutrophils go into NETosis, (i) the nuclear and granular 
membranes disintegrate, (ii) the chromatin decondenses and mixes with granule-derived 
antimicrobial enzymes in the cytosol, and finally (iii) the plasma membrane ruptures to facilitate 
the release of the decondensed chromatin decorated with antimicrobial enzymes (Figure 5) (36).  
 
Upon ligand binding to neutrophil receptors, calcium stores of the endoplasmic reticulum release 
calcium into the cytosol to increase protein kinase C (PKC) activity. PCK activity leads to assembly 
of the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase complex at cytoplasmic or 
phagosomal membranes; once assembled, NADPH oxidases produce vast amounts of reactive 
oxygen species (ROS) which subsequently (i) cause the granular and nuclear envelope to rupture, 
(ii) activate protein arginine deiminase 4 (PAD4) to deiminate histones and promote chromatin 
decondensation, and finally (iii) phosphorylate mixed lineage kinase domain-like (MLKL) pores to 
facilitate plasma membrane rupture (37). As this pathway results in the death of the neutrophil, 
it is generally referred to as ‘suicidal’ NETosis (38). In addition to ‘suicidal’ NETosis, an alternative 
pathway through which neutrophils release NETs has been described. Although the molecular 
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events leading to this alternative form of NETosis have not been clarified yet, this pathway does 
not depend on ROS formation and neither results in overt neutrophil cell death. Consequently, 
this pathway of NET release is termed ‘vital’ NETosis (39), which is a contradictio in terminis since 
the “osis” of NETosis implies death and “vital” implies alive. 
 
 
 
 
Figure 5. Schematic representation of the molecular pathway of NETosis. Upon stimulation of neutro-
phils, calcium levels rise and activate protein kinase C (PKC) (stage 1). PKC activity leads to the formation 
of reactive oxygen species (ROS) which disintegrate the nuclear and granular membranes and cause 
chromatin decondensation as the result of histone deimination by protein arginine deiminase 4 (PAD4) 
(stage 2). Finally, mixed lineage kinase domain-like (MLKL) pores are formed at the plasma membrane 
under the influence of ROS, which causes lysis of the neutrophil and the expulsion of its NET (stage 3). 
 
 
 
 
 
 
 
 
 
 
5. Outline and scope of this thesis 
 
The scope of this thesis is two-fold. Although NETs are pivotal structures that protect the host 
against intruding pathogens, they can also be involved in the pathogenesis of autoimmune 
diseases. In order to be able to understand the pathological role of NETs in disease, a more 
thorough understanding of the factors that drive NET release is required. The first part of this 
thesis focuses on factors that determine whether neutrophils go into NETosis. As outlined, NETs 
need to be rapidly degraded and removed in order to limit collateral tissue damage and to avoid 
the presentation of NET-associated autoantigens to the immune system. A disbalance between 
the release of NETs and its subsequent removal may therefore play an important role in the 
development of SLE or the aggravation of already existing SLE. In the second part of this thesis, 
the pathogenic role of NETosis in the autoimmune response and in the development of renal 
inflammation in SLE patients was studied in detail. 
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5.1. Factors that drive NETosis 
 
Upon encountering a pathogen, the neutrophil either internalizes the pathogen (i.e. phagocytosis) 
or kills it extracellularly through the release of NETs. It is unclear how the neutrophil tailors its 
antimicrobial strategy to a certain pathogen. In other words, what drives the decision to inter-
nalize the pathogen through phagocytosis or kill it through NETosis? By studying NETosis in the 
context of hyperuricemia (chapter 2) and Gram-negative infection (chapter 3), factors that drive 
the neutrophil to go into NETosis were evaluated.  
 
 
5.2. NETosis in the pathogenesis of SLE 
 
In chapter 4, the available literature on the role of apoptosis and NETosis in the pathogenesis of 
SLE is reviewed. This review specifically focused on apoptosis-associated histone modifications 
that have been linked to the autoimmune response in SLE. Although NETosis and apoptosis are 
two self-contained entities in the pathogenesis of SLE, a possible connection between both cell 
death pathways was investigated in chapters 5 and 6. 
 
 
 
5.3. The role of NETosis in lupus nephritis 
 
During the filtration of blood by our kidneys, small and soluble waste products are passing the 
glomerular filtration barrier and end up in the urine. Cells or large proteins are hereby retained 
within the blood as they do not pass this barrier. Since large NET-derived protein complexes are 
circulating in the blood of SLE patients, it can be hypothesized that circulating NETs may ultimately 
deposit in the glomerular capillaries, thereby causing renal inflammation. The effects of NETs on 
glomerular endothelial cells in SLE were studied in chapter 7. 
 
 
5.4. NETs as a source of modified histones 
 
It has long been acknowledged that histones become modified during the process of apoptosis 
(40-42), which may play an important role in the actual break of immunological tolerance toward 
chromatin. In chapter 8, it was investigated whether histones are also modified during the process 
of NETosis. Chapter 9 evaluated whether modified histones within NETs can be used as a marker 
to distinguish between NETs that have been generated through ‘vital’ or ‘suicidal’ NETosis.  
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5.5. Summary and future perspectives 
 
In chapters 10 and 11, a summary of all findings is provided and put into a future perspective for 
research as well as for the management of SLE. 
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1. Abstract 
 
Hyperuricemia is strongly linked to cardiovascular complications including atherosclerosis and 
thrombosis. In individuals with hyperuricemia, needle-shaped monosodium urate crystals 
(nsMSU) frequently form within joints or urine, giving rise to gouty arthritis or renal calculi, 
respectively. These nsMSU are potent instigators of neutrophil extracellular trap (NET) formation. 
Little is known on the mechanism(s) that prevent nsMSU formation within hyperuricemic blood, 
which would potentially have detrimental consequences for the host. Here, we report that 
complement proteins and fetuins facilitate the continuous clearance by blood-borne phagocytes 
and resident macrophages of small urate microaggregates (UMA; < 1 µm in size) that initially form 
in hyperuricemic blood. If this clearance fails, UMA exhibit bipolar growth to form typical full-sized 
nsMSU with a size up to 100 µm. In contrast to UMA, nsMSU stimulated neutrophils to release 
NETs. Under conditions of flow, nsMSU and NETs formed densely packed DNase I-resistant tophus-
like structures with a high obstructive potential, highlighting the importance of an adequate and 
rapid removal of UMA from the circulation. Under pathological conditions, intravascularly formed 
nsMSU may hold the key to the incompletely understood association between (NET-driven) 
cardiovascular disease and hyperuricemia. 
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2. Introduction 
 
Hyperuricemia (uric acid blood levels ≥ 6 (women) or 6.8 (men) mg/dL) is the major risk factor for 
the development of gout (1, 2). When the concentration of uric acid exceeds its solubility limit, 
monosodium urate crystals (cMSU) may form. Such cMSU initially appear as round-shaped 
bifringent urate microaggregates (UMA; ≤ 1 µm in size), which can subsequently grow in a bipolar 
manner to form needle-shaped monosodium urate crystals (nsMSU; up to 100 µm in size) (3). In 
gout, arthritis occurs due to the deposition of nsMSU in the peripheral joints. These nsMSU may 
also develop within the urine, giving rise to renal calculi. The inflammatory response towards 
nsMSU is in part characterized by neutrophils that undergo oxidative burst and release their 
chromatin as neutrophil extracellular traps (NETs) during a process known as NETosis (4-7). NETs 
are found in the synovial fluids and tissue of patients with gout, especially in those with gouty 
flares or granuloma formation (4, 8). At high neutrophil densities, NETs and nsMSU can form 
densely packed aggregates, that appear as tophus-like structures (9, 10).  
 
 
 
 
In contrast to the synovial fluids or urine of hyperuricemic patients, the presence of nsMSU has 
never been described in blood. The presence of nsMSU in blood could have detrimental 
consequences for the host, since the intravascular formation of nsMSU and the consecutive 
induction of NETosis bear the risk of life-threatening atherosclerosis, increased vascular 
permeability, and thrombosis (11-13).  
 
 
 
 
In the present study, we investigated the crystallization of uric acid in hyperuricemic blood. We 
elucidated a novel mechanism by which blood-borne phagocytes remove small UMA initially 
formed in hyperuricemic blood before these can actually develop into NET-inducing nsMSU. If this 
mechanism fails, nsMSU and NETs form DNase I-resistant tophus-like aggregates with a high 
obstructive potential. 
 
 
 
 
 
 
3. Materials and Methods 
 
Patient material. Serum and heparinized whole blood was collected from eight hyperuricemic 
patients and normouricemic controls and uric acid concentrations were determined by routine 
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laboratory methods. All patient samples analyzed were anonymously donated to our research 
faculty and exceeded a uric acid concentration of 12 mg/dL. Some samples were found to be 
hypersaturated with uric acid up to 21 mg/dL, fairly above the solubility limit of approximately 7 
mg/dL. Serum and whole blood was incubated at 4°C and 37°C and analyzed for the formation of 
crystalline structures employing polarized light video microscopy. Healthy donors served as 
controls. For some experiments, serum was collected from complement deficient patients (C4A, 
C4B, C4, C2 or C1q). Informed consent for blood donation was obtained from all subjects for all 
methods. All experiments with human material were performed in accordance with institutional 
guidelines and were approved by the Ethical committee of the University Hospital Erlangen. 
 
Animals. Balb/c mice were bred at the Danylo Halytsky Lviv National Medical University, Lviv, 
Ukraine, during Jan – August 2014 and kept on a standard diet with drinking water available ad 
libitum. All animal studies were performed in accordance with the guidelines determined by the 
Law of Ministry of Healthcare of Ukraine, No. 281 from 01.11.2011 for the care and use of labo-
ratory animals and approved by the Ethics Council of the Danylo Halytsky Lviv National Medical 
University, protocol 1/6, dated June 24, 2013. 
 
 
Clearance of UMA in vivo. 1 mg UMA or nsMSU were intravenously injected in 250 µl PBS into 
Balb/c mice. Cryosections of heart, kidneys, lungs, spleen and liver were prepared without any 
fixation 24 hours after the injection and analyzed by polarization microscopy. Since animals 
immediately died after injection of nsMSU, we only used UMA for our analyses for ethical reasons. 
 
 
Isolation of neutrophils. Neutrophils were isolated from heparinized (20 U/mL) blood by density 
gradient centrifugation using Lymphoprep (Stemcell Technologies). Briefly, whole blood was 
diluted 1:1 in PBS to a volume of 30 mL and slowly layered on top of 15 mL Lymphoprep. The blood 
was then centrifuged at 800g for 20 minutes and neutrophils were collected from the high density 
fraction. Residual erythrocytes were eliminated by repetitive hypotonic lysis. Viable neutrophils 
were counted by trypan blue exclusion in a Neubauer cell counting chamber.  
 
 
Phagocytosis assays. For ex vivo phagocytosis experiments, anticoagulated fresh whole blood was 
incubated at 37°C with UMA. Erythrocytes were subsequently removed by hypotonic lysis. 
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Leukocytes were stained with anti-CD16 (cat. no. B-E16-FITC, Abcam) and anti-CD14 (cat. no. 
61D3-PE, eBioscience) and analyzed by flow cytometry. For in vitro phagocytosis experiments, 
purified neutrophils (2 x 106 cells/ml) were stimulated with 50 pg of UMA per cell in the presence 
of 10% autologous serum. Serum had been pre-treated as indicated. The phagocytic indices (PhIx) 
for UMA were calculated by multiplying the percentage of cells with increased side scatter with 
the mean side scatter value. Where indicated, phagocytosis was confirmed by exposing 
neutrophils to UMA in the presence of 100 nM pHrodo Red SE (Life Technologies) and 
subsequently analyzing cell-borne fluorescence by flow cytometry. Flow cytometry and data 
analyses were performed employing the Gallios cytofluorometer and Kaluza software, respec-
tively (Beckman Coulter). 
 
 
Neutrophil-macrophage co-cultures. Monocytes from healthy donors were isolated from 
peripheral blood mononuclear cells (PBMC) by plastic adherence for 2 hours in serum-free media. 
They (1 x 106 cells/ml) were cultured for 7 days in RPMI1640 (Gibco) supplemented with 10% FCS 
and 25 ng/ml GM-CSF (Peprotech) to obtain monocyte-derived macrophages (MDMs). For 
neutrophil-macrophage co-culture experiments, purified neutrophils were stimulated with 50 pg 
of UMA per cell for 30 minutes and subsequently co-incubated with MDMs for 4 hours at a 
neutrophil:macrophage ratio of 4:1. At the indicated time points, neutrophils were harvested and 
analyzed by flow cytometry. Internalization of UMA-containing neutrophils (labeled with PKH26, 
Sigma-Aldrich) by MDMs was confirmed by immunofluorescence microscopy. Macrophages were 
visualized by staining the actin cytoskeleton using phalloidin-FITC (Sigma-Aldrich). Where 
indicated, neutrophils were pre-labeled with 30 nM pHrodo Red SE (for 30 min, followed by 
washing twice) prior to their use in co-culture experiments with macrophages. To check the status 
of neutrophils after UMA exposure, we stained neutrophils for phosphatidylserine (Annexin V-
FITC, cat. no. K101-100, Biovision; according to the manufacturer’s instructions), CD11a (cat. no. 
559875, BD Biosciences), CD18 (cat. no. 555923, BD Biosciences) and CD31 (cat. no. MHCD3101, 
ThermoFisher) and analyzed the expression of these surface molecules by flow cytometry after 2 
and 4 hours exposure to UMA.  
 
 
 
NETosis assays. Purified neutrophils were stimulated with 50 pg of crystals per cell (either UMA 
or nsMSU) for up to 4 hours, either under static conditions or under conditions of flow. For the 
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latter, cells were either treated with crystals on a rocking table or within a pump system yielding 
a laminar flow rate of 20 ml/min (Ibidi). NETosis was assessed by quantifying DNA release with 
fluorometry or by immunofluorescence microscopy. For both techniques, DNA was stained with 
100 nM Sytox Orange. The activity of NET-associated neutrophil elastase (NE) and myelo-
peroxidase (MPO) was determined by colorimetry, using 100 µM N-methoxysuccinyl-Ala-Ala-Pro-
Val 4-nitroanilide (Sigma-Aldrich) or 1 mM 3,3,5,5-tetra-methylbenzidine (eBioscience) as sub-
strates for NE and MPO, respectively. For the measurement of ROS, neutrophils were stimulated 
in the presence of 40 µM 2’,7’-dichlorofluorescin diacetate (Sigma-Aldrich). 
 
 
 
 
Endothelial cell culture and real-time PCR. Confluent monolayers of human umbilicial vein 
endothelial cells (HUVEC) were treated under flow with UMA or nsMSU, either in the presence or 
absence of purified leukocytes (i.e. erythrocyte-depleted whole blood). The viability and activation 
status of endothelial cells were analyzed by trypan blue exclusion assays, immunofluorescence 
microscopy or qRT-PCR. For immunofluorescence microscopy, HUVEC were stained for von 
Willebrand factor (Dako, A0082), NFKB p65 (Santa Cruz, sc-8008) and VE-cadherin (Santa Cruz, sc-
6458). For qRT-PCR analyses, RNA was isolated from HUVEC with TRIzol© reagent (Ambion) and 
qRT-PCR analyses were performed on tumor necrosis factor alpha (TNF-α; forward 5’-
CCCAGGCAGTCAGATCATCTTC-3’ and reverse 5’-GGCAGAGGTAGGTCTGGTTC-3’), interleukin 6 (IL-
6; forward 5’-AGCCACTCACCTCTTCAGAAC-3’ and reverse 5’-CGGGACTCTTTCCTCTGTACA-3’) and 
transforming growth factor beta (TGF-β; forward 5’-GGATGGTGGAAGGTCTCATTTTA-3’ and 
reverse 5’-CGACTATGGTAGGGTTATCGACA-3’). GAPDH (forward 5’-GAAGGTGAAGGTCGGAGT-3’ 
and reverse 5’-CTTTAGGGTAGTGGTAGA-3’) was used as housekeeping gene.  
 
 
 
 
Production of nsMSU and UMA. A solution of 10 mM uric acid and 154 mM NaCl (pH 7.2) was 
agitated for 3 days to form nsMSU. The resultant crystals were washed with ethanol and sterilized 
at 180°C for 2 hours prior to storage in PBS. For experiments with UMA, we extensively grinded 
nsMSU under sterile conditions using Precellys ceramic (1.4 mm) beads.  
 
 
 
Statistical analyses. Results are represented as mean ± SEM of at least three experiments. 
Significance was either determined by Student’s t-test or one-way ANOVA followed by Bonferroni 
correction using GraphPad Prism. P-values ≤ 0.05 were considered as statistically significant. 
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4. Results 
 
 
 
Uric acid crystallizes in hyperuricemic serum and whole blood ex vivo. To assess whether high 
uric acid levels can promote crystal formation in serum or whole blood, we analyzed samples from 
eight hyperuricemic patients and normouricemic healthy donors ex vivo. Uric acid levels in 
hyperuricemic patients were above 12 mg/dL, thereby exceeding the theoretical threshold of 
solubility for uric acid. Serum and whole blood was incubated at 4°C or 37°C and analyzed for 
crystalline structures at set time points using polarized light microscopy. After 6 hours of 
incubation, round-shaped UMA were observed in the sera of hyperuricemic patients (Figure 1a) 
but not in those from healthy donors (not shown). Prolonged incubation (up to 24 hours) did not 
further increase UMA formation in hyperuricemic serum (Figure 1b). Furthermore, healthy donor 
sera remained negative for UMA after ex vivo incubation up to 72 hours (not shown). In whole 
blood smears, we also detected UMA after 6 hours of incubation ex vivo. However, UMA were 
exclusively present within blood-borne phagocytes (Figure 1c). Based on these observations, we 
hypothesized that blood-borne phagocytes clear UMA from hyperuricemic blood, thereby 
preventing the intravascular formation of nsMSU and the consecutive induction of NETosis. 
 
 
 
 
 
 
Blood-borne phagocytes rapidly internalize UMA. To determine whether blood-borne phago-
cytes internalize UMA, we incubated healthy donor whole blood with in vitro generated UMA and 
evaluated their uptake by blood-borne phagocytes by flow cytometry and polarized light micro-
scopy. In response to UMA, CD14+ monocytes dose-dependently displayed an increased side 
scatter when compared to untreated cells (Figure 2a). A similar result was observed for CD16+ 
neutrophils. To confirm that the increased side scatter represented UMA internalization, we 
exposed neutrophils to UMA in the presence of pHrodo, which is a dye that becomes co-ingested 
during phagocytosis and becomes fluorescent in the acidic milieu of the phagosome. Indeed, 
neutrophils with an increased side scatter were positive for pHrodo, in contrast to neutrophils 
with a normal side scatter, thereby confirming uptake of UMA (Suppl. Figures 1a and 1b). 
Importantly, the phagocytic index (PhIx) of cells exposed to UMA, as calculated by multiplying the 
percentage of cells with increased side scatter with the mean side scatter value, directly correlated 
to the mean fluorescence intensity of pHrodo (Suppl. Figure 1c). Finally, the uptake of UMA by 
neutrophils was recorded using polarized light video microscopy (Figure 2b; Movie S1). 
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Figure 1. Uric acid crystallizes in hyperuricemic serum and whole blood ex vivo. (A) Small, round-shaped 
urate microaggregates (UMA) developed after in vitro incubation of hyperuricemic serum. Repre-
sentative images are shown. (B) Crystallization of uric acid preferentially occurred at colder tem-
peratures and was saturated after 6 hours of incubation of hyperuricemic serum. The amount of UMA 
was scored by polarized light microscopy whereby the number of UMA per field of view (FOV; 200x 
magnification) was scored. (C) Incubation of hyperuricemic whole blood for 6 hours ex vivo showed 
intracellular presence of UMA within blood-borne phagocytes (white arrows) in blood smears. Red 
arrows represent erythrocytes. Representative images are shown from two hyperuricemic gout 
patients. Scale bars: 20 µm (inserts: 5 µm). 
 
 
 
 
 
 
 
 
Complement proteins and fetuins facilitate phagocytosis of UMA. It has been previously reported 
that complement can be activated by nsMSU, which results in opsonization (14-17). To assess a 
possible role for complement proteins in the phagocytosis of UMA, we stimulated purified 
neutrophils with UMA in the presence of (I) 10% active autologous serum, (II) 10% heat-inactivated 
serum, (III) 10% autologous Ca2+ depleted serum by EDTA (500 µM) or 10% autologous serum 
supplemented with either (IV) heat-aggregated IgG (1 mg/mL) or (V) cobra venom factor (20 
U/ml). The two latter treatments (IV, V) cause complement consumption and depletion. Thus, only 
the fresh autologous serum (I) contained active complement and supported the uptake of UMA 
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into purified neutrophils (Figure 2c, Suppl. Figure 1d). Heat-aggregated IgG and EDTA are broad-
spectrum inhibitors of the complement system, whereas cobra venom factor specifically inhibits 
the alternative pathway due to C3 consumption. To more specifically investigate the role of the 
classical complement pathway in UMA phagocytosis, we performed these assays in 10% serum 
derived from patients deficient in complement factors C4A, C4B, C4, C2 and C1q. All complement-
deficient patients showed an impaired/abrogated uptake of UMA (Figure 2d).  
 
 
 
Figure 2. Blood-borne phagocytes rapidly internalize UMA. (A) Whole blood was incubated with 100 or 
200 µg/ml UMA. Then their uptake by CD14+ monocytes (‘mono’) or CD16+ neutrophils (‘PMN’) was 
assessed by flow cytometry. (B) Purified neutrophils contained UMA as soon as 15 min after incubation. 
(C) Purified neutrophils ingested significantly more UMA in the presence of serum containing active 
complement, whereas heat inactivation (H.I; 30 min, 56°C) of serum or treatment of active serum with 
cobra venom factor (CVF; 20U/ml), EDTA (500 µM) and heat-aggregated IgG (1 mg/ml) prevented UMA 
ingestion. (D) Uptake of UMA by purified neutrophils was impaired in the presence of complement 
deficient sera, when compared to sera from normal healthy donors. (E) Spiking active serum with fetuin 
(Fet; 1 mg/ml) or its enzymatically desialyated form asialofetuin (A-Fet; 1 mg/ml) boosts the 
phagocytosis of UMA by neutrophils. Scale bars: 20 µm (inserts: 10 µm). *** p < 0.001, ** p < 0.01, * p 
< 0.05, when compared to control where not indicated. The phagocytic indices (PhIx) were calculated 
by multiplying the percentage of cells with increased side scatter by the mean side scatter value. 
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Fetuins are carrier proteins that bind and solubilize crystal germs from calcium phosphate (18). 
Therefore, we tested whether fetuins also facilitated the phagocytosis of UMA. We observed an 
increase of 40% in the phagocytosis of UMA by neutrophils when 10% active autologous serum 
was supplemented with 1 mg/mL fetuin or with its desialyated form asialofetuin (Figure 2e). 
Interestingly, employing 10% heat-inactivated autologous serum, neither asialofetuin nor fetuin 
facilitated the phagocytosis of UMA by neutrophils. Taken together, our data reveal a cooperative 
mechanism between fetuins and complement in facilitating UMA phagocytosis by neutrophils. 
 
 
 
 
 
Macrophages recognize and clear UMA-loaded phagocytes. Macrophages and neutrophils share 
cooperative effector activities, of which one modality comprises the ability of macrophages to 
internalize neutrophils that express “eat-me” signals (19). We hypothesized that the ingestion of 
UMA by blood-borne phagocytes results in the clearance of these cells by splenic and/or hepatic 
macrophages. To test this, we incubated purified neutrophils with UMA and performed co-culture 
experiments with monocyte-derived macrophages. After 4 hours of co-culture with macrophages, 
the amount of UMA-loaded neutrophils was significantly reduced, whereas naive neutrophil 
counts remained stable (Figure 3a). Notably, in particular the percentage of neutrophils with an 
increased side scatter decreased in these co-cultures (Figures 3b). In line with this, we confirmed 
by immunofluorescence microscopy that neutrophils were observed within or attached to 
macrophages when these neutrophils had been loaded with UMA (Figure 3c).  
 
 
 
 
 
 
 
 
 
 
 
 
 
The uptake of UMA-loaded neutrophils by macrophages was further confirmed by using 
neutrophils pre-labeled with pHrodo. A pHrodo-derived fluorescent signal was obtained after  co-
culturing macrophages with neutrophils pre-loaded with UMA, in contrast to neutrophils that 
were not exposed to UMA (Figure 3d). Finally, to assess how macrophages may recognize UMA-
loaded neutrophils, we analyzed the expression of phosphatidylserine (PS; expressed on apoptotic 
cells), CD11a/CD18 (LFA-1) and CD31 on neutrophils before and after exposure to UMA. It has 
previously been shown that these cell surface markers facilitate interactions between neutrophils 
and macrophages (20-22). We observed that UMA-loaded neutrophils remained viable, i.e. did 
not expose PS, and did not alter LFA-1 expression, whereas CD31 expression was diminished 
(Suppl. Figure 2). In conclusion, macrophages recognize and engulf viable CD31-negative neutro-
phils that have previously internalized (substantial amounts of) UMA. 
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Figure 3. Monocyte-derived macrophages recognize and engulf UMA-containing neutrophils. (A) After co-
incubation with macrophages for 4 hours, the amount of UMA-stimulated neutrophils, normalized to 
neutrophils before co-culture, significantly declined in culture supernatants (left panel). Particularly the 
percentage of neutrophils with an increased side scatter decreased in these co-cultures (right panel). 
(B) Representative flow cytometry charts showing that macrophages selectively recognize neutrophils 
with an increased side scatter (gate A). (C) PKH26-labeled neutrophils (red; PMN) are either attached to 
or taken up by monocyte-derived macrophages (green), where unstimulated neutrophils (control) are 
not. (D) pHrodo-labeled neutrophils pre-loaded with UMA are engulfed by macrophages, whereas 
neutrophils not exposed to UMA are not. Scale bars: 20 µm. *** p < 0.001, * p < 0.05, when compared 
to control situation where not indicated. 
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Impaired UMA clearance promotes nsMSU-induced NET release. We observed that UMA 
ultimately grow at their longitudinal ends into nsMSU (15 – 20 µm in size) in the absence of 
phagocytes (Figure 4a; Movie S2). The growth of UMA into nsMSU also occurred in the presence 
of phagocytes and heat-inactivated hyperuricemic serum, thus in a condition in which the 
clearance of UMA by phagocytes is impaired due to the lack of complement proteins (Suppl. Figure 
3). In contrast, nsMSU were not observed in the presence of phagocytes and hyperuricemic serum 
that was not heat-inactivated. Collectively, these data indicate that the impaired clearance of UMA 
by blood-borne phagocytes can promote the development of nsMSU in hyperuricemic serum. 
Since neutrophils can sense microbe sizes and selectively release NETs toward large pathogens 
(23), we assessed whether the size of crystals (UMA versus nsMSU) influences NET release. For 
this purpose, we incubated purified neutrophils for 4 hours separately with UMA (≤ 1 µm) or 
nsMSU (15-20 µm) and analyzed ROS production, extracellular DNA release and the presence of 
citrullinated histone H3 as markers of NETosis.  
 
 
 
Neutrophils stimulated with UMA had a highly granular phenotype, indicative for the uptake of 
these crystals, but barely stained positive for citrullinated histone H3 (Figures 4b and 4c, left 
panel). In line with this, no extracellular DNA was detected when neutrophils were incubated with 
UMA (Figure 4c, middle panel). In contrast, nsMSU promoted substantial citrullination of histone 
H3 and induced robust DNA release by neutrophils. Intriguingly, ROS production was increased in 
response to both UMA and nsMSU with a reciprocal difference in favor of UMA (Figure 4c, right 
panel). Together, these data indicate that neutrophils distinguish small from big crystals and 
selectively release NETs in response to the big nsMSU, which can occur when UMA are not cleared. 
 
 
Clearance of UMA in vivo. When we injected 1 mg UMA intravenously into Balb/c mice, we 
observed the crystals within the sinusoids of the liver and in the marginal zones of the spleen 
(Figure 5a). The heart, kidneys and lungs contained no UMA (Figure 5b), and UMA could not be 
detected in blood smears either (not shown). The observation that the lungs, which are the first 
organs to pass after injecting UMA in the tail vein, did not contain UMA implies that UMA are 
cleared from the circulation by specific organs, i.e. the spleen and the liver. Experiments with 
nsMSU could not be performed in vivo since these crystals caused sudden death in pilot 
experiments. Therefore, we studied nsMSU under condition of flow in vitro.         . 
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Figure 4. Impaired phagocytosis of UMA leads to the formation of nsMSU with NET-inducing potential. (A) 
In the absence of phagocytes, nsMSU developed in hyperuricemic serum. (B) Ingestion by neutrophils 
of huge amounts of UMA and nsMSU (left panels) caused moderate and substantial hypercitrullination 
of histone H3 in cultured cells (right panels, white arrows), respectively. (C) Citrullination of histone H3 
(left panel) and the release of DNA (middle panel) preferentially occurred in response to nsMSU, 
whereas ROS production increased in response to both UMA as well as nsMSU (right panel). Scale bars: 
30 µm (inserts: 10 µm). *** p < 0.001, * p < 0.05, when compared to control situation where not 
indicated.  
 
 
 
 
 
 
 
Under venous flow, UMA and nsMSU both induce NETosis. Next, we repeated our assays under 
conditions simulating a venous flow rate. At the same crystal concentrations used in earlier 
experiments,  we observed  that  UMA  and nsMSU formed tiny  and  massive  crystal  aggregates,  
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Figure 5. Circulating UMA undergo splenic and hepatic clearance in vivo. (A) Intravenously injected UMA 
(1 mg) are cleared in mice in the sinusoids of the liver or in the marginal zone of the spleen. (B) UMA 
were absent in lung, heart and kidney cryosections (FOV = field of view). Scale bar: 100 µm.  
 
 
 
 
 
 
 
 
 
 
respectively (Figure 6a). This appeared to be a physical flow-dependent process occurring in the 
absence of leukocytes. However, the high concentration of UMA is a non-physiological condition, 
since UMA are physiologically taken up by blood-borne phagocytes as soon as they emerge and 
are then unloaded in the sinusoids of liver or spleen (Figure 5). The size of these aggregates 
drastically increased in the presence of leukocytes (Figure 6b, left panels ‘Brightfield’) forming 
macroscopic tophus-like structures with a diameter up to 3 mm (Figure 6b, right panels 
‘Macroscopic’). Further analyses revealed that UMA- and nsMSU aggregates both contained high 
amounts of extracellular DNA (Figure 6b, middle panels ‘Immunofluorescence’). Thus, in contrast 
to static culture conditions, high amounts of UMA aggregates appear capable of inducing NETosis 
under flow. This is presumably caused by physical aggregation of these crystals forming structures 
too large for immediate phagocytic clearance. The extracellular DNA appeared particularly densely 
packed in nsMSU aggregates. Importantly, DNA aggregates containing nsMSU resisted digestion 
by  DNase I,  most  likely  by  stabilization  of  the  aggregate  by   the  large  sized  crystal  framework, 
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Figure 6. cMSU-induced NETosis promotes tophus formation. (A) Under conditions of flow, high 
concentrations of UMA and nsMSU formed large aggregates of crystals. (B) Leukocytes were attracted 
to UMA and nsMSU aggregates (left panels) and released NETs (DNase-INEG; middle panels), thereby 
forming macroscopic tophus-like structures (right panels). Aggregates of NETs and nsMSU resisted 
DNase I-mediated degradation (DNase-IPOS; middle panels), whereas UMA-induced NETs were 
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completely dissolved. (C) nsMSU-containing tophi were highly positive for active myeloperoxidase 
(MPO), neutrophil elastase (NE) and extracellular DNA. Scale bars: (A) 30 µm (inserts: 10 µm); (B) 
‘brightfield’ 30 µm, ‘immunofluorescence’ 100 µm, ‘macroscopic’ 3 mm. ^ p < 0.001 compared to 
control situation, $ p < 0.05 compared to control situation, *** p < 0.001 between indicated conditions. 
 
 
 
whereas UMA-containing DNA aggregates were sensitive to DNase I and got fully dissolved (Figure 
6b, middle panels ‘Immunofluorescence’). Notably, nsMSU-containing DNA aggregates contained 
much more myeloperoxidase activity, neutrophil elastase activity, and extracellular DNA than 
UMA-containing DNA aggregates (Figure 6c). In sum, UMA and nsMSU induce NETosis under flow, 
by which large macroscopic aggregates of NETs and crystals are formed. Whereas UMA-based 
aggregates are readily dismantled by DNase I, nsMSU-based aggregates are not. 
 
 
 
 
NETosis shields endothelial cells from pro-inflammatory UMA and nsMSU. Intravascular NETosis 
was previously linked to an altered vascular integrity during acute lung injury (13). We therefore 
assessed the consequences of UMA- and nsMSU-induced NETosis on endothelial cells. For this 
purpose, we stimulated confluent HUVEC monolayers under flow for 6 hours with UMA or nsMSU. 
In the absence of leukocytes, both UMA and nsMSU induced an upregulation of TNF-α and IL-6 
mRNA in HUVEC, whereas TGF-β mRNA levels remained constant (Figure 7a). However, in the 
presence of leukocytes, i.e. erythrocyte-depleted whole blood, TNF-α and IL-6 mRNA levels in 
HUVEC were not upregulated compared to unstimulated HUVEC, indicating that leukocytes shield 
endothelial cells from the pro-inflammatory effects of cMSU. Notably, we did not observe 
cytotoxicity of these structures to  endothelial  cells  despite  the  formation  of  large  macroscopic 
aggregates in culture supernatants, which contained cytotoxic histones and active proteases. The 
endothelial cells and the integrity of the endothelial monolayer remained intact, as determined 
by immunofluorescence imaging of the adherens junction protein VE-cadherin (CD144) (Figure 
7b). In addition, we found no release of von Willebrand factor (vWF) or nuclear translocation of 
NFKB (Figure 7b), indicating that endothelial cells are also not activated by the crystal-containing 
aggregates. In summary, leukocytes protect endothelial cells from cMSU-induced damage. 
 
 
 
 
 
 
 
 
 
5. Discussion 
 
The formation and  growth  of cMSU is a complex  process that is  influenced by  multiple factors,  
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including temperature, calcium levels, pH and/or mechanical shock (24). Preferentially, nsMSU 
develop within the relatively cold synovial fluids or within the acidic urine, giving rise to gouty 
arthritis and renal calculi, respectively. Whether uric acid also crystallizes within hyperuricemic 
blood has long been a subject of debate. The observation that the solubility of uric acid increases 
in the presence of albumin has supported the notion that uric acid does not crystallize in blood 
(25). However, the role of albumin in uric acid crystallization is controversial. Some investigators 
suggested that albumin strongly inhibits nsMSU formation, some claimed that albumin has 
absolutely no effect, while others reported that albumin accelerates the crystallization process 
(3). Our data refute the notion that albumin inhibits uric acid crystallization. We found that small, 
round-shaped UMA developed within hyperuricemic serum as well as whole blood ex vivo. These 
UMA were taken up by blood-borne phagocytes and cleared from the circulation. They finally en-
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Figure 7. NETosis protects endothelial 
cells from the pro-inflammatory effects 
of UMA and nsMSU. (A) UMA and 
nsMSU induce mRNA upregu-lation in 
HUVEC of tumor necrosis factor α 
(TNF-α) and interleukin (IL) 6, whereas 
mRNA expression of trans-forming 
growth factor β (TGF-β) re-mained 
constant. The upregulation of TNF-α 
and IL-6 mRNA in HUVEC was 
prevented by the presence of leu-
kocytes (i.e. whole blood depleted of 
erythrocytes). (B) Immunofluores-
cence images of HUVEC show that 
tophus-like structures of UMA or 
nsMSU and extracellular DNA did not 
promote release of von Willebrand 
factor (vWF; upper panels), nuclear 
translocation of NFKB p65 (middle 
panels) or loss of VE-cadherin 
(CD144)-mediated junctions (lower 
panels). Scale bar: 20 µm. ^ p < 0.001 
compared to control, *** p < 0.001 
between indicated conditions, ** p < 
0.05 between indicated conditions. 
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ded up in the sinusoids of the liver and in the spleen. The abundant plasma proteins fetuin (also 
known as alpha-2-HS-glycoprotein) and complement promoted the clearance of UMA by blood-
borne phagocytes. Indeed, complement proteins can bind to and get activated by cMSU (14-16). 
A role for fetuin in the phagocytosis of crystallized uric acid has not been reported yet, although 
its contribution to the clearance of calprotein-like particles (26), apoptotic cells (27) and poly-
styrene nanospheres (28) is well established. Interestingly, fetuin enhanced the phagocytosis of 
UMA only in the presence of active complement. Cooperative effects of fetuin and serum proteins 
were previously reported in the context of calcium phosphate crystal nidi (29).  
 
 
 
 
UMA intravenously injected into mice were traced back in the macrophage-rich zones of the liver 
and spleen (Figure 5). These tissues are known to harbor resident macrophages, classified as part 
of the reticuloendothelial system. Resident tissue macrophages are discretely positioned and tran-
scriptionally programmed for the encounter of pathogens or environmental challenges, thus 
serving as immune sentinels (30). Our observations suggest that the clearance of UMA by blood-
borne phagocytes results in their hepatic or splenic exit from the circulation, where they were 
phagocytosed by specialized macrophages (31). The phagocytosis by macrophages of UMA-loaded  
neutrophils may be facilitated through the observed loss of CD31 on neutrophils that contain 
UMA. It has been proposed that CD31 expression on neutrophils prevents the ingestion of 
neutrophils by macrophages through transmitting active ‘detachment’ signals, whereby the loss 
of CD31 thus facilitates the ingestion of neutrophils by macrophages (20).  
 
 
 
 
 
 
In hyperuricemic serum, in the absence of leukocytes, punctate UMA slowly formed and 
subsequently grew to nsMSU (Movie S2). This whole process is kinetically controlled and takes 
several hours. In contrast to UMA, single nsMSU triggered the release of potentially pro-coagulant 
NETs by blood-borne neutrophils in static culture conditions. Thus, an impaired clearance of UMA 
may bear the risk for thrombus formation and vascular injury. From previous work, we know that 
the release of NETs in response to nsMSU involves the generation of ROS (4). We observed that 
both UMA and nsMSU induced ROS production in neutrophils, whereas citrullination of histone 
H3 and DNA release, two major hallmarks of NETosis, were particularly observed in response to 
nsMSU. This suggests that the inflammatory response of neutrophils towards crystallized uric acid 
is dependent on the size of the crystals. Indeed, neutrophils possess the ability to sense pathogen 
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size (23). The observation that high amounts of UMA, forming extended aggregates under flow, 
induced NETosis supports this line of thought. Of note, in contrast to other work (32, 33), we did 
not observe cytotoxic effects of crystal-induced NETs to endothelial cells. Instead, the presence of 
leukocytes diminished the pro-inflammatory effects of UMA and nsMSU on endothelial cells. This 
process involved the trapping of the crystals by extended aggregated NETs. Importantly, DNase I 
only dismantled and dissolved UMA-containing aggregated NETs, whereas those composed of 
nsMSU were rather resistant to DNase I activity.  
 
 
 
Figure 8. Hypothetical model for the mechanisms beyond and the relevance of UMA clearance from 
hyperuricemic blood. High uric acid (UA) levels lead to formation of urate microaggregates (UMA) in 
hyperuricemic blood. UMA are instantly taken up by blood-borne phagocytes (PMN) before they grow 
to nsMSU. This phagocytosis is fostered by opsonization with complement and fetuin. The UMA-loaded 
phagocytes are consecutively cleared from the circulation by resident macrophages in the marginal zone 
of the spleen or the sinusoids of the liver. If not properly cleared, UMA grow to hazardous NET-inducing 
nsMSU. This carries the risk of intravascular thrombus formation and obstruction of the vessel.  
 
 
 
 
 
 
 
 
 
 
Taken together, we elucidated a mechanism in which complement proteins and fetuins facilitate 
the cooperative clearance by blood-borne phagocytes and resident macrophages of UMA that 
spontaneously form in hyperuricemic blood (Figure 8). The relevance of this clearance mechanism 
is reflected by the capacity of nsMSU to induce NETosis, which may have detrimental effects if it 
occurs in the vasculature. In otherwise healthy individuals with hyperuricemia, UMA will be rapidly 
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cleared from the circulation in statu nascendi. This prevents a further crystal growth and the 
formation of dangerous nsMSU. Since the clearance of UMA is impaired in the absence of comple-
ment factors or fetuin, patients with chronic kidney disease and/or low levels of these plasma 
proteins (34-38) may potentially be at risk to develop (NET-driven) vascular inflammation. 
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Supplementary Information        Suppl. Fig. 1 
 
 
Figure S1. Phagocytosis of UMA by neutrophils. (A) Neutrophils dose-dependently increase in side scatter 
when exposed to UMA. (B) Neutrophils with an increased side scatter stain positive for pHrodo, 
indicating that those cells have truly internalized UMA. (C) The MFI of pHrodo correlates to the 
phagocytic index (PhIx) as calculated in our assays. (D) The percentage of UMA-containing neutrophils 
(i.e. pHrodo-positive neutrophils with increased side scatter) drops from 44% to 14% when serum is 
heat-inactivated (30 min, 55°C) or pre-treated with 500 µM EDTA to remove divalent cations. 
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Supplementary Information        Suppl. Fig. 2 
 
Figure S2. UMA-positive neutrophils remain viable but loose CD31 expression. Unstimulated neutrophils 
or neutrophils exposed to UMA for 2 or 4 hours were stained for phosphatidylserine (Annexin V staining) 
(A), CD31 (B), CD11a (C) and CD18 (D) and analyzed by flow cytometry. UMA-positive neutrophils were 
gated based on an increased side scatter (SSc). 
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Supplementary Information        Suppl. Fig. 3 
 
Figure S3. Impaired UMA clearance yields NET-inducing nsMSU. UMA were incubated in hyperuricemic 
serum (uric acid levels of 20 mg/dL) in the presence of PKH26-labeled neutrophils (red) and the 
extracellular DNA-binding dye 4',6-diamidino-2-phenylindole (DAPI; blue) for 8 hours. Hyperuricemic 
serum was either heat-inactivated or not. In hyperuricemic heat-inactivated (H.I.) serum (two right 
panels), UMA grew into nsMSU (black arrows in BF; brightfield) and triggered the release of NET-like 
extracellular DNA. Such nsMSU and extracellular DNA were not observed for hyperuricemic serum that 
had not been heat-inactivated (middle panel). Scale bar: 50 µm (insert: 25 µm). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary movies are accessible via www.nature.com/articles/srep38229 
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1.  Abstract 
 
The release of neutrophil extracellular traps (NETs), either during ‘suicidal’ or ‘vital’ NETosis, 
represents an important strategy of neutrophils to combat Gram-negative bacteria. 
Lipopolysaccharide (LPS), a major component of the outer membrane of Gram-negative bacteria, 
is a reported stimulus for NET formation. Although it is widely acknowledged that the structural 
diversity in LPS structures can elicit heterogeneous immune responses, species- and serotype-
specific differences in the capacity of LPS to trigger NET formation have not yet been investigated. 
In the present study, we compared the NET-inducing potential of LPS derived from Escherichia coli 
(serotypes O55:B5, O127:B8, O128:B12, O111:B4 and O26:B6), Salmonella enterica (serotype 
enteritidis) and Pseudomonas aeruginosa (serotype 10), under platelet-free and platelet-rich 
conditions in vitro, and in whole blood ex vivo. Here, we demonstrate that under serum- and 
platelet-free conditions, mimicking tissue circumstances, neutrophils discriminate between LPS of 
different bacterial sources and selectively release NETs only in response to LPS derived from E. coli 
O128:B12 and P. aeruginosa 10, which both induced ‘suicidal’ NETosis in an autophagy- and ROS-
dependent, but TLR4-independent manner. Intriguingly, in whole blood cultures ex vivo, or in vitro 
in the presence of platelets, all LPS serotypes induced ‘vital’ NET formation. This platelet-
dependent release of NETs occurred rapidly without neutrophil cell death and was independent 
from ROS formation and autophagy, but required platelet TLR4 and CD62P-dependent platelet-
neutrophil interactions. Taken together, our data reveal a complex interplay between neutrophils 
and LPS, which can induce both ‘suicidal’ and ‘vital’ NETosis, depending on the bacterial origin of 
LPS and the presence or absence of platelets. Our findings suggest that LPS sensing by neutrophils 
may be a critical determinant for restricting NET release to certain Gram-negative bacteria only, 
which in turn may be crucial for minimizing unnecessary NET-associated immunopathology. 
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2.  Introduction 
 
 
Neutrophils are the most abundant terminally differentiated leukocytes circulating in the blood. 
Attracted by a chemotactic gradient of chemokines, neutrophils can rapidly traffic to inflammatory 
sites, where they utilize their antimicrobial arsenal of effector mechanisms to eradicate 
pathogens. In addition to phagocytosis and degranulation, the release of neutrophil extracellular 
traps (NETs) represents a key antimicrobial strategy of neutrophils (1). NETs are released during a 
highly complex cell death pathway known as ‘suicidal’ NETosis and comprise an expelled web of 
chromatin fibers that can bind pathogens, thereby inhibiting their spreading and facilitating their 
elimination (2, 3). Recent evidence indicates that NETs can also be released from viable 
neutrophils during an alternative pathway called ‘vital’ NETosis, which requires activated platelets 
and is therefore thought to occur predominantly during sepsis (4, 5).  
 
 
 
 
The release of NETs has been observed in response to many different bacteria, viruses, fungi and 
parasites (6). Nevertheless, it is still incompletely understood how pathogens induce signaling 
events that result in NETosis. For Gram-negative bacteria, lipopolysaccharide (LPS) has been 
reported as important stimulus for NETosis (1). However, seemingly contradicting data in 
literature question whether the interaction between LPS and neutrophils can indeed trigger NET 
formation. Some reports describe that LPS often protects neutrophils against apoptosis but fails 
to induce NETosis (7, 8), whereas other reports claim that LPS-induced NETosis is only observed 
when additional factors are present, such as the immunomodulatory GM-CSF (9), apoptotic 
microparticles (10) or platelets (11). 
 
 
 
 
LPS has three main structural components: lipid A, a core domain containing an oligosaccharide 
component and a repetitive glycan polymer referred to as the O antigen (12). Whereas the lipid A 
structure is relatively conserved, there is great variability in the composition of the O-antigen 
between bacterial strains, which provides the major basis for bacterial serotyping. The structural 
diversity in LPS has been associated with heterogeneous immune responses (13-16). However, 
species- and serotype-specific differences in the capacity of LPS to trigger NET formation have not 
yet been investigated. This study was undertaken to investigate the hypothesis that neutrophils 
are able to discriminate between LPS structures and thereby selectively release NETs in response 
 
 
 
Source-dependent NETosis by lipopolysaccharides 
50 
 
to certain structures, which could partly explain the seemingly contradicting data concerning LPS-
induced NETosis. Here, we compared the NET-inducing potential of commercially available LPS 
derived from seven different bacterial sources, i.e. Escherichia coli (serotypes O55:B5, O127:B8, 
O128:B12, O111:B4 and O26:B6), Salmonella enterica (serotype enteritidis) and Pseudomonas 
aeruginosa (serotype 10), under serum- and platelet-free or platelet-rich conditions, mimicking 
tissue and blood circumstances, respectively. 
 
3.  Materials and Methods 
 
Antibodies, proteins and chemicals. Reagents were obtained from the following manufacturers: 
Sytox Orange (ThermoFisher Scientific), N-Methoxysuccinyl-Ala-Ala-Pro-Val p-nitroanilide (Sigma-
Aldrich), phorbol 12-myristate 13-acetate (PMA; Sigma-Aldrich), micrococcal nuclease (MNase; 
Worthington Biochemical Corporation), TNF-α (eBioscience), IL-6 (Prospec), IFN-α (Prospec), 
wortmannin (Enzo Life Sciences), diphenyleneiodonium chloride (DPI; Enzo Life Sciences), PKH26 
Red Fluorescent Cell Linker Kit (Sigma-Aldrich), polyclonal anti-TLR4 (InvivoGen), anti-
myeloperoxidase (BioLegend), anti-neutrophil elastase (Abcam), anti-CD62P (Santa Cruz). All LPS 
structures used in this study were purchased from Sigma-Aldrich and are listed in Table 1. 
 
 
 
 
 
 
 
 
 
 
Table 1. LPS structures used in this study. 
Species Serotype Abbreviation Cat. No. 
Escherichia coli O55:B5 LPS-O55 L6529 
 O127:B8 LPS-O127 L4516 
 O128:B12 LPS-O128 L2755 
 O111:B4 LPS-O111 L4391 
 O26:B6 LPS-O26 L2654 
Salmonella enterica Enteritidis LPS-SE L7770  
Pseudomonas aeruginosa 10 LPS-PA L9143 
 
 
 
 
 
 
 
 
 
 
 
 
 
Isolation of neutrophils. Neutrophils were isolated as described earlier (17). Briefly, neutrophils 
were isolated at room temperature from EDTA-anticoagulated whole blood by Ficoll density 
gradient centrifugation using Lymphoprep (Stemcell Technologies). After centrifugation for 20 min 
at 800g, the lower cellular fraction with neutrophils was collected and residual erythrocytes were 
lysed in a hypotonic buffer. Neutrophils were counted with CASY cell counting technology (Scharfe 
System) and adjusted to 1 million cells per milliliter in serum-free DMEM/F12 (Life Technologies). 
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Isolation of platelets. After Ficoll density gradient centrifugation, platelet-rich plasma was 
collected and diluted 10 times in a buffer of PBS, 1% FCS and 1 mM EDTA. Remaining leukocytes 
were pelleted at 190g for 15 min at room temperature, after which the remaining supernatant 
with platelets was pelleted at 2500g for 5 min at room temperature. The platelet pellet was then 
immediately and carefully resuspended in DMEM/F12 medium to an equivalent volume as they 
were in the blood, yielding a solution of 100% platelets (v/v). 
 
 
Induction and quantification of NETosis. Purified neutrophils (3x105 cells per cm2) were seeded 
in well plates and stimulated with LPS from different bacterial sources, at the indicated 
concentrations and conditions, for 3 to 5 hours at 37°C. Where indicated, stimulation of 
neutrophils with 100 nM PMA served as a positive control. After stimulation, neutrophils and 
adherent NETs were carefully washed twice with pre-warmed PBS (37°C) and isolated by partial 
NET digestion in DMEM/F12 medium supplemented with 5U/mL MNase (20 min at 37°C). 
Extracellular DNA in NET-containing supernatants was stained with 100 nM Sytox Orange and 
quantified by fluorometry (excitation/emission 530/640 nm). The activity of NET-associated 
neutrophil elastase and myeloperoxidase was determined colorimetrically, using 100 μM N-
methoxysuccinyl-Ala-Ala-Pro-Val 4-nitroanilide (at 405 nm) or 1 mM 3,3,5,5-tetra-methyl-
benzidine (at 605 nm) as substrates for NE and MPO, respectively. 
 
 
Immunofluorescence imaging. Purified neutrophils (3x105 cells per cm2) were seeded in slideflask 
chambers (Thermo Scientific) and stimulated with LPS from different bacterial sources, at the 
indicated concentrations and conditions, for 3 to 5 hours at 37°C. Where indicated, stimulation of 
neutrophils with 100 nM PMA served as a positive control. After stimulation, cells and NETs were 
fixed in 4% paraformaldehyde (30 min, room temperature) and slides were stained for DNA (Sytox 
Orange; 100 nM), neutrophil elastase (dilution 1:200; antibody listed above) and/or myelo-
peroxidase (dilution 1:100; antibody listed above). Slides were embedded in Vectashield Mounting 
Medium (Brunschwig Chemie) and analyzed with a Zeiss fluorescence microscope. 
 
 
Statistical analyses. Values are expressed as mean ± SEM. Significance was either determined by 
Student’s t-test or one-way ANOVA followed by Bonferroni correction using GraphPad Prism 5.0. 
P-values less than 0.05 were considered as statistically significant. 
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4.  Results 
 
Neutrophils selectively release NETs in response to different LPS structures. To evaluate whether 
LPS is capable of inducing NETosis, and whether there are species- and/or serotype-specific 
differences in the capacity of LPS to induce NETosis, purified neutrophils were exposed to seven 
different LPS structures (at a concentration of 8 pg LPS per neutrophil, equivalent to ~10 µg/ml 
LPS) under platelet- and serum-free conditions (thereby largely approaching tissue circum-
stances), after which NETosis was quantified by measuring DNA release. Extracellular DNA was 
only detected when neutrophils were exposed to LPS-O128 and LPS-PA, whereas the other LPS 
serotypes did not induce DNA release (Figure 1a). For LPS-O128 and LPS-PA, the amount of 
extracellular released DNA approached ~ 40 - 50% of the total cellular DNA, as determined in total 
cell lysates, indicating that approximately half of the neutrophils were lysed and released NETs. 
Measurement of extracellular elastase activity in the same culture supernatants revealed that only 
LPS-O128 and LPS-PA were  able  to induce the release  of  proteolytic  active  elastase (Figure 1b). 
The  release  of  both extracellular DNA and  elastase  clearly  suggested  that NETs  were  released. 
 
 
 
 
 
 
 
 
                   
Figure 1. Neutrophils selectively release NETs in response to LPS structures. (A) LPS-O128 and LPS-PA 
stimulate neutrophils to release DNA after 180 min. of incubation in platelet-free cell cultures. (B) The 
release of DNA by LPS-O128 and LPS-PA coincides with extracellular activity of neutrophil elastase. LPS 
was used at a concentration of 8 pg LPS per neutrophil. * p < 0.05 and *** p < 0.001, when compared 
to control. Data represent mean values ± SEM of at least three experiments.  
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Indeed, the presence of NETs could be confirmed by immunofluorescence imaging, where typical 
DNA filaments (‘spread’ NETs) as well as ‘diffused’ NETs could be observed (Figure 2). In sum, LPS-
induced NETosis is, under tissue circumstances, species- and serotype-dependent and is, amongst 
the seven LPS structures investigated here, limited to LPS-O128 and LPS-PA. 
 
 
 
 
 
 
 
 
Figure 2. Neutrophils selectively release NETs in response to LPS structures. NET release in response to 
LPS-O128 and LPS-PA was confirmed by immunofluorescence microscopy, in which DNA was stained 
with 100 nM Sytox Orange (yellow). Both ‘spread’ NETs (red arrows) and ‘diffused’ NETs (white arrows) 
were observed. NET release in response to 100 nM PMA served as positive control. LPS was used at a 
concentration of 8 pg LPS per neutrophil. Scale bar: 30 µm.  
 
 
 
 
 
 
 
 
LPS-O128 and LPS-PA induce NETosis only when present above a threshold value. Next, the NET-
inducing capacity of LPS-O128 and LPS-PA was tested at lower concentrations under the same 
serum- and platelet-free circumstances. Intriguingly, lowering LPS concentrations did not result in 
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a gradual decrease of the number of neutrophils undergoing NETosis, but instead all neutrophils 
remained unaffected below concentrations of 8 pg of LPS-O128 and LPS-PA per neutrophil (Figure 
3). This indicates that a certain minimum quantity of LPS-O128 and LPS-PA is required to exceed a 
threshold value that induces NETosis in neutrophils. It can be hypothesized that a pro-
inflammatory milieu, i.e. the presence of pro-inflammatory cytokines, might lower the threshold 
for the induction of NETosis by LPS-O128 and LPS-PA. To test this, neutrophils were pre-incubated 
for 1 hour with the cytokines TNF-α (10 ng/ml), IL-6 (10 ng/ml), or IFN-α (100 ng/ml), or a mixture 
of these cytokines, after which LPS was added at a concentration just below the threshold (6 pg 
LPS per neutrophil). The pro-inflammatory cytokines did not induce NETosis themselves nor 
lowered the threshold for NETosis induced by LPS-O128 and LPS-PA (Figure 4a). In addition, LPS-
O111 did not gain NET-inducing capacity by priming neutrophils with pro-inflammatory cytokines. 
The pro-inflammatory cytokines did also not enhance NETosis by LPS-O128 and LPS-PA at a 
concentration of 8 pg LPS per neutrophil (Figure 4b). In sum, LPS-O128 and LPS-PA trigger NETosis 
when present above a certain threshold value, independent from a pro-inflammatory milieu. 
 
 
 
             
 
Figure 3. LPS-O128 and LPS-PA induce NETosis when present above a threshold value. (A) LPS-O128 and 
(B) LPS-PA induce NET release only at high concentrations of 8 pg LPS per neutrophil (PMN). * p < 0.05, 
*** p < 0.001, compared to control. Data represent mean values ± SEM of at least three experiments. 
 
 
 
 
 
 
LPS-O128 and LPS-PA induce ROS- and autophagy-dependent ‘suicidal’ NETosis. As outlined, 
NETs can be generated in several ways, i.e. through cell death-associated ‘suicidal’ NETosis or 
through ‘vital’ NETosis (4). Since the viability of neutrophils stimulated with LPS-O128 and LPS-PA  
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Figure 4. Cytokines do not influence LPS-induced NETosis. (A) Priming of neutrophils for 1 hour with 
recombinant TNF-α (10 ng/ml), IL-6 (10 ng/ml), IFN-α (100 ng/ml), or a mixture of all, does not promote 
NET release nor prime neutrophils for LPS-induced NETosis by LPS-O111, LPS-O128 and LPS-PA at a 
concentration of 6 pg LPS per neutrophil. In these graphs, NETosis induced by LPS-O128 and LPS-PA at 
8 pg LPS per neutrophil is shown in dark as positive controls. (B) Cytokines do not enhance NETosis by 
LPS-O128 or LPS-PA at LPS concentrations of 8 pg LPS per neutrophil. * p < 0.05, ** p < 0.01 and *** p 
< 0.001, when compared to control. Data represent mean values ± SEM of at least three experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
under serum- and platelet-free conditions (i.e. tissue circumstances) appeared heavily altered 
(Figure 1b), as  witnessed by  altered lobulated nuclei  and decondensed chromatin, we tested the 
hypothesis that LPS-O128 and LPS-PA trigger the canonical cell death-associated pathway of 
‘suicidal’ NETosis, which is dependent on reactive oxygen species (ROS) and autophagy and usually 
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takes hours to complete (7). Indeed, LPS-induced NETosis typically occurred after 3 hours (Figure 
5a) and could be fully prevented by inhibition of autophagy (using wortmannin) or ROS (using 
diphenyleneiodonium; DPI) (Figures 5b and 5c). Since LPS signaling is heavily dependent on TLR4, 
and  arguably to  a lesser extent on  TLR2, we  assessed whether  blockade of TLR2  and TLR4  could  
 
   
Figure 5. LPS-PA and LPS-O128 induce ROS- and autophagy-dependent ‘suicidal’ NETosis. (A) DNA release 
in response to 100 nM PMA, LPS-O128 or LPS-PA was monitored by fluorometry using 100 nM Sytox 
Orange during an incubation period of 5 hours. (B) NETosis induced by LPS-O128 and LPS-PA can be 
inhibited by 5 µM wortmannin (inhibitor of autophagy) or 40 µM diphenyleneiodonium (DPI; inhibitor 
of ROS), but not by anti-TLR2 and anti-TLR4 neutralizing antibodies (5 µg/ml). (C) The inhibitory effects 
of wortmannin and DPI on NET release by LPS-PA were confirmed by immunofluorescence microscopy, 
in which DNA was stained with 100 nM Sytox Orange (yellow). Immunofluorescence imaging also 
confirmed that anti-TLR2 and anti-TLR4 neutralizing antibodies did not prevent NETosis induced by LPS-
PA. LPS was used at a concentration of 8 pg LPS per neutrophil. Scale bar: 30 µm. ** p < 0.01 and *** p 
< 0.001, when compared to control, $ p < 0.05 and # p < 0.01, when compared to LPS-PA alone. Data 
represent mean values ± SEM of at least three experiments. 
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prevent NET release in response to LPS-O128 and LPS-PA. However, inhibition of TLR2 and TLR4 
did not alter NET release in response to either LPS structure, suggesting that LPS-induced NETosis 
occurs in a TLR4- and TLR2-independent manner (Figure 5b). Collectively, these data indicate that 
LPS-PA and LPS-O128 induce ‘suicidal’ ROS- and autophagy-dependent NETosis under tissue 
circumstances, which does not require TLR2- or TLR4. 
 
LPS induces ‘vital’ NETosis in the presence of platelets. It was recently demonstrated that LPS-
activated platelets induce ‘vital’ NETosis during sepsis (4, 5). This form of NET release is 
fundamentally different from ‘suicidal’ NETosis; hence, ‘vital’ NETosis occurs much faster, is not 
dependent on autophagy or ROS, and is not associated with direct lytic cell death. Therefore, the 
NET-inducing capacity of all seven LPS structures was re-tested in the presence of platelets. 
Intriguingly, in whole blood ex vivo, thus in the presence of platelets, NET-like DNA lattices could 
be identified in response to all seven LPS structures (Figure 6).  
 
 
 
 
Figure 6. All LPS structures induce NETosis in the presence of platelets. Typical NET-like extracellular DNA 
filaments (white arrows) were observed in whole blood cultures ex vivo after 180 min. of incubation 
with the seven different LPS serotypes. Scale bar: 20 µm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
An in vitro co-culture setting of neutrophils and isolated platelets indeed revealed NETosis in 
response to LPS structures that previously failed to induce NETosis under platelet-free conditions, 
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for instance LPS-O111 (Figure 7). Whereas platelets alone or LPS-O111 failed to trigger NET 
release, the combination of platelets and LPS-O111 resulted in robust NET formation (Figure 7, 
panels 2 - 4). Platelet-dependent LPS-induced NETs were observed already within 60 min. of 
incubation and the majority of neutrophils retained the capacity to exclude the vital dye Sytox 
Orange, which is indicative for ‘vital’ NETosis (Figure 7, panel 4). On the contrary, neutrophils 
stimulated with LPS-PA only did not exclude Sytox Orange anymore, which is indicative for 
‘suicidal’ NETosis (Figure 7, panel 5). Importantly, ‘suicidal’ NETosis induced by LPS-PA could be 
largely prevented by the addition of platelets (Figure 7, panels 5 and 6).  
 
 
 
 
 
 
Figure 7. LPS structures induce ‘vital’ NETosis in the presence of platelets. Platelets (panel 2) or LPS-O111 
(panel 3) alone do not induce NETosis after 180 min. of incubation with neutrophils, whereas the 
combination of both (panel 4) stimulates NET formation without lytic cell death. Massive neutrophil cell 
death is observed in response to LPS-PA alone (panel 5), based on the failure to exclude the vital dye 
Sytox Orange (yellow), which can be largely prevented by the addition of platelets (panel 6). LPS was 
used at a concentration of 8 pg LPS per neutrophil. Scale bars: white = 20 µm and red = 40 µm. 
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Finally, to confirm that the extracellular DNA fibers in response to LPS-exposed platelets represent 
‘vital’ NETs, double stainings for DNA with either myeloperoxidase (MPO) or elastase (NE) were 
performed. Indeed, extracellular DNA co-localized with MPO and NE when neutrophils were 
stimulated with platelets exposed to LPS-PA (Figure 8a), thereby confirming that the observed 
DNA structures are ‘vital’ NETs. However, the proteolytic activity of both MPO and NE within ‘vital’ 
NETs appeared lower when compared to ‘suicidal’ NETs induced by LPS-PA alone (Figure 8b). In 
sum, LPS-exposed platelets mediate ‘vital’ NETosis independent from the bacterial origin of LPS. 
 
 
Platelet TLR4 and CD62P are required for LPS-induced ‘vital’ NETosis. The mechanisms involved 
in platelet-dependent LPS-induced ‘vital’ NETosis may involve platelet TLR4, which was previously 
shown to be required for ‘vital’ NETosis (11). Indeed, anti-TLR4 neutralizing antibodies could 
inhibit NET release in response to LPS-O111 to a large extent (Figures 9a and 9b). The inhibition 
of ROS (with DPI) or autophagy (with wortmannin) did not influence ‘vital’ NETosis induced by LPS-
O111 (Figures 9a and 9b). Besides promoting ‘vital’ NETosis, platelets apparently also exerted 
inhibitory effects on ‘suicidal’ NETosis induced by LPS-PA (Figure 7, panels 5 and 6). In the 
presence of platelets, LPS-PA hardly promoted cell death, while NETs remained present to the 
same extent as for neutrophils exposed to LPS-PA in the absence of platelets. Thus, platelets seem 
to be important mediators in directing the neutrophil’s fate during NET release: whereas LPS-PA 
induces ‘vital’ NETosis in the presence of platelets, ‘suicidal’ NETosis is induced when platelets are 
not present.  
 
As an explanation for this observation, it can be hypothesized that LPS-exposed platelets are 
internalized by neutrophils, thereby delivering neutrophil elastase to phagosomes and 
sequestering neutrophil elastase from the nucleus, which in turn inhibits ‘suicidal’ NETosis since 
nuclear elastase is required in this pathway (18, 19). To test this hypothesis, PKH26-labeled 
platelets exposed to LPS-PA were co-cultured with neutrophils, after which PKH26-labeled 
platelets and neutrophil elastase were visualized by immunofluorescence imaging. Apparently, 
platelets were not internalized by neutrophils, but instead formed large aggregates with 
neutrophils (Figure 9c, middle panel). The platelet-neutrophil aggregates coincided with the 
presence of NETs, consisting of extracellular filaments of DNA and neutrophil elastase (Figure 9c, 
insert right panel). The formation of platelet-neutrophil aggregates was further analyzed by flow 
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cytometry, which revealed an increased forward scatter and PKH26-positivity in the neutrophil 
population (Figure 9d). Since CD62P is crucial for platelet-neutrophil interactions (20), PKH26-
labeled platelets exposed to LPS-PA were co-cultured with neutrophils in the presence of CD62P-
neutralizing antibodies. Indeed, CD62P-neutralizing antibodies could largely prevent the for-
mation of LPS-PA-induced platelet-neutrophil aggregates (Figures 9c and 9d) and decreased NET 
release (Figure 9e). Collectively, these data demonstrate a dominant role for platelets in LPS-
induced ‘vital’ NETosis, which occurs in an autophagy- and ROS-independent but platelet TLR4- 
and CD62P-dependent manner. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. ‘Vital’ NETs lack proteolytic active myeloperoxidase and elastase. (A) ‘Vital’ NETs induced by 
platelets exposed to LPS-PA, as well as ‘suicidal’ NETs induced by LPS-PA alone, stain positive for both 
myeloperoxidase (MPO) and neutrophil elastase (NE). Note the granular and intact neutrophil 
phenotype (i.e. lobulated nuclei) for ‘vital’ NETs (white arrows) when compared to the altered 
neutrophil phenotype (i.e. decondensed chromatin) for ‘suicidal’ NETs (blue arrows). (B) ‘Vital’ NETs 
induced by platelets exposed to LPS-PA lack proteolytic active myeloperoxidase (MPO) and neutrophil 
elastase (NE) when compared to ‘suicidal’ NETs induced by LPS-PA alone. For these assays, NETs were 
isolated through digestion with micrococcal nuclease and normalized on the basis of DNA content in 
NET-containing supernatants. Scale bars: white = 40 µm and red = 20 µm. *** p < 0.001, when compared 
to control. Data represent mean values ± SEM of at least three experiments. 
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Figure 9. Platelet-mediated ‘vital’ NETosis requires platelet TLR4 and CD62P. (A) ‘Vital’ NETosis induced 
by LPS-O111 and platelets is insensitive to inhibition by 5 µM wortmannin (inhibitor of autophagy) or 
40 µM diphenyleneiodonium (DPI; inhibitor of ROS), but can be prevented by pre-treatment of platelets 
with anti-TLR4 neutralizing antibodies (5 µg/ml). Representative images are merged pictures of 
extracellular DNA (yellow, as stained with 100 nM Sytox Orange) and neutrophils (brightfield channel). 
The images show abundant NETs despite exclusion of Sytox Orange by neutrophils, indicating cell death-
independent NET release (i.e. ‘vital’ NETosis). (B) Quantification of NET release was performed by fluoro-
metry, as outlined. (C) PKH26-labeled platelets (red) stimulated with LPS-PA form aggregates with neu-
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trophils (NE; neutrophil elastase) after 30 min. of incubation. This aggregate formation is inhibited by 
anti-CD62P neutralizing antibodies. (D) Flow cytometry analysis confirms the formation of platelet-
neutrophil aggregates, since cells within the predefined neutrophil gate increase in size (FSc; forward 
scatter) and stain positive for PKH26-labeled platelets after LPS-PA stimulation. (E) Anti-CD62P 
neutralizing antibodies decrease platelet-mediated ‘vital’ NETosis induced by LPS-PA, as measured by 
fluorometry. LPS was used at a concentration of 8 pg LPS per neutrophil. Scale bars: red = 100 µm; white 
= 30 µm; yellow = 10 µm. * p < 0.05 and *** p < 0.001, when compared to control, where not indicated. 
Data represent mean values ± SEM of at least three experiments. 
 
 
 
 
 
5.  Discussion 
 
This study shows that neutrophils are able to discriminate between LPS of different bacterial 
sources and thereby selectively release NETs. Under serum- and platelet-free conditions, thereby 
mimicking tissue circumstances, neutrophils released NETs in response to two out of seven tested 
different LPS structures, of which LPS derived from P. aeruginosa (LPS-PA) appeared particularly 
potent. P. aeruginosa is a pathogen that typically infects the respiratory and urinary tract, as well 
as chronic wounds, and is a significant cause of morbidity and mortality in hospitalized patients 
(21). It is well-accepted that neutrophils comprise a pivotal component of host protection against 
P. aeruginosa (22). It was recently reported that P. aeruginosa is a robust instigator of NET 
formation in vitro and in vivo within the lungs, which contributes to the pathogenesis of airway 
changes in patients with bronchiectasis and cystic fibrosis (23-26). It remains unelucidated why 
LPS-PA is particularly potent in eliciting NET release when compared to the LPS derived from other 
bacterial species. Since P. aeruginosa is generally perceived as a non-virulent opportunist, it is 
unclear why this micro-organism would elicit an antimicrobial defense mechanism (i.e. NETosis) 
that is associated with collateral tissue damage (6), rather than triggering conventional 
phagocytosis. Reasoning otherwise, the potent NET-inducing capacity of LPS-PA could explain why 
this bacterium is actually perceived as an opportunist; hence, NETosis represents an extremely 
powerful strategy of constraining bacterial traits (27). An explanation for the NET-inducing 
capacity of LPS-PA may lie in the fact that P. aeruginosa is well-known for its ways to circumvent 
phagocytosis, for example through the formation of biofilms (28). Thus, NETosis may provide an 
immune response to those bacteria that have evolved strategies to circumvent phagocytic killing. 
Indeed, multiple other pathogens notorious for their attempts to evade phagocytosis, such as 
Streptococcus pneumonia (29), Haemophilus influenzae (30), and Klebsiella pneumoniae (31), are 
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potent stimuli for NETosis. Thus, phagocytosis and NETosis may have a complementary role, 
whereby the failure to phagocytose may elicit NET release. In line with this is the observation that 
NETosis is triggered by fungi that are too large for phagocytosis, whereas small hyphae become 
phagocytosed without inducing NETosis (18).  
 
 
 
 
 
 
 
 
 
 
 
 
In addition to LPS-PA, LPS from E. coli (serotype O128:B12; LPS-O128) induced NETosis under 
tissue circumstances. Of note, four other tested LPS serotypes of E. coli (serotypes O55:B5, 
O127:B8, O111:B4 and O26:B6) did not elicit NET release. Thus, LPS-induced NETosis is not only 
bacterial species-specific but also serotype-specific. Growing evidence supports the notion that 
inflammatory responses triggered by LPS vary among serotypes. For instance, in a murine model 
of infection-induced preterm labor, four different E. coli LPS serotypes yielded highly variable 
outcomes (32). Our data suggest that subtle changes in the sugar composition of the O-antigen 
can impact NET release in response to LPS. It has been shown that modulation of the O-antigen 
composition alters the recognition and consecutive phagocytosis of LPS molecules by 
macrophages (33), which may also hold for neutrophils. In line with the reciprocal relationship 
between NETosis and phagocytosis described above, NETosis may thus be triggered by certain O-
antigens that facilitate bypassing of phagocytosis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Notably, the selectivity of NET release in response to LPS structures in our study was lost when 
neutrophils were co-cultured with platelets. Also, extracellular chromatin fibers typical for NETs 
could be identified in whole blood ex vivo in response to all seven different LPS structures. Thus, 
in the presence of platelets there is no selectivity of NET release in response to the different LPS 
structures. We observed that neutrophil-platelet interactions induced a rapid release of NETs (< 
60 min) in response to all LPS structures which occurred in a ROS-independent manner and 
preceded without evident lysis of neutrophils. This form of rapid NET release could largely be 
inhibited through the blockade of platelet CD62P. Indeed, it has previously been shown that 
CD62P promotes NETosis in mice (34). The binding of CD62P, also known as P-selectin, to P-
selectin glycoprotein ligand-1 (PSGL-1) on neutrophils thus causes signaling events that result in 
NETosis. However, the exact mechanisms responsible for CD62P-induced NETosis remain elusive. 
Nevertheless, many downstream pathways of PSGL-1, such as the Src/Syk, PI3K/Akt and p38 MAPK 
pathways, have in other contexts already been shown to be involved in NET release (35-37).  
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Our observations that LPS-exposed platelets rapidly induce NET release independent from ROS 
and independent from neutrophil lysis closely resemble a form of NETosis which has previously 
been referred to as ‘vital’ NETosis (4). However, the existence of a non-cell death ‘vital’ NETosis 
program has been doubted by some critics, who question whether a neutrophil can still live and 
function without an intact nucleus (38, 39). Nevertheless, there is evidence that anuclear 
granulocytes are metabolically active and able to perform cellular functions (40, 41). 
Simultaneously, some researchers have been critical towards fundamental aspects of ‘suicidal’ 
NETosis, who perceive ‘suicidal’ NETosis rather harmful than beneficial for the host (42). 
Furthermore, it remains controversial whether ‘suicidal’ NETosis is truly a unique form of cell 
death or whether it in fact reflects other forms of cell death (39, 43). Nonetheless the above, we 
have adapted the terms ‘suicidal’ and ‘vital’ NETosis in this manuscript, since these terms have 
been defined in previous work in which the reported observations correspond to our findings. 
However, we agree that at least the term ‘vital’ NETosis is a contradictio in terminis, since the 
“osis” of NETosis implies death and “vital” implies alive. Although our data support the coexistence 
of both ‘suicidal’ and ‘vital’ NETosis, whereby platelets direct the neutrophil’s fate, further 
investigation is required to fully understand ‘vital’ and ‘suicidal’ processes and to assess the 
reciprocal relationship between both. Moreover, there should be international consensus about 
the terminology applied to describe the different forms of NET release and neutrophil cell death. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The structure of ‘vital’ NETs induced by LPS-exposed platelets appeared highly refined and 
sophisticated, forming much larger structures of thinly interwoven DNA filaments when compared 
to ‘suicidal’ NETs. Furthermore, we found that peroxidase and elastase activity was lacking in ‘vital’ 
NETs, in contrast to ‘suicidal’ NETs. These two characteristics (i.e. the complex web-like structure 
and the lack of proteolytic activity) make ‘vital’ NETs highly suitable for trapping and encapsulating 
pathogens, but presumably not for direct extracellular killing. However, since neutrophils appear 
to remain viable during ‘vital’ NETosis, subsequent phagocytosis of entrapped pathogens may 
follow, and this combination of NET release and phagocytosis may provide an efficient strategy to 
combat pathogens in the bloodsteam during sepsis without inducing protease-mediated collateral 
tissue damage to the vessel lumen. Thus, aside from the idea that NETosis may occur when 
phagocytosis is impaired, there is also evidence that NETosis and phagocytosis by neutrophils can 
occur simultaneously and complement each other (44). 
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In addition to the biological relevance, our data may also have technical experimental implications. 
Since many studies addressing the contribution of NETosis to disease conditions depend on the in 
vitro induction and isolation of NETs for downstream assays, the choice for LPS as an inducer of 
NET release should be selected carefully in light of the current data (6, 45-47).  
 
 
 
Taken together, our data reveal a complex interplay between neutrophils and LPS, which can 
induce both ‘suicidal’ and/or ‘vital’ NETosis, depending on the quantity and structure of the LPS 
and the presence or absence of platelets (Figure 10). Although the present study compares the 
effects of a single molecule (LPS) from different bacterial sources, it is tempting to speculate that 
similar results may be obtained for whole microbes. This could be addressed in future research. 
 
 
 
 
Figure 10. Differential regulation of LPS-induced NET release under platelet-free and platelet-rich 
circumstances. Under serum- and platelet-free conditions, mimicking tissue circumstances, LPS-PA and 
LPS-O128 trigger ‘suicidal’ NET release in extravasated neutrophils, whereas other LPS structures (LPS-
O26, LPS-O55, LPS-SE, LPS-O127, LPS-O111) do not. In the presence of platelets, mimicking blood 
circumstances, neutrophils release ‘vital’ NETs in response to all LPS structures. 
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1. Abstract 
 
Systemic lupus erythematosus (SLE) is a fairly heterogeneous autoimmune disease of unknown 
etiology that mainly affects women in the childbearing age. SLE is a prototype type III hyper-
sensitivity reaction in which immune complex depositions cause inflammation and tissue damage 
in multiple organs. Two cell death pathways, apoptosis and NETosis, gained a great deal of interest 
among scientists, since both processes seem to be deregulated in SLE. There is growing evidence 
that histone modifications induced by these cell death pathways exert a central role in the 
induction of autoimmunity. In this review, we discuss how abnormalities in apoptosis, NETosis and 
histone modifications may lead to a break in immunological tolerance in SLE. 
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2. Introduction 
 
Autoimmune disorders are disturbances of the immune system that arise when the immune 
system responds to self. Immunological tolerance to self relies on the immune system to 
discriminate self from non-self. Systemic lupus erythematosus (SLE) is a systemic autoimmune 
disorder, in which primarily nuclear constituents, i.e. DNA, histones and ribonucleoproteins, are 
targeted (1). In a substantial subset of SLE patients, autoantibodies also target proteins from the 
cytoplasm of neutrophils (2). Since these nuclear self-antigens are normally shielded from the 
extracellular space by the nuclear membrane and the cell membrane, the key question is how 
these nuclear self-antigens are released and become exposed to the immune system. Anno 2014, 
abnormalities in two pathways of cell death, apoptosis and NETosis, are recognized as central 
processes that provide nuclear autoantigens and drive the autoimmune response in SLE (3).  
 
3. Two sources of autoantigens 
 
For over 20 years, apoptosis has been considered as the major source of autoantigens in SLE (4). 
Apoptosis is a highly organized and immunologically silent cell death pathway that plays an 
important role in tissue homeostasis. In processes characterized by a high-rate of tissue turnover, 
such as embryogenesis in human development, apoptosis is a crucial mechanism that allows 
tissues to remodel without triggering inflammation. Many cellular pathways and signals can 
activate proteolytic caspases to break down the cell in a strictly controlled and fine-tuned manner 
that distinguishes apoptosis from any other form of cell death. Apoptosis can be induced actively 
through ligation of cell surface receptors or passively through lack of survival signals. Apoptotic 
cells undergo a series of distinct morphological changes, including cell shrinkage, cytoskeletal 
disruption, DNA fragmentation and plasma membrane blebbing (5). It has been shown that the 
nuclear autoantigens targeted in SLE are concentrated within apoptotic blebs (6, 7). 
 
A specialized form of neutrophil cell death, termed NETosis, has been described a decade ago (8). 
NETosis has been linked to SLE as an additional source of autoantigens (9). During NETosis, 
neutrophils extrude fibrillary networks composed of DNA, citrullinated histones and granule 
peptides such as neutrophil elastase, myeloperoxidase and cathepsin G. These structures are 
termed Neutrophil Extracellular Traps (NETs) and serve to entrap and dismantle extracellular 
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bacteria, but also viruses, fungi and parasites (10-12). In addition to pathogens, sterile inflam-
matory mediators such as monosodium urate (MSU) crystals, IL-8, IL-1β, platelet-activating factor 
(PAF) and TNF-α have been reported to induce NETosis (13). NETosis requires a very rapid 
disintegration of the nuclear envelope, translocation of granule peptides to the nucleus, PAD4-
mediated citrullination of the chromatin, binding of granule peptides to citrullinated chromatin, 
and finally rupture of the plasma membrane (14). Where apoptosis is organized and planned, 
NETosis seems much faster and less well coordinated.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. Increased cell death 
 
MRL/lpr mice, the most commonly studied murine model for lupus-like disease, develop an 
autoimmune disease that reflects pathologies of human SLE, including lymph node enlargement, 
increased IgG levels, antinuclear autoantibody production, glomerulonephritis, proteinuria and 
development of skin lesions (15). MRL/lpr mice express a defective form of the Fas receptor that 
under physiological conditions stimulates cells to undergo apoptosis. This initially led to the belief 
that SLE patients have a similar defect in Fas-mediated apoptosis that underlies the failure of self-
tolerance. However, it has become clear that SLE is quite the opposite from being a disease with 
decreased apoptosis. Substantially evidence correlates increased lymphocyte, neutrophil, macro-
phage and monocyte apoptosis directly to SLE disease activity (16-19). It has been demonstrated 
that SLE serum has a strong apoptosis-inducing capacity in macrophages, monocytes and 
lymphocytes from healthy donors (20). In addition, it has been reported that autoreactive T cells 
show an increased expression of the apoptotic ligands TRAIL, TWEAK and FasL that directly 
mediate the apoptosis of monocytes (21).  
 
 
 
 
Since various bactericidal NET proteins were found to be present at much higher levels in blood 
from patients with SLE compared to healthy donor blood, increased NETosis is also implicated in 
the genesis and/or amplification of the autoimmune response in SLE (22-24). The pro-
inflammatory cytokines IL-17A, TNF-α, IL-1β and IL-8 have all been reported to induce NETosis, 
suggesting that NETs are extensively formed in an inflammatory environment such as occurs in 
SLE (25-27). Elevated levels of interferon-alpha (IFN-α), a cytokine that under physiological 
conditions is important for antiviral responses and immune activation, have been correlated with 
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disease activity in SLE (28). Recent evidence indicates that NETosis is enhanced in SLE due to 
priming of neutrophils by IFN-α (29). Certain autoantibodies that are highly present in the majority 
of SLE patients, such as anti-LL37, anti-HNP and anti-RNP, can also stimulate neutrophils to 
produce NETs (30-32). Furthermore, a distinct subset of neutrophils in SLE patients, so-called low-
density granulocytes (LDGs), have been described with an increased NET releasing capacity due to 
their ability to synthesize IFN-α in an autocrine manner (33). 
 
Taken together, it is presumed that both apoptosis and NETosis occurs excessively in patients with 
SLE, which results in an increased load of nuclear autoantigens. However, can this excessive 
release of nuclear autoantigens explain the break of immunological tolerance to nuclear antigens 
in SLE? Apoptosis and NETosis are physiological forms of cell death. In our daily battle against 
pathogens we daily release NETs, whereas between 50 and 70 billion cells die daily due to 
apoptosis. Humans evolved redundant mechanisms to clear apoptotic material and NETs. This 
clearance is usually accompanied by secretion of anti-inflammatory cytokines (34). Multiple 
groups tried to immunize mice with apoptotic cells/blebs or NETs, but this never lead to 
considerable immune activation (35, 36). Therefore, it can be concluded that increased apoptosis 
or NETosis on its own is not sufficient to break immunological tolerance to nuclear autoantigens 
in SLE, and that additional factors are required to turn apoptotic material or NETs into dangerous 
triggers of autoimmunity. 
 
 
 
 
 
 
 
 
5. Clearance deficiency 
 
In 1980, it was for the first time described that macrophages from SLE patients show an impaired 
phagocytic activity for yeast (37). Later, it was described that the phagocytosis of autologous 
apoptotic material by monocyte-derived macrophages is also disturbed in about 50% of the SLE 
patients (38). This was later confirmed by other groups (18, 39). Interestingly, macrophages 
differentiated from CD34 positive stem cells of SLE patients show a different morphology than 
those generated from healthy donors; they are relatively small and poorly ingest apoptotic 
material (40). Furthermore, the amount of Tingible Body Macrophages (TBMs) found in germinal 
centers appears to be strongly reduced in SLE patients (41). Apoptotic material in germinal centers 
is normally internalized by TBMs. In SLE patients with a reduced number of TBMs, apoptotic 
material was observed to be directly associated with the surface of follicular dendritic cells, which 
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may provide survival signals for autoreactive B cells. Monocytes and granulocytes from SLE 
patients display a reduced phagocytic activity as well (42), which may be explained by the relative 
low expression of the phagocytic receptor CD44 on both cell types (43).  
 
 
In addition to well-functioning healthy phagocytes, serum proteins have an important impact on 
the clearance of apoptotic cells as well. Adequate removal requires a clear recognition of apoptotic 
cells, which is, in addition to the exposure of phosphatidylserine on the outer leaflet of its plasma 
membrane, strongly dependent on opsonizing proteins such as immunoglobulin M (IgM), 
mannose-binding lectin (MBL), serum amyloid P (SAP), C-reactive protein (CRP), and C1q. 
Numerous studies ascribe a role for these opsonins in the defective clearance of apoptotic 
material in SLE. It has been shown that decreased IgM levels and increased MBL levels correlate 
with an increased disease activity in SLE (44, 45), that administration of SAP and CRP significantly 
delays disease onset and alleviates disease symptoms (46, 47) and that C1q-deficient mice rapidly 
develop autoantibodies against nuclear autoantigens (48). Polymorphisms at the loci of the genes 
encoding these opsonins as well as the formation of autoantibodies against opsonins are 
considered to be the underlying cause for their absence or defective functioning in SLE (49-52).  
 
 
 
 
 
 
 
 
 
 
 
 
 
There is also evidence for an impaired clearance of NETs. Deoxyribonuclease I (DNase I) plays a 
crucial role in the degradation of NETs, which is not surprising since the backbone of NETs is 
composed of nuclear DNA. The relevance of proper DNase I activity is reflected by the fact that 
DNase I-deficient mice develop a syndrome that closely resembles to SLE (53). A considerable 
number of SLE patients display a reduced DNase I activity (54). These patients develop relative 
high titers of anti-dsDNA autoantibodies and suffer from more severe symptoms. Low DNase I 
activity in SLE may have a genetic cause (55) but can also be the result of inhibitory molecules or 
anti-DNase I autoantibodies. In a Taiwanese cohort, 62% of the SLE patients appeared to be 
positive for anti-DNase I autoantibodies compared to only 8% of normal controls (56). Comparing 
sera from healthy donors and patients with SLE in their capability of degrading NETs in vitro 
revealed that 98.1% of the healthy donor sera degraded NETs normally, whereas a significant 
percentage of the SLE sera did not (36.1%) (57). Interestingly, those patients who could not 
degrade NETs developed lupus nephritis significantly more frequently than those who could 
degrade NETs. Depleting autoantibodies from SLE sera considerably enhanced NET degradation, 
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suggesting that NET-bound autoantibodies inhibit NET degradation by preventing the access for 
DNase I to the NET. In addition, it was shown that NET-bound C1q also inhibits NET degradation 
(58) via the same mechanism. Lastly, it has been shown that the antimicrobial peptides LL-37 and 
HMGB1 prevent NET degradation (59). This latter observation is interesting, since it has been 
described that these antimicrobial peptides are highly present in NETs from SLE patients but not 
in those from healthy donors (32).  
 
 
 
 
 
 
 
 
 
 
 
 
 
The relative contribution of intrinsic phagocyte defects and absent/deficient serum factors to the 
impaired clearance of apoptotic material and/or NETs in SLE seems clear. However, it is believed 
that there are numerous additional factors and pathways that could play a role in the complex 
pathogenesis of SLE. Although many different pathways may be deregulated, that all lead to a 
comparable SLE phenotype, it is assumed that accumulation of apoptotic material and NETs in 
tissues is the common denominator between all patients with SLE (42). Nevertheless, the question 
remains how such an accumulation of apoptotic material and NETs can break immunological 
tolerance. After all, it involves an accumulation of endogenous material that is not supposed to 
elicit an autoimmune response.  
 
 
An important hypothesis that gains growing support states that biochemical reactions, such as 
cleavage by caspases and protein modifications by protein modifying enzymes, lead to enrichment 
of protein modifications in not efficiently cleared NETs or apoptotic cells (60). Certain protein 
modifications may give rise to proteins with neoantigens who may act as danger signals with the 
ability to initiate an autoimmune response. Whereas neoantigens in NETs appear to be directly 
exposed to the immune system, apoptotic blebs require to undergo secondary necrosis, a late 
apoptotic stage characterized by the loss of membrane integrity and the leakage of cellular con-
stituents, for exposure of these neoantigens to the immune system (61). Neoantigens may be 
ingested, digested and presented in an immunogenic way by antigen presenting cells (such as 
dendritic cells and macrophages) to autoreactive T cells, who subsequently instruct autoreactive 
B cells to produce autoantibodies against them. The concept of epitope spreading may ultimately 
lead to the wide arsenal of autoantibodies that are characteristic for SLE. An important group of 
proteins in which posttranslational modifications have previously been shown to play an impor-
tant role in (the induction of) autoimmune responses in SLE are histones (62). 
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6. Histone modifications 
 
Histones are a group of chromatin proteins that are abundantly present in apoptotic blebs as well 
as in NETs. Anti-histone autoantibodies are frequently found in SLE and are disease-specific (63). 
Histones play under physiological conditions a critical role in the packaging of nuclear DNA. 
Eukaryotic cells possess five major families of histones: H1/H5, H2A, H2B, H3 and H4. Histones 
H2A, H2B, H3 and H4 are known as the core histones: two copies of each of the four core histones 
assemble and are wrapped with ~146 base pairs of DNA to form the fundamental unit of 
chromatin, also known as the nucleosome. Histones were originally thought to solely function as 
a static scaffold for DNA packaging. Nowadays it is evident that histones are highly dynamic 
proteins, undergoing multiple types of post-translational modifications (PTMs) that regulate vital 
processes within the cell such as transcription, replication, recombination and DNA repair. PTMs 
on histones mainly occur at the N-terminal tails and include (but are not limited to) acetylation, 
methylation, ubiquitination, poly(ADP-ribosyl)ation and citrullination. These PTMs are described 
below, with a focus on modifications associated with cell death, which have been specifically 
related to autoimmune situations such as SLE (Figure 1). 
 
 
6.1. Acetylation 
 
Acetylation and deacetylation of lysine residues at the N-terminal tails of histones plays an 
important role in the regulation of transcription. Acetylation removes positive charges, thereby 
reducing the affinity between histones and DNA and maintaining an open and accessible 
conformation of DNA that is available for the binding of factors of the transcriptional machinery. 
Acetylation and deacetylation reactions are catalyzed by enzymes with histone acetyltransferase 
(HAT) or histone deacetylase (HDAC) activity, respectively. Various studies have investigated the 
significance of histone acetylation in SLE. Hypoacetylation of histones H3 and H4 has been found 
in CD4+ T cells from SLE patients and splenocytes from MRL/lpr mice (64, 65). Treatment of these 
MRL/lpr mice with histone deacetylase inhibitor Trichostatin A reset the hypoacetylation of 
histones H3 and H4 and lead to an improved disease phenotype. In addition, it has been shown 
that mice deficient in histone acetyltransferase p300 develop an autoimmune disease similar to 
SLE in its pathological manifestations (66). Altered histone acetylation in unstimulated disease-
relevant cells has been primarily linked to an altered gene expression. In contrast to unstimulated 
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cells, apoptotic blebs or NETs from SLE patients contain hyperacetylated histones when compared 
to healthy donors (submitted data of our group). Hyperacetylation of histones appears to occur 
early during cell death. In the past, our group showed that hyperacetylated nucleosomes and 
acetylated histone peptides display an enhanced capability in activating the immune system (67). 
Hyperacetylated nucleosomes were able to mature  bone marrow-derived  dendritic cells (DCs) in  
 
 
 
 
 
 
 
 
 
Figure 1. Impaired clearance of apoptotic cells and/or neutrophil extracellular traps (NETs) leads to an 
enduring exposure of modified histones to the immune system. Insufficiently cleared apoptotic cells by 
macrophages (Mɸ) undergo secondary necrosis (SNeC), thereby externalizing autoantigens such as 
histones that become highly modified by histone-modifying enzymes (HME) during cell death. Modified 
histones are also highly present in NETs, which are also not properly cleared in SLE due to 
polymorphisms in the DNase I gene (not shown), inhibitory anti-DNase I autoantibodies or NET-bound 
proteins such as HMGB1, LL-37, C1q (not shown) and NET-bound autoantibodies (anti-NET) that prevent 
the accessibility for DNase I to the NET. The PTMs that are shown are associated with apoptosis (purple), 
NETosis (red)  or both (green) and are linked to the autoimmune response in patients with SLE.  
 
 
 
Citrullination   Methylation  Ubiquitination  Acetylation  Poly(ADP-ribosyl)ation 
 
 
 
 
 
 
 
 
 
 
vitro, which produced increased levels of IL-6 and TNF-α compared with DCs cultured in the 
presence of normally acetylated nucleosomes. In addition, DCs cultured in the presence of hyper-
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acetylated nucleosomes were able to activate syngeneic T cells. Furthermore, subcutaneous ad-
ministration of a specific tri-acetylated H4 peptide to pre-diseased MRL/lpr mice significantly 
enhanced mortality, proteinuria, skin lesions and glomerular IgG depositions. In addition to a 
direct immunogenic effect, it is speculated that hyperacetylated histones in apoptotic blebs or 
NETs enhance the recruitment and binding of ‘dangerous’ antimicrobial peptides such as LL-37, 
HMGB1 and HNPs. It has been shown that these antimicrobial peptides display a high 
immunogenic potential in NETs (59). Our group showed that autoantibodies in SLE patients 
frequently target acetylated epitopes in the N-terminal tails of histones H2A, H2B and H4. We 
characterized two monoclonal autoantibodies derived from MRL/lpr mice, KM-2 and LG11-2, that 
recognize tri-acetylated H4 at lysines 8, 12 and 16 and acetylated H2B (K12), respectively (67, 68). 
Both autoantibodies showed an increased reactivity with histones isolated from apoptotic cells 
and also from NETs (submitted data of our group), suggesting that these modifications are 
associated with apoptosis and NETosis. Another study also showed that IgG autoantibodies from 
histone-reactive SLE patients show high reactivity for acetylated H2B, whereas an increase in H4 
acetylated at lysine 5 in NETs was demonstrated as well (36).  
 
6.2. Methylation 
 
Histone methylation is the process by which methyl groups are transferred by histone 
methyltransfer-ases (HMTs) to lysine or arginine residues of histones. Similar to acetylation, 
histone methylation regulates transcription and silencing of genes, depending on the target sites. 
Di-methylation of H3 at lysine 9 and mono-, di- and tri-methylation of H4 at lysine 20 increases 
upon NETosis (36). Methylation of histone H4 at lysine 20 has also been associated with apoptosis 
(69). Our group recently demonstrated that autoantibodies present in the plasma from SLE mice 
and patients preferentially recognize tri-methylated H3 at lysine 27 (70). This latter reactivity was 
specific for SLE as there was hardly any reactivity in plasma samples from patients with 
rheumatoid arthritis or systemic sclerosis and healthy controls. Tri-methylation of H3 at lysine 27 
also increases upon NETosis, as demonstrated by Liu et al. in ATRA-differentiated HL-60 cells (36). 
In our hands, this epitope is also highly present in NETs formed by primary neutrophils (submitted 
data of our group). Methylation of histones seems to be associated with an increased immuno-
genic potential of chromatin, similar to the aforementioned acetylation of histones, but additional 
research is required to unravel the exact mechanisms. 
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6.3. Ubiquitination 
 
The process of ubiquitination involves the conjugation of ubiquitin to other cellular proteins, 
thereby regulating a broad range of eukaryotic cell functions such as apoptosis, antigen 
processing, DNA transcription and repair, cell division and immune responses. Ubiquitination may 
signal proteins for their degradation via the proteasome, alter their cellular location, affect their 
activity and promote or prevent protein-protein interactions. In human, 10% of all H2A proteins is 
monoubiquinated at lysine 119 (UH2A) (71). Autoantibodies against UH2A are frequently found in 
SLE and appear to be disease-specific (72). Between 60 to 70% of SLE patients are positive for anti-
UH2A autoantibodies, compared to 10% of patients with systemic sclerosis. In rheumatoid 
arthritis, juvenile chronic arthritis or Sjögren’s syndrome these autoantibodies are virtually absent. 
Deposits of UH2A have been identified in more than 50% of the renal biopsies from SLE patients 
with glomerulonephritis (73). Disappearance of UH2A (deubiquitination) is linked to late apoptotic 
processes and is likely to be disturbed in SLE (74, 75). Polymorphisms in the TNFAIP3 gene, the 
gene that encodes for the deubiquitinating enzyme A20, are highly associated with SLE (76). These 
polymorphisms lead to a reduced expression of A20 and result in increased ubiquitination, as 
demonstrated by Jury et al. in T cells from SLE patients (77). Due to the inhibitory effect of A20 on 
the NFκB signaling pathway, TNFAIP3 polymorphisms also cause hyperactive NFκB signaling. The 
ribunocleoprotein SSA/Ro is, in addition to UH2A, also a ubiquitinated protein that is frequently 
target of SLE autoantibodies (78). Hyperubiquitinated histones released from late apoptotic cells 
or NETs are likely to display an increased antigenicity and immunogenicity, but the underlying 
mechanisms are not fully elucidated yet.  
 
 
 
 
6.4. Poly(ADP-ribosyl)ation 
 
Poly(ADP-ribosyl)ation of proteins involves the addition of poly(ADP-ribose) moieties (PARs), 
mediated by poly(ADP-ribose) polymerases (PARPs). These reactions are involved in cell signaling 
and the control of many cell processes, including DNA repair, telomere maintenance and 
apoptosis. Autoantibodies that bind to PARs or to the two zinc finger motifs of PARPs are 
frequently found in patients with autoimmune rheumatic and bowel diseases, including SLE (79-
81). Anti-PARP autoantibodies do not significantly affect the enzyme activity of PAPRs, but prevent 
the cleavage of PARPs by caspase-3 (82). This cleavage is important in the proper execution of 
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apoptosis. Inefficient cleavage of PARPs has shown to prolong cell survival ex vivo and may 
therefore cause failure to eliminate autoreactive lymphocytes and sustain autoimmune 
stimulation. Anti-PARP autoantibodies can penetrate cells in relative late stages of apoptosis, 
thereby neutralizing PARP activity. As a result of energy depletion, prolongation of cell survival 
may ultimately result in necrosis, thereby releasing poly(ADP-ribosyl)ated proteins that may 
possess high antigenic and immunogenic potential. It has been shown that oligo(ADP-ribosyl)ated 
histones are involved in the production of anti-PARP autoantibodies in SLE patients (83). Lysine 13 
of H2A, lysine 30 of H2B, lysine 37 of H3 and lysine 16 of H4 have all been identified as ADP-ribose 
acceptor sites (84). 
 
 
 
 
 
 
 
 
 
6.5 Citrullination 
 
Citrullination (also known as deamination) involves the conversion of arginine residues into 
citrulline, a process catalyzed by enzymes known as peptidylarginine deiminases (PADs). While 
most of the previously discussed PTMs are reversible and associated with reversible events 
involved in signal transduction, citrullination is not reversible. Citrullination has an important role 
in the normal function of the immune system, skin keratinization, the insulation of neurons and 
the plasticity of the central nervous system including its essential role in gene regulation. In 
rheumatoid arthritis (RA), autoantibodies to citrullinated proteins (anti-CCP) is considered a key 
pathogenic event. The presence of anti-CCP autoantibodies is a powerful biomarker that allows 
the diagnosis of RA to be made at a very early stage (85). Many groups investigated the role of 
NETs in the production of anti-CCP autoantibodies in RA, as the PAD4-mediated citrullination of 
histones appears the essential initiator for NETosis via decondensation of the chromatin (86). 
Khandpur et al. correlated accelerated NETosis in RA with anti-CCP levels (25), but this correlation 
has raised the following question: if NETosis, initiated by citrullination of histones, plays a 
pathogenic role in both RA and SLE, then why is the presence of anti-CCP autoantibodies highly 
sensitive and specific for RA only and not for SLE? Hence, anti-CCP autoantibodies are present in 
only 10-30% of SLE patients compared to 80-90% of RA patients (87, 88). Interestingly, SLE patients 
with arthritis are significantly more positive for anti-CCP than those without arthritis, suggesting 
that these autoantibodies have a predictive value for the development of arthritis in SLE (89). A 
groundbreaking publication by Romero et al. questions the contribution of NETs to anti-CCP 
production (90). This group showed that proteins highly present in RA synovial fluid cells become 
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hypercitrullinated due to membranolysis of these cells by perforins and the membrane attack 
complex (MAC) of the complement system. This membranolysis results in a massive calcium influx 
that activates PADs to citrullinate various substrates, such as vimentin, fibronectin and α-enolase. 
Although it seems that citrullinated histones, present in NETs and to a lesser extent also in 
apoptotic blebs, do not exert an important role in the induction of anti-CCP autoantibody 
production, they may still play a pathogenic role. To our knowledge, studies about the immuno-
genic effects of citrullinated histones in NETs or apoptotic cells have not yet been conducted. The 
antimicrobial peptide LL-37 is highly present in NETs from SLE patients and has recently been 
found to be also a substrate of PADs (91). Citrullinated LL-37 showed to be more chemotactic to 
PBMCs and more pro-inflammatory compared to unmodified LL-37. Comparable results may also 
hold for citrullinated histones, although additional research is required.  
 
7. Concluding remarks 
 
The exact etiopathogenesis of SLE is far from understood. Many different environmental factors 
are believed to act together to induce SLE in those who are genetically predisposed. There is a 
growing body of evidence that shows that disturbances in two cell death pathways, apoptosis and 
NETosis, are causative for initiating the disease or amplifying existing disease. However, the 
relative contribution of apoptosis and NETosis to the genesis of SLE is unclear and is likely to differ 
from patient to patient. Regardless of this, it is assumed that disturbances in both cell death 
pathways interact with each other and create multiple positive feedback loops that lead to 
chronification or exacerbation of the disease (Figure 2). Despite the heterogeneity in the 
underlying (molecular) defects and pathways that cause SLE, it appears that accumulation of 
apoptotic material and NETs in tissues is the common denominator between all patients with SLE. 
Enrichment of protein modifications, and in particular specific histone modifications in not 
efficiently cleared apoptotic cells or NETs, may generate neoantigens/danger signals with an 
increased antigenic and immunogenic potential. In addition to PTMs, another process to be 
considered in the generation of neoantigens/danger signals is proteolytic cleavage of histones and 
other chromatin-associated proteins by for example caspases, neutrophil elastase and/or 
cathepsins. It is conceivable that chromatin-derived PTMs and/or cleavage products, related to 
apoptosis and/or NETosis, specifically ligate to receptors on antigen presenting cells, thereby 
activating these cells and resulting in their immunogenic presentation. Improving or intensifying 
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the clearance of apoptotic cells and/or NETs may prevent the formation of immunogenic nuclear 
autoantigens. In addition, neutralizing and tolerizing strategies using specific chromatin-derived 
PTMs related to apoptosis and/or NETosis may represent future therapies for SLE. 
 
 
 
 
 
 
 
 
Figure 2. Positive feedback loops arising from the interaction between apoptosis and NETosis, leading to 
chronification and/or exacerbation of SLE. Modified autoantigens, derived from apoptotic cells, may be 
presented by antigen presenting cells to autoreactive T cells, which can lead to the production of 
autoantibodies by B cells, including anti-dsDNA or anti-RNP antibodies. These autoantibodies can induce 
NETosis or form immune complexes with their antigen(s). Immune complexes deposit on basal 
membranes, and incite a local inflammation (organ damage), or stimulate plasmacytoid dendritic cells 
to produce IFN-α and other pro-inflammatory cytokines. Pro-inflammatory cytokines such as IL-1β, TNF-
α or IFN-α induce NETosis or prime neutrophils for NETosis: NETs may serve as B cell autoantigens and 
lead to further autoantibody production or directly cause organ damage. Proteins from neutrophil 
granules, present in NETs, have shown to be highly toxic to glomerular structures and endothelium. 
Endothelial or glomerular damage causes further production of pro-inflammatory cytokines and leads 
to a new load of apoptotic cells. 
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1.  Abstract 
 
Circulating chromatin-containing apoptotic material and/or neutrophil extracellular traps (NETs) 
have been proposed as an important driving force for the anti-chromatin autoimmune response 
in patients with systemic lupus erythematosus (SLE). We aimed to determine the exact nature of 
microparticles that circulate in SLE patients, and assess their effects on the immune system. For 
this purpose, we analyzed microparticles isolated from plasma of patients with SLE, rheumatoid 
arthritis (RA) or systemic sclerosis (SSc), and healthy subjects, and determined their effects on 
blood-derived DCs and neutrophils. In SLE patients, we identified microparticles highly positive for 
annexin V and apoptosis-modified chromatin, not present in healthy subjects or RA and SSc 
patients. These microparticles were mostly CD31+/CD45- (endothelial), partially CD45+/CD66b+ 
(granulocyte), and negative for B and T cell markers. Microparticles isolated from plasma of SLE 
patients increased the expression of co-stimulatory surface molecules CD40, CD80, CD83 and 
CD86 and production of pro-inflammatory cytokines IL-6, TNF-α and IFN-α by blood-derived 
plasmacytoid dendritic cells (pDCs) and myeloid dendritic cells (mDCs). SLE microparticles also 
primed blood-derived neutrophils for NETosis. Microparticles from healthy subjects and RA or SSc 
patients exhibited no significant effects on mDCs, pDCs and NETosis. In conclusion, circulating 
microparticles in SLE patients include a population of apoptotic cell-derived microparticles that 
has pro-inflammatory effects on pDCs and mDCs, and enhances NETosis. These results underline 
the important role of apoptotic microparticles in driving the autoimmune response in SLE patients. 
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2.  Introduction 
 
Microparticles are generally defined as small vesicles with a size between 100 nm and 1 µm which 
are formed by budding of the cell membrane upon stimulation or during the late stages of 
apoptosis (1). Circulating microparticles are ubiquitous in the blood of healthy individuals, where 
they are mostly derived from (activated) platelets or erythrocytes and to a lesser extent from 
(activated) endothelial and immune cells. These microparticles play an active role in coagulation 
and intercellular communication, and assist in activation or suppression of the immune system 
depending on their parental cell origin (2). Changes in the concentration and/or composition of 
circulating microparticles have been described in various autoimmune diseases, including 
rheumatoid arthritis (3), systemic sclerosis (4), polymyositis/dermatomyositis (5), and SLE (6-10). 
For SLE, the reported microparticle-related changes remain somewhat inconclusive. Especially the 
identification and characterization of circulating microparticles derived from apoptotic cells, 
which have been proposed as an important trigger for the anti-chromatin autoimmune response 
that typically occurs in SLE patients (11-12), has not been assessed.  
 
 
 
 
 
Processing of potential damage-associated molecular patterns (DAMPs) during apoptosis largely 
determines whether the immune system will react to dying cells or not (13). In general, DAMPs 
remain hidden inside the cell during early apoptosis, while later on DAMPs can be released. The 
role of apoptotic microparticles in the processing of DAMPs is still unclear, although they contain 
potential DAMPs like HMGB1 (14) and IL-1α (15). Additionally, the basic components of chromatin, 
DNA and histones, have been identified as ligands for pattern recognition receptors TLR-2, TLR-4, 
and TLR-9 (16-18). Interestingly, mice lacking caspase-activated DNase are unable to form 
apoptotic microparticles, and were protected against a pristane-induced autoimmune response 
against chromatin (19). We have previously shown that apoptotic microparticles could stimulate 
murine bone marrow-derived dendritic cells (DC), while apoptotic cell bodies that remain after 
the release of microparticles did not (20-21).  
 
 
 
 
In addition, we have observed that specific apoptosis-associated histone modifications, which are 
targeted by lupus autoantibodies, are incorporated in in vitro generated apoptotic microparticles 
(22-24). These histone modifications include acetylation of H4-K8,12,16, acetylation of H2B-K12, 
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and trimethylation of H3-K27. Importantly, hyperacetylated nucleosomes, and not non-apoptotic-
derived nucleosomes, could induce maturation of murine bone marrow-derived DC (22). Injection 
of a H4-K8,12,16ac peptide in pre-diseased lupus mice aggravated disease symptoms, while injec-
tion of the unmodified peptide equivalent exhibited no effect on lupus disease. Others have also 
observed that apoptotic microparticles have the capacity to activate murine and human DC; 
however, studies regarding the contents and immunological effects of apoptotic microparticles 
focused so far on in vitro generated microparticles (25-29). In addition to apoptotic microparticles, 
neutrophil extracellular traps (NETs) have recently been proposed as a potential source for 
circulating chromatin in SLE patients (30-34). 
 
 
 
In this study, we investigated the presence, contents and origins of apoptotic microparticles in 
plasma of SLE patients and evaluated their potential role in the activation of blood-derived 
dendritic cells and neutrophils. 
 
 
 
 
3.  Materials and Methods 
 
Patients. Blood samples from patients with biopsy-proven proliferative lupus nephritis (WHO class 
III, IV, Vc or Vd), rheumatoid arthritis, systemic sclerosis or healthy controls were collected at the 
Radboud University Medical Center. All patients with SLE had ≥ 4 American College of Rheu-
matology (ACR) criteria (35). Disease activity was measured with the SLE disease activity index 
(SLEDAI) (36). The use of blood was approved by the local ethics committee and by written consent 
from the patients and healthy controls. 
 
 
 
Isolation and characterization of microparticles. Plasma was centrifuged for 5 minutes at 500g 
and subsequently the supernatant was centrifuged for 10 minutes at 20.800g at 4°C. The pellet 
containing the microparticles was washed with PBA (PBS containing 0.1% BSA) and microparticles 
were incubated with monoclonal antibodies for 30 minutes at 4°C. For staining of chromatin in 
microparticles, we employed a panel of lupus-derived monoclonal antibodies consisting of #34 
(anti-H3, ref 37), KM-2 (anti-H4-K8,12,16ac, ref 22), BT164 (anti-H3-K27me3, ref 23), and LG11-2 
(anti-H2B-K12ac, ref 24). Purification of these monoclonal antibodies was performed as described 
before (22-24, 37). The specificity for each batch of purified monoclonal antibody was validated 
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by comparing the reactivity in ELISA with the respective modified histone peptide,  H3(18-37) (#34) 
H4(1-22)-K8,12,16ac (KM-2), H2B(1-18)-K12ac (LG11-2) and H3(21-34)-K27me3 (BT164) and its 
unmodified equivalent. After washing, microparticles were incubated with Alexa 488-conjugated 
goat anti-human-Ig(H+L) (Life Technologies) for 20 minutes at 4°C. After washing, samples were 
analyzed using a FACS Calibur flow cytometer (BD Biosciences). All buffers were filtrated through 
a 0.2 µm filter, and buffers without plasma-derived microparticles exhibited a neglectable amount 
of counts. Where indicated, plasma-isolated microparticles were stained with PE-conjugated anti-
CD3 (UCHT1, Beckman Coulter), anti-CD19 (J3-119, Beckman Coulter), anti-CD31 (WM59, BD 
Biosciences) or mouse IgG1 (MOPC-21, BD Biosciences), and/or FITC-conjugated anti-CD45 (J33; 
Beckman Coulter), anti-CD66b (80H3, Beckman Coulter) or mouse IgG1 (MOPC-21, BD 
Biosciences). Additionally, microparticles were taken up in Annexin V-buffer and stained with FITC-
conjugated Annexin V according to the manufacturer’s protocol (BioVision). For determining the 
concentration of microparticles, AccuCheck calibrated beads were added according to the 
manufacturer’s protocol (Life Technologies). For experiments with DCs, microparticles were 
isolated according to the method described above, subsequently the microparticle pellet was 
resuspended in the same volume of medium without serum, and the protein concentration was 
determined using the bicinchoninic acid assay (Sigma-Aldrich). Hereafter, serum was directly 
added to the microparticle preparation and adjusted to acquire equal amounts in microparticle-
derived protein equivalents. 
 
 
 
 
Isolation of pDCs and mDCs. Buffy coats were obtained from volunteers according to institutional 
guidelines and after written consent. CD1c+ mDCs and pDCs were purified by positive selection 
using anti-CD1c- and anti-BDCA-4-conjugated magnetic microbeads, respectively (Miltenyi 
Biotec), as described previously (38). Purity was routinely up to 95%, as assessed by double 
staining BDCA-2+/CD123+ for pDCs and CD11c+/CD1c+ for mDCs (Miltenyi Biotec). pDCs (with 10 
ng/ml recombinant human IL-3 (Cellgenix)) and mDCs were cultured overnight in X-VIVO 15 
medium (Lonza) with 2% human serum, at a concentration of 105 cells/100 µl/well in a 96-well 
round bottom plate. To determine the effect of microparticles on pDCs and mDCs, microparticles 
were isolated from plasma as described above and added for 16 hours at a concentration of 20% 
(v/v). As a positive control for activation, pDCs and mDCs were activated overnight in the presence 
of 5 mg/ml R848 (M362, Axxora) or 1 µg/ml LPS (tlrl-3pelps, InVivogen), respectively. 
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Flow cytometry and enzyme-linked immune sorbent assay (ELISA). The phenotype of pDCs and 
mDCs was determined using PE-conjugated anti-CD80, anti-CD83, and mouse IgG1; APC-
conjugated CD86 and mouse IgG1 (all BD Bioscience) and PE-conjugated anti-CD40 (Beckman 
Coulter). For determination of cytokine production, supernatants were collected from pDC/mDC 
cultures after 16 h of incubation. IFN-α and IL-6 production was analyzed by standard ELISA 
techniques using murine monoclonal capture and HRP-conjugated anti-IFN-α antibodies (Bender 
MedSystems) or anti-IL-6 antibodies (Sanquin). TNF-α production was measured using a human 
TNF-α ELISA kit according to the manufacturer’s protocol (BD Biosciences). 
 
 
 
 
Induction and analysis of NETosis. PMNs were isolated from EDTA-anticoagulated whole blood 
using Lymphoprep (Stemcell Technologies), as previously described (39). Isolated PMNs were then 
stimulated for 3 hours with either 10 µg/ml LPS (E. coli O55:B5, Sigma-Aldrich) alone or a 
combination of 10 µg/ml LPS with 20% (v/v) plasma-derived microparticles. Subsequently, NETs 
were harvested with 5 U/ml micrococcal nuclease (MNase; Worthington Biochemical Corporation) 
and quantified by measuring NET-derived DNA content on a Tecan Infinite® 200 PRO multimode 
reader with Sytox Orange (Life Technologies). All measurements were confirmed by immuno-
fluorescence microscopy on an Axio Imager M1 fluorescence microscope (Zeiss).   
 
 
 
Statistics. Values are expressed as mean ± SEM of at least three experiments. Significance was 
either determined by Student’s t-test, Mann-Whitney U, or one-way ANOVA followed by 
Bonferroni correction using GraphPad Prism (GraphPad Software). P values less than 0.05 were 
considered as significant. 
 
 
 
4.  Results 
 
Apoptotic microparticles are present in the plasma of SLE patients. We measured the total 
concentration of microparticles in plasma of SLE patients with biopsy-proven proliferative lupus 
nephritis and active disease, and healthy individuals. As shown in Figure 1a, we observed no 
significant difference in the concentration of microparticles between SLE patients and healthy 
individuals. Counted events represented membrane-containing structures, since treatment with 
1% Triton X-100, which destroys membranous particles, completely abolished the population (not 
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shown). Subsequently, we evaluated the presence of apoptosis-modified histones by staining 
isolated microparticles with our panel of monoclonal anti-histone antibodies (22-24, 37). While 
apoptosis-modified histones were largely absent in samples from healthy controls, plasma-
derived microparticles from the majority of SLE patients contained apoptosis-associated 
modifications as probed with mAbs KM-2 and LG11-2 recognizing histone H4-K8,12,16ac and H2B-
K12ac, respectively (Figure 1b). This resulted in significant differences in the MFI signal obtained 
with these mAbs between SLE patients and healthy controls. A similar tendency was observed for 
histone H3 as probed with mAb #34 (anti-H3). In contrast, there was no difference for the staining 
with mAb BT164 (anti-H3-K27me3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Plasma of SLE patients does not contain a higher concentration of microparticles compared to 
healthy subjects, but contain more apoptosis-modified chromatin. (A) The concentration of micro-
particles was determined in plasma of SLE patients (n=27) and healthy controls (NHD; n=11) by flow 
cytometry using 6.4-µm counting beads. (B) Microparticles isolated from plasma of SLE patients and 
healthy controls were stained with mAbs #34 (anti-H3), KM-2 (anti-H4-K8,12,16ac), BT164 (anti-H3-
K27me3) or LG11-2 (anti-H2B-K12ac) and analyzed by flow cytometry. Background of the respective 
microparticles determined by staining with an isotype control (mouse IgG2A) was subtracted. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interestingly, in plasma of SLE patients we observed a particular population of microparticles, 
characterized by a relatively high FSC and low SSC, which was absent in plasma of healthy subjects 
(Figure 2, arrows in left panels). We determined that the size of SLE microparticles was distributed 
between 300 nm and 1.5 µm (Suppl. Figure S1). In addition, SLE plasma-derived microparticles 
contained a population with high Annexin V expression (Figure 2, middle panels), which corres-
A                                         B  
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ponded to the SLE-associated population observed in the FSC/SSC plot (Figure 2, right panels). 
Microparticles positive for mAb LG11-2 (anti-H2B-K12ac) were also predominantly present in this 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Microparticles circulating in SLE patients include a specific population that represents apoptotic 
cell-derived microparticles. Representative examples of a FSC/SSC plot of plasma-derived microparticles 
from two SLE patients (SLE #1 and #2), with different amounts of the SLE-associated population, and 
two examples of healthy controls (NHD #1 and #2). Microparticles were stained with Annexin V-FITC 
(middle panel), and the population highly positive for Annexin V was back-gated into the FSC/SSC plot 
(right panel), as shown for the plasma of 2 SLE patients.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
same population (Figure 3). Similar results were observed for microparticles positive for mAbs KM-
2 and #34 (not shown). Microparticles in plasma of healthy controls were weakly positive for 
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Annexin V and anti-histone mAbs, and no association with a specific FSC/SSC-population was 
found. Concluding, plasma of SLE patients contains a specific population of microparticles, which 
is absent in plasma of healthy subjects. The strong staining for Annexin V and the presence of 
apoptosis-modified histones clearly indicates that these microparticles must originate from 
apoptotic cells. 
 
SLE-derived apoptotic microparticles are primarily derived from endothelial cells. We next 
determined the cellular origin of the apoptotic cell-derived microparticles in SLE patients. Since 
our population of microparticles was positive for chromatin we could exclude non-nucleated 
platelets and erythrocytes as a potential source. The majority of the apoptotic cell-derived  micro-                   
d 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Microparticles circulating in SLE patients include a specific population that represents apoptotic 
cell-derived microparticles. Representative examples are shown of SLE-derived microparticles (panel 1) 
that were stained with anti-histone mAbs #34 (anti-H3), KM-2 (anti-H4-K8,12,16ac), BT164 (anti-H3-
K27me3), LG11-2 (anti-H2B-K12ac) or mouse IgG2A (isotype) (panel 2). Microparticles that were 
positive for LG11-2 were backgated into the FSC/SSC plot (panel 3). 
 
 
 
 
 
 
 
 
particles stained positive for CD31 (Figure 4a), ranging from 65 to 95% between patients (Figure 
4d), which is commonly used as a marker for endothelial cells but is also present on certain hema-
topoietic cells. Subsequently, double staining with CD45, a marker for all hematopoietic cells, 
demonstrated that approximately 15% of the CD31+ apoptotic microparticles were also CD45+. We 
then analyzed markers for T cells (CD3), B cells (CD19) and granulocytes (CD66b) to determine 
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which cell type could be the origin of the CD45+ microparticles. 5-15% of the CD31+ apoptotic cell-
derived microparticles were positive for CD66b (Figure 4b), while apoptotic microparticles were 
negative for CD3 and CD19 (Figure 4c). In sum, circulating microparticles in SLE patients are mostly 
derived from endothelial cells (CD31+/CD45-; ~60%), and to a lesser extent from granulocytes 
(CD31+/CD66b+; ~15%) and other yet unidentified sources (~25%). 
 
 
 
 
 
 
 
 
Figure 4. Apoptotic microparticles in SLE patients are primarily derived from endothelial cells. (A) 
Microparticles isolated from plasma of SLE patients were stained using anti-CD31-PE and anti-CD45-
FITC. The SLE-specific (apoptotic cell-derived) population, based on the FSC/SSC, was gated for further 
analysis (left panel). Representative examples are shown of the single and double staining for CD31 and 
CD45. The respective isotype antibody was used as a control for background staining, and is shown in 
the graph (grey). In addition, SLE-derived apoptotic microparticles were analyzed using anti-CD66b-FITC 
in combination with CD31-PE (B), anti-CD3-PE or anti-CD19-PE (C). (D) The median percentage of 
apoptotic microparticles positive for the different markers is shown for 6-9 SLE patients. 
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SLE-derived microparticles activate blood-derived pDCs and mDCs. We isolated microparticles 
from  plasma  of SLE  patients  or  healthy controls and evaluated their effects on CD1c+ mDCs and 
BDCA4+ pDCs isolated from peripheral blood of healthy donors. Incubation of pDCs with 
microparticles from SLE patients resulted in a significant increase of the expression of the co-
stimulatory molecules CD80, CD83 and CD40, while incubation with healthy control-derived 
microparticles exhibited no significant effect (Figure 5a). Expression of CD86 was not affected by 
addition  of   microparticles  of  SLE  patients  or  healthy controls. Microparticles  from  SLE  patients 
 
 
 
 
 
                               
                               
 
 
 
Figure 5. SLE-derived microparticles have the capacity to stimulate pDCs. Freshly isolated pDCs from 
healthy blood donors were incubated overnight with microparticles isolated from plasma of healthy 
controls (NHD MPs) or SLE patients (SLE MPs) or left unstimulated (with pDCs in the presence of IL-3). 
Subsequently, surface expression levels of co-stimulatory molecules CD80, CD83, CD86 and CD40 were 
determined by flow cytometry (A) and supernatants of stimulated pDC cultures were analyzed for the 
cytokines IFN-α and TNF-α by ELISA (B). R848 was used as a positive control for pDC activation. 
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also induced a more pronounced production of pro-inflammatory cytokines IFN-α and TNF-α in 
pDCs, while microparticles from healthy controls had no effect on cytokine production (Figure 5b). 
When mDCs were incubated with plasma-derived microparticles from SLE patients or healthy 
controls, we observed a small increase in the expression of CD86 (Figure 6a). The expression of 
CD80 and CD83 was only increased in the presence of microparticles from SLE patients, while no 
significant effect of microparticles on the expression of CD40 was found. Furthermore, SLE micro-
particles induced the production of both IL-6 and TNF-α by mDCs (Figure 6b).  
 
 
 
 
 
                              
                          
                              
 
 
 
Figure 6. SLE-derived microparticles have the capacity to stimulate mDCs. Freshly isolated mDCs from 
healthy blood donors were incubated overnight with microparticles isolated from plasma of healthy 
controls (NHD MPs) or SLE patients (SLE MPs) or left unstimulated. Subsequently, surface expression 
levels of co-stimulatory molecules CD80, CD83, CD86 and CD40 were determined by flow cytometry (A) 
and supernatants of stimulated mDC cultures were analyzed for the pro-inflammatory cytokines IL-6 
and TNF-α by ELISA (B). LPS was used as a positive control for mDC activation.  
 
A               CD40                            CD80                   B                  IL-6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                CD83                             CD86                                     TNF-α 
 
 
 
 
 
 
 
 
 
 
Chapter 5 
103 
 
In summary, in contrast to microparticles derived from healthy controls,  microparticles isolated 
from plasma of SLE patients are able to activate both pDCs and mDCs as indicated by a significant 
upregulation of several co-stimulatory molecules and a more pronounced production of inflam-
matory cytokines.        
 
 
Microparticles from RA and SSc patients do not contain chromatin and do not induce DC 
activation. To determine if the above described characteristics of plasma-derived microparticles 
were specific for SLE, we also tested microparticles from plasma of patients with rheumatoid 
arthritis (RA) or systemic sclerosis (SSc). We found that plasma of RA and SSc patients also 
contained an AnV+/CD31+ microparticle population (Figures 7a and 7b). However, these micro-
particles exhibited a low signal for our panel of anti-chromatin mAbs (Figure 7c), which was 
comparable to healthy controls (Figure 1b). In addition, plasma-derived microparticles of RA and 
SSc patients could not induce the production of pro-inflammatory cytokines in pDCs and mDCs 
(Figure 7d). Therefore, the chromatin content and pro-inflammatory capacity of AnV+/CD31+ 
microparticles in SLE is distinct from RA and SSc. 
 
 
 
SLE-derived microparticles enhance NETosis in blood-derived PMNs. NETs have recently been 
associated with propagation of the anti-chromatin response in SLE patients (30-34, 39). We 
hypothesized that a change in the composition of circulating microparticles in SLE patients might 
also influence the formation of NETs by neutrophils. Therefore, we evaluated whether plasma-
derived microparticles could either directly induce NETosis or affect LPS-induced NETosis in blood-
derived polymorphonuclear neutrophils (PMNs). Isolated PMNs from healthy controls incubated 
with microparticles (either derived from plasma of healthy donors or SLE, RA or SSc patients) alone 
did not result in a significant release of NETs (Figure 8). In contrast, incubation of PMNs with a 
combination of SLE microparticles and 10 µg/ml LPS (E. coli, serotype O55:B5) resulted in robust 
NET formation, whereas microparticles from healthy donors or RA and SSc patients did not 
influence NETosis (Figure 8). Interestingly, LPS alone failed to induce NET formation, which is in 
agreement with work from others who show that LPS alone may not be sufficient to induce 
NETosis but that additional ‘priming’ stimuli (e.g. GM-CSF, IL5/IFNg) are required (40). In con-
clusion, circulating microparticles derived from SLE patients specifically prime neutrophils for LPS-
induced NETosis in blood-derived neutrophils. 
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Figure 7. Microparticles derived from plasma of rheumatoid arthritis (RA) and systemic sclerosis (SSc) 
patients contain low amounts of chromatin and do not stimulate DCs. (A) Representative examples of a 
FSC/SSC plot of plasma-derived microparticles from a RA and SSc patient. (B) Microparticles from RA 
and SSc patients were stained with Annexin V-FITC or for CD31. The percentage of positive micro-
particles is shown for 5 RA and 5 SSc patients. (C) Plasma-derived microparticles of RA and SSc patients 
were stained with mAbs #34 (anti-H3), KM-2 (anti-H4-K8,12,16ac), BT164 (anti-H3-K27me3) or LG11-2 
(anti-H2B-K12ac) and analyzed by flow cytometry. (D) Supernatants of microparticle-stimulated pDC 
and mDC cultures were analyzed for the pro-inflammatory cytokines IFN-α, IL-6 and TNF-α. Error bars 
represent at least 5 individual donors.  
 
 
 
 
 
 
 
 
5. Discussion 
 
We show that microparticles present in the circulation of SLE patients have different 
characteristics compared to those in healthy controls. In particular, we found that plasma of SLE 
patients possessed a specific microparticle-population with a different size and granularity, which 
was highly positive for annexin V and contained apoptosis-modified chromatin. Although an 
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increase in the concentration of circulating microparticles has been observed in SLE patients (9-
10, 28), we and others found a change in the composition of microparticles without an increase in 
the concentration (6-7). Importantly, we determined the total concentration of microparticles 
without using specific cell markers, while others sometimes used specific cell markers. In addition, 
plasma of RA and SSc patients contained CD31+/AnV+ microparticles as well, but did not contain 
(apoptotic) chromatin as in SLE-derived microparticles. These data are in agreement with existing 
literature (3-4), which describes disease-related changes in endothelial microparticles in these 
autoimmune diseases. Moreover, the absence of microparticles that contain chromatin in RA and 
SSc, is in accordance with the notion that circulating apoptotic chromatin is a hallmark of SLE. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
There are several arguments to conclude that the SLE-associated microparticle-population 
observed in our study was derived from apoptotic cells. First, the presence of modified histones 
in the microparticles indicates that apoptosis is involved, since the translocation of chromatin into 
Figure 8. SLE-derived microparticles (MPs) prime 
neutrophils for LPS-induced NETosis. Freshly 
isolated PMNs from healthy donors release NETs 
in response to a combination of 10 µg/ml LPS and  
20% (v/v) SLE-derived microparticles, as deter-
mined by fluorometry (A) and immunofluor-
escence microscopy (B). In contrast, micropar-
ticles from normal healthy donors (NHD) or RA 
and SSc patients did not prime neutrophils for 
LPS-induced NETosis. 
NHD MPs              SSc MPs                 RA MPs                   SLE MPs 
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microparticles exclusively occurs during cell death. Second, the increase in forward scatter of the 
SLE-specific microparticle population as observed with flow cytometry, fits with previous 
observations of an increased size of apoptotic microparticles as compared to microparticles 
released by living cells (1). Furthermore, the SLE-specific microparticle population expresses phos-
phatidylserine which is massively externalized during apoptosis. Finally, we could demonstrate 
that our flow cytometry results should indeed be attributed to microparticles, and not to protein 
complexes as described by György et al. (41-42), since treatment with 1% Triton X-100 abolished 
the population (not shown). 
 
 
 
Based on the expressed surface molecules, we could show that SLE-associated microparticles 
originate mostly from endothelial cells and partially from granulocytes. To our knowledge, this is 
a first clue to the origin of circulating apoptotic microparticles in SLE patients. In addition, these 
findings support a recent study that demonstrated an increase of endothelial-derived micro-
particles in SLE patients with active disease, which was reduced after immunosuppressive therapy 
(43). Interestingly, injection of microparticles derived from apoptotic endothelial cells induces an 
inflammatory response in mice (15). Although circulating endothelial microparticles are 
sometimes used as a marker for endothelial damage in patients (44), including those with renal 
disease (45), these studies did not specifically examine well-defined apoptotic microparticle 
populations. Instead, these studies included microparticles derived from activated, non-apoptotic 
endothelial cells. Nonetheless, we cannot exclude that vascular damage contributes to the gene-
ration of apoptotic endothelial microparticles in our cohort of SLE patients. In addition, as all of 
our patients were experiencing active (renal) disease at the time of plasma-retrieval, micro-
particles from other sources could play a more prominent role during the initial disease phase. 
 
 
 
Importantly, we could demonstrate that microparticles isolated from plasma of SLE patients can 
activate blood-derived pDCs and mDCs, while microparticles from plasma of healthy controls or 
RA and SSc patients did not exhibit such an effect. This is in line with previous experiments using 
apoptotic microparticles that were generated in vitro after induction of apoptosis in either cell 
lines or blood-derived cells (20-21, 25-27). We particularly observed an increase in the production 
of pro-inflammatory cytokines, while the increased expression of co-stimulatory molecules was 
less pronounced. IFN-α production is independent of NF-κB activation in pDCs, and therefore it is 
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possible to dissociate CD80-and CD86 induction from IFN-α. However, one would expect that TNF-
α and IL-6 production would coincide with CD80, CD83 and CD86 expression. Others have also 
found this discordance between cytokine production and the expression of co-stimulatory 
molecules (26, 33), which could be explained by the difference in the type and sensitivity of the 
assay used (flow cytometry versus ELISA).  
 
The mechanisms involved in microparticle-induced activation of DCs is not completely clear. While 
activation of mDCs by apoptotic microparticles was found to be independent on cytosolic TLRs 
(20), TLR9 was implicated in the sensing of microparticle-derived DNA (27). Importantly, the latter 
occurred independently of FcγRIIA, in contrast to activation by nucleic acid-containing immune 
complexes (46). We suggest that apoptosis-modified histones in microparticles can interact with 
cell surface receptors such as TLR2 and TLR4 (16), which have been implicated in the pathogenesis 
of SLE (47-49). Further experiments would be needed to further unravel the exact receptors and 
pathways used by microparticles to activate mDCs and pDCs. Finally, we found that SLE-derived 
microparticles, but not RA- and SSc-derived microparticles, primed neutrophils for LPS-induced 
NETosis. The formation of NETs in SLE patients has been associated with activation of neutrophils 
by nucleic acid-containing immune complexes (33-34). Regarding microparticles, only an effect of 
placental microparticles on the formation of NETs has been demonstrated (50). Our findings imply 
that the presence of a high concentration of apoptotic microparticles in the circulation of SLE 
patients can enhance the formation of NETs, which amplifies the autoimmune response and 
chronicity of the disease. 
 
In conclusion, apoptotic microparticles have been proposed as an important driver of the 
chromatin-directed immune response in SLE patients. We show that SLE patients have distinct 
apoptotic cell-derived microparticles in their circulation, which have a pro-inflammatory effect on 
pDCs and mDCs, and enhance NETosis. 
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Supplementary Information        Suppl. Fig. 1
 
Figure S1. Characterization of SLE plasma-derived microparticles. (A) Ultra-structural analysis of SLE 
plasma-derived MPs. Representative electron microscopy picture of SLE plasma-derived microparticles. 
The size bar is indicated in the picture. (B) Size determination of the MP-population detected in flow 
cytometry. FSC/SSC plot of SLE plasma-derived microparticles, including calibrated beads of different 
sizes. The size of the calibrated beads is indicated in µm. 
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1.  Abstract 
 
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the presence of 
autoantibodies against nuclear components. Lupus nephritis (LN) is the major cause of morbidity 
and mortality in patient with SLE. Central to the pathogenesis of SLE is the accumulation of cellular 
waste, especially apoptotic microparticles (MPs), which stimulates diverse immune reactions 
including the formation of neutrophil extracellular traps (NETs). In this study, we investigated the 
content of MPs from SLE patients with and without (active) LN, their capacity to stimulate NET 
release and assessed the molecular mechanisms underlying MP-induced NETosis. For this 
purpose, MPs from SLE patients with biopsy-proven active LN, remissive LN, without LN and 
healthy controls were characterized by flow cytometry. Isolated neutrophils were exposed to MPs 
derived from either patient plasma or apoptotic human umbilical vein endothelial cells (HUVEC), 
and NET release was quantified by immunofluorescence imaging, spectrofluorometry or an in-
house developed NET ELISA. Furthermore, we assessed the ability of endonucleases to degrade 
NET-derived DNA in our patient cohort. Here, we report that MPs from SLE patients with active LN 
contain higher levels of acetylated chromatin compared to MPs from those with remissive LN, 
without LN or healthy controls. MPs enriched in hyperacetylated chromatin are more potent in 
inducing NETosis when compared to MPs containing moderate acetylated chromatin. The release 
of NETs in response to MPs occurs rapidly (< 1 hour) in a concentration-dependent manner and 
proceeds independent from the formation of reactive oxygen species (ROS). Circulatory 
endonucleases from patients with active or remissive LN are unable to degrade NETs, in contrast 
to endonucleases from patients without LN or healthy individuals. Altogether, our data implicate 
that MPs containing acetylated chromatin drive ROS-independent NET release in SLE patients with 
active LN, which in combination with the inability to degrade NETs may lead to the glomerular 
deposition of NETs and subsequent NET-driven lupus nephritis. 
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2.  Introduction 
 
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the presence of 
autoantibodies against nuclear antigens, such as nucleosomes, DNA and histones (1). Immune 
complexes of autoantibodies and chromatin form depositions and trigger serious inflammatory 
conditions in multiple organs, including lupus nephritis (LN) in the kidneys. LN is a major cause of 
morbidity and mortality in patients with SLE and causes proteinuria and a gradual decline of kidney 
function (2-4). During disease course, states of quiescent disease can alternate with periods of 
active disease, so called flares. Although the triggers of these flares are largely unknown, they lead 
to increased production of autoantibodies and enhancement of  inflammatory processes (5-7). 
 
The presence of nuclear antigens in the circulation of patients with SLE can be explained by 
increased apoptosis and/or an impaired clearance of apoptotic cells. An imbalance in the 
formation and clearance of apoptotic material leads to the continuous presence of apoptotic cell-
derived constituents within the extracellular space, thereby triggering immune reactions by innate 
and adaptive immune cells (8-12). Apoptotic cells can give rise to the formation of microparticles 
(MPs), which are small vesicles generally defined as ˂ 1 µm in size that carry a range of 
immunostimulatory proteins, including apoptosis-modified chromatin enriched in methylated and 
particularly acetylated histone residues (13-15). MPs have been identified and characterized in 
plasma of SLE patients and were previously shown to be highly pro-inflammatory (16, 17). 
Especially MPs derived from endothelial cells carry the aforementioned histone modifications 
(16). Autoantibodies against these apoptosis-associated histone modifications can be found in 
patients with SLE, suggesting that these modifications play a role in breaking immunological 
tolerance (5, 18-20). 
 
In addition to apoptosis, abnormalities in the formation and degradation of neutrophil 
extracellular traps (NETs) have been linked to the autoimmune response in SLE and in particular 
to the development of LN (21). NETs are formed during a specialized cell death program of 
neutrophils, referred to as NETosis, and are generally described as web-like structures composed 
of DNA and antimicrobial proteins, e.g. myeloperoxidase (MPO) and neutrophil elastase (NE) (22). 
Although being essential for antimicrobial defense, NETs can also cause tissue damage and evoke 
autoimmune responses, when persistently present in the extracellular space (23-25).  
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Recently, we showed that MPs from patients with SLE but not MPs from patients with other 
autoimmune diseases can activate blood-derived dendritic cells and induce the formation of NETs 
(16). However, the reason for the increased immunogenicity of MPs from patients with SLE re-
mained unanswered. Moreover, the mechanisms by which MPs induce NET formation remained 
to be established. In the present study, we investigated the mechanisms and clinical relevance of 
MP-induced NETosis in SLE. For this purpose, we characterized MPs from SLE patients with active 
LN, SLE patients with LN in remission, SLE patients without LN and healthy controls, and evaluated 
their capacity to stimulate NETosis. Furthermore, we used in vitro generated endothelial cell-
derived MPs to unravel the mechanisms underlying MP-induced NETosis. Overall, we show that 
acetylated chromatin present within apoptotic MP determines their potency to elicit NETosis in 
SLE patients with active LN. 
 
3.  Materials & Methods 
 
Human material. Blood samples were collected from SLE patients and healthy controls that either 
participated in the Dutch SLE Nephritis Study (26) or in subsequent studies at the Radboud 
University Medical Center, The Netherlands. All patients fulfilled at least 4 American College of 
Rheumatology criteria for SLE and were either defined as patients with (i) active LN, (ii) remissive 
LN or (iii) without LN. Patients with active LN were defined as having glomerular hematuria or 
proteinuria of ≥ 0.5 g/24 hours and LN was confirmed by renal biopsy. Patients with active LN were 
longitudinally followed and new blood was retrieved at the time proteinuria was ≤ 0.5 g/24 hours 
and/or hematuria had disappeared (remissive LN). Patients with LN were treated with cyclophos-
phamide or a combination of azathioprine and methylprednisolone pulses, both combined with 
oral prednisone until reaching criteria for remission. Blood samples of patients categorized as 
active LN were collected before the start of treatment. Clinical parameters, such as C3 levels, anti-
dsDNA titers, creatinine and proteinuria, and SLE disease activity index (SLEDAI (27)) were 
determined in our diagnostic facility by routine measurements (Suppl. Table 1). The collection of 
human blood samples was approved by the ethics committees of all participating hospitals. 
Written informed consent was obtained from all subjects. 
 
 
 
 
 
 
 
 
 
Isolation of MPs. Whole blood was centrifuged for 10 min at 3,000g and platelet-poor plasma was 
isolated and stored at -80°C until further use. For the isolation of plasma-derived MPs, plasma was 
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thawed and diluted in PBS and centrifuged for 5 min at 500g at 4°C. Subsequently, the supernatant 
was centrifuged 10 min at 20,800g at 4°C. The pellet of MPs was resuspended in DMEM/F12 
medium and adjusted to indicated MP concentrations for their use in co-culture experiments with 
neutrophils or stained for flow cytometry. 
 
In vitro generation of endothelial cell-derived apoptotic MPs. Human umbilical vein endothelial 
cells (HUVEC), isolated from umbilical cords by perfusion and 20 min. incubation with trypsin at 
37°C, were maintained in fibronectin-coated Corning cell culture flasks (Sigma-Aldrich) in EGM2-
medium supplemented with 2% FCS and EGM-2 SingleQuots (Lonza). HUVEC were cultured in a 
humidified incubator with 5% CO2 at 37°C. Apoptosis in HUVEC was induced by treatment with 10 
µM 4 nitroquinoline 1 oxide (4-NQO; Sigma-Aldrich) for 24 hours. Culture supernatants were then 
centrifuged (5 min, 500g, 4°C) to remove large cellular debris, followed by an additional centri-
fugation step (10 min, 20,800g, 4°C) to pellet endothelial cell-derived MPs. The pellet of MPs was 
resuspended in DMEM/F12 medium for use in neutrophil co-culture experiments or stained for 
flow cytometry. Where indicated, HUVEC were pre-treated with the histone deacetylase inhibitor 
trichostatin A (Sigma-Aldrich) for 24 hours prior to the induction of apoptosis to generate MPs 
enriched in hyperacetylated chromatin. 
 
Flow cytometry. Isolated MPs were extensively washed with PBS containing 0.1% bovine serum 
albumin (BSA), and incubated for 30 min at 4°C with the monoclonal anti-histone antibodies KM-
2 (anti-H4K8,12,16Ac (13)) and LG11-2 (anti-H2BK12Ac (14)) or their appropriate isotype controls 
(UPC-10; Sigma). MPs were subsequently incubated for 30 min at 4°C with Alexa Fluor 488–
conjugated goat anti-human IgG (Thermo Fisher Scientific). Finally, MPs were extensively washed 
and resuspended in PBS containing 0.1% BSA and analyzed using a FC500 flow cytometer 
(Beckman Coulter). All buffers were filtered through a 0.2-µm filter, and buffers without MPs 
exhibited a negligible number of counted events. Where indicated, microparticles were 
resuspended in Annexin V buffer and stained with FITC-conjugated Annexin V according to the 
manufacturer’s protocol (BioVision). For determination of MP concentrations, AccuCheck 
calibrated beads were added according to the manufacturer’s protocol (Thermo Fisher Scientific). 
 
Isolation of neutrophils and induction of NETosis. Neutrophils were isolated from human whole 
blood by Ficoll density gradient centrifugation using Lymphoprep (Stemcell Technologies), as 
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described previously (28). Isolated neutrophils (3 x 105 cells per cm2) were seeded in well plates in 
serum-free DMEM/F12 (Sigma-Aldrich) and exposed to MPs at indicated concentrations. Addition 
of 100 nM PMA (Sigma-Aldrich) or activated platelets to neutrophil cultures served as positive 
controls for NETosis induction. Platelets were isolated from whole blood and activated with lipo-
polysaccharide (LPS from E. coli O111:B4, Sigma-Aldrich), as described previously (29). Where 
indicated, neutrophils were pre-treated for 1 hour with the ROS-inhibitor diphenyleneiodonium 
(DPI, Enzo Life Sciences) prior to the addition of MPs or PMA. 
 
Quantification of NETs. After stimulation of neutrophils, adherent NETs were isolated by partially 
digesting the NETs in DMEM/F12 medium (Life Technologies) supplemented with 5U/ml 
micrococcal nuclease (MNase, Worthington Biochemical Corporation). Soluble NET fragments 
were subsequently quantified by using either Sytox Orange or an in-house developed NET ELISA. 
NET-derived DNA was incubated with 200 nM Sytox Orange (Thermo Fisher Scientific) and 
detected using a Tecan Infinite 200 multimode reader (Tecan industries). For the NET ELISA, 
soluble NET fragments were captured using an anti-dsDNA antibody (antibody #36, mouse IgG2a, 
1:4000, (30)), blocked with 2% fish gelatin (Sigma-Aldrich), and detected with an anti-MPO 
antibody (mouse IgG1, 1:6000, Biolegend). An HRP-conjugated antibody (goat anti-mouse IgG1, 
1:5000, Jackson Immunoresearch) was used to detect the anti-MPO antibody. Absorbance was 
measured at 450 nm after addition of TMB substrate (Biolegend) and sulfuric acid.  
 
 
Immunofluorescence microscopy. Purified neutrophils (3 × 105 cells per cm2) were seeded in slide-
flask chambers (Thermo Scientific) and exposed to MPs at the indicated concentrations and 
conditions. After stimulation, cells and NETs were fixed in 4% paraformaldehyde (15 min, 4°C), and 
slides were stained for DNA (Sytox Orange; 200 nM), neutrophil elastase (1:200, Abcam), and/or 
MPO (1:400, Biolegend). Goat anti-rabbit and goat anti-mouse antibodies labeled with Alexa Fluor 
488 (1:200, Thermo Fisher Scientific) were used to detect anti-NE and anti-MPO, respectively. 
Slides were embedded in Vectashield Mounting Medium (Brunschwig Chemie), and pictures were 
obtained with a Zeiss fluorescence microscope with Axiovision soſtware. 
 
 
 
DNase activity. DNA degradation was assessed according to the protocol of Hakkim et al. (21) with 
modifications. Briefly, NET-associated DNA or calf thymus-derived DNA was adjusted to a con-
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centration of 500 ng/ml and incubated with 10% recalcified plasma. After 180 min. of incubation 
at 37°C, remaining DNA was quantified with 200 nM Sytox Orange using fluorometry. 
 
 
 
Statistical analyses. Data are reported as the means ± SEM of at least 3 experiments. Significance 
was determined by Student’s t-test, Mann-Whitney U test, and one-way or two-way ANOVA 
followed by Bonferroni correction. Correlations were analyzed using Spearmans correlation 
coefficient. GraphPad Prism software (Version 5.03) was used for statistical testing. P values less 
than 0.05 were considered as statistically significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.  Results 
 
MPs from patients with active LN are enriched in acetylated chromatin. We have previously 
described that SLE-derived MPs are capable of enhancing NETosis in neutrophils. Since aberrant 
NETosis has been particularly associated with the development of LN in SLE, we explored whether 
MPs from SLE patients with active LN have an increased NETosis-inducing capacity when 
compared to MPs from SLE patients with remissive LN or without LN. We first characterized and 
quantified circulating MPs in the defined patient cohorts. MPs isolated from patients with active 
LN showed an increased reactivity with the anti-histone antibodies KM-2 and LG11-2, targeting 
apoptosis-induced acetylated histone H4 (at K8,12,16) and H2B (at K12) respectively, when 
compared to patients with remissive LN or without LN (Figures 1a, 1c and 1d). The total number 
of MPs did not significantly differ between all groups (Figure 1b), but MPs from patients with 
active LN showed a higher forward and side scatter compared to MPs from patients with remissive 
LN or without LN (Figures 1e and 1f), suggesting that these MPs originate from apoptotic cells, 
since they are generally larger in size and have more content compared to MPs derived from 
resting or activated cells (31). In summary, circulating MPs in patients with active LN are relatively 
large and have more apoptosis-associated chromatin modifications, which decline during the 
remission of LN and are even lower in patients without LN. 
 
 
 
 
HUVEC-derived MPs induce NETosis in a concentration-dependent manner. We previously 
showed that apoptotic MPs in SLE patients predominantly originate from endothelial cells (16). 
Others  also  reported  that  the  number  of  endothelial  cell-derived MPs  increases  during  active  
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Figure 1. Degree of acetylation of histones in microparticles isolated from patients with SLE is increased 
during active LN. (A) Representative flow cytometry plots of one patient showing MPs stained for 
acetylated histone H4K8,12,16 (left panel; stained with monoclonal antibody KM-2) and acetylated 
histone H2BK12 (right panel; stained with monoclonal antibody LG11-2) during active and remissive 
period of disease. (B) MP count in plasma, determined with counting beads. (C, D) Mean fluorescence 
intensity of MPs stained for H4K8,12,16Ac (C) and H2BK12Ac (D) from patients with active LN (n = 18) 
compared to patients with LN at remission (n = 18) or patients without LN (n = 18) and healthy controls 
(NHD; n = 11). (E, F) Mean forward scatter (E) and side scatter (F) of unstained MPs. Data are presented 
for each patient separately with indication of the median of the groups. *** p < 0.001 compared to 
active disease patients, determined by one-way ANOVA followed by Bonferroni corrected post-hoc test. 
# p < 0.05, ## p < 0.01 compared to active disease patients by paired Students t-test. 
 
 
 
 
 
disease (32). Therefore, we used in vitro generated MPs derived from apoptotic HUVEC as a model 
to study the mechanisms involved in MP-induced NETosis. Apoptotic MPs derived from HUVEC 
showed similar characteristics compared to MPs isolated from patient plasma as analyzed by flow 
cytometry. HUVEC-derived MPs contained apoptotic chromatin modification as defined by KM-2 
and LG11-2, and showed forward and side scatter characteristics similar to MPs isolated from 
patients with SLE (Figures 2a and 2b). HUVEC-derived MPs induced NETosis in neutrophils isolated 
from healthy donors as visualized by immunofluorescence microscopy, where fine stretches of 
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DNA decorated with MPO were seen (Figure 2c). The induction of NETosis by HUVEC-derived MPs 
appeared to be concentration-dependent as quantified by NET ELISA (Figure 2d). Together, these 
data indicate that HUVEC-derived MPs can be used as a model to study MP-induced NETosis. 
 
 
 
 
 
 
 
 
   
Figure 2. Microparticles from apoptotic endothelial cells induce NETosis. (A) HUVEC-derived MPs stained 
for H4K8,12,16Ac (KM-2; left panel) and H2BK12Ac (LG11-2; right panel) as measured by flow cytometry. 
(B) Mean forward and side scatter of HUVEC-derived MPs (n = 4) and MPs isolated from patients with 
active LN (n = 18) and healthy donors (n = 11). (C) HUVEC-derived MPs induce the formation of NETs 
identified by colocalization of myeloperoxidase (MPO) and DNA. (D) HUVEC-derived MPs dose-
dependently stimulate NETosis, as measured with NET ELISA (n = 4). Data are represented for each 
patient separately with median (in B) and mean (in D). Scale bar: 50 µm. * p < 0.05, ** p < 0.01, *** p < 
0.001 compared to unstimulated control (in D) by Students t-test or compared to all other conditions 
(in B) by one-way ANOVA with Bonferroni corrected post-hoc test. 
 
 
 
 
 
 
HUVEC-derived MPs rapidly induce ROS-independent NETosis. Although NETosis was initially 
described as a ROS-dependent cell death pathway (22), a significant number of reports have 
indicated that NETs can also be released in a rapidly occurring ROS-independent manner (33, 34). 
For instance, activated platelets rapidly trigger ROS-independent NETosis (29, 35). Similarly to 
activated platelets, we observed that HUVEC-derived MPs induced NETosis already within 30 
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minutes of incubation. In contrast, exposure of neutrophils to PMA, a frequently used stimulus for 
ROS-dependent NETosis, resulted in NET release typically after 3 hours of incubation (Figures 3a 
and 3b). Furthermore, exposure of neutrophils to PMA resulted in the complete rupture of nearly 
all neutrophils, as observed by immunofluorescence microscopy (Figure 3a, right panel), whereas 
HUVEC-derived MPs and LPS-activated platelets resulted in the release of NET-like structures 
without evidently altering neutrophil morphology (Figure 3a, second and third panel). Finally, we  
 
 
 
Figure 3. HUVEC-derived MPs rapidly induce ROS-independent NETosis. (A, B) Neutrophils exposed to 
HUVEC-derived MPs, LPS-activated platelets or PMA were analyzed at different time points for NET 
formation by immunofluorescence microscopy (A) or NET ELISA (B). (C, D) Pre-treatment of neutrophils 
with diphenyleneiodonium (DPI) does not reduce MP-induced NETosis as analyzed by NET ELISA (C) or 
immunofluorescence microscopy (D). Data are presented as mean with SEM. Scale bar: 50 µm. ** p < 
0.01, *** p < 0.001 tested by one-way ANOVA followed by Bonferroni corrected post-hoc test. 
 
 
assessed whether inhibition of ROS by diphenyleneiodonium (DPI) could inhibit NET release in 
response to HUVEC-derived MPs. While the release of NETs in response to PMA was reduced by 
DPI, this was not the case for HUVEC-derived MPs (Figures 3c and 3d). In summary, these data 
indicate that HUVEC-derived MPs rapidly induce NETosis in a ROS-independent manner. 
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Acetylated histones in MPs contribute to the NETosis-inducing  capacity of MPs. As acetylated 
histones bear a great immunostimulatory potential and have been demonstrated to play a role in 
the pathogenesis of SLE (13, 28), we hypothesized that acetylated histones within apoptotic cell-
derived MPs determine the potency of MPs to induce NETosis. To investigate this, we treated 
HUVEC with the histone deacetylase inhibitor trichostatin A (TSA) prior to the induction of 
apoptosis and the isolation of HUVEC-derived MPs. In this way, we generated HUVEC-derived MPs 
containing increased amounts of hyperacetylated histones compared to MPs from HUVEC that 
had not been pre-treated with TSA (Figure 4a). Indeed, hyperacetylated MPs led to an increase in 
NET production, compared to a similar concentration of normally acetylated MPs (Figures 4b and 
4c). To assess the importance of the degree of acetylation in MPs from SLE patients, we compared 
 
  
 
Figure 4. Degree of histone acetylation in MPs determines their NETosis inducing capacity. (A) Pre-
treatment of HUVEC with trichostatin A (TSA) before the induction of apoptosis renders MPs enriched 
in H4K8,12,16Ac (KM-2; left panel) and H2BK12Ac (LG11-2; right panel). (B) MPs from TSA-treated 
HUVEC show an increased NET-inducing capacity. (C) Different concentrations of MPs from TSA-treated 
HUVEC and normal MPs were co-incubated with neutrophils and NETosis was measured using NET ELISA 
(n = 4). (D) MPs with high and low acetylation scores (KM-2, n = 4) in each patient group were pooled 
and co-incubated with neutrophils. NETs were quantified by NET ELISA and results for highly acetylated 
MPs were set to 100% (n = 3 experiments). (E) Proteinase K (ProtK) treatment diminishes the NET-
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inducing capacity of HUVEC MPs (n = 3 experiments). Data are presented as mean with SEM. Scale bar: 
50 µm. * p < 0.05, ** p < 0.01 determined by two-way or one-way ANOVA with Bonferroni corrected 
post-hoc test and Student’s t-test. 
 
 
 
 
 
 
plasma-derived MPs from SLE patients with high acetylation levels with MPs from SLE patients 
with low acetylation levels. In each patient group, MPs from four patients, with either the highest 
or lowest signal for our KM-2 antibody, were isolated and pooled. Indeed, MPs with a high degree 
of acetylation were more potent in inducing NETosis compared to MPs with a low degree of 
acetylation (Figure 4d). However, only in SLE patients with LN, either active or in remission, the 
difference between higher and lower acetylated MPs reached significance. Additionally, ProtK-
mediated degradation of all proteins, including histones, present in MPs diminished their potency 
to induce NETosis (Figure 4e). Taken together, the presence of acetylated histones in HUVEC- or 
SLE-derived MPs determines their NETosis-inducing capacity. 
 
DNase activity is impaired in patients with LN. DNase activity is important for the degradation of 
both NET-derived as well as MP-derived chromatin (21, 36). To assess the activity of DNase in our 
patient population, we tested the ability to degrade different DNA substrates in vitro. Patients 
with LN (both active and remissive) were impaired in their capacity to degrade NETs (Figure 5a) as 
well as calf thymus-derived DNA (Figure 5b), which has also been reported earlier (21, 37). In 
addition, DNase activity inversely correlated with the degree of modified chromatin present in 
MPs (Figures 5c and 5d), suggesting that patients with an impaired DNase activity also fail to 
degrade apoptotic cell-derived chromatin in vivo. Altogether, these data implicate that the failure 
to degrade extracellular chromatin is unique for SLE patients with LN.  
 
5.  Discussion 
 
In SLE, an imbalance between the formation and clearance of apoptotic cells causes the persistent 
presence of apoptotic debris, including apoptotic cell-derived MPs, in the circulation. Circulating 
MPs in SLE patients are considered pro-inflammatory (38, 39), and previously we showed that SLE-
derived MPs have the capacity to enhance NETosis in blood-derived neutrophils (16). In the 
present study, we describe that the presence of hyperacetylated chromatin within apoptotic MPs 
is a critical determinant for the NETosis-inducing capacity of MPs in SLE patients with active LN. 
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Figure 5. DNase activity is impaired in patients with lupus nephritis. (A, B) Plasma of patients with active 
LN (n = 18), remissive LN (n = 18), SLE patients without LN (n = 18) and NHD (n = 11) were incubated 
with NETs (A) or DNA from calf thymus (B) to determine DNase activity, expressed as the percentage of 
degraded DNA after incubation with plasma. (C, D) Correlation of DNase activity with chromatin content 
of MPs as measured by flow cytometry. Data are presented for each patient separately with indication 
of the median of the groups. *** p < 0.001 determined by one-way ANOVA followed by Bonferroni 
corrected post-hoc test. Correlations are reported as Spearman correlation coefficients.  
 
 
 
 
 
A unique feature of MPs released from dying cells is that they contain nuclear components such 
as histones and DNA, which carry apoptotic modifications (40). Furthermore, MPs derived from 
apoptotic cells tend to be bigger compared with MPs released from living cells (31). We found that 
MPs present in patients with active LN showed a relatively high reactivity with anti-histone 
antibodies recognizing apoptosis-associated histone modifications and had on average a larger 
forward and side scatter on flow cytometric analyses. Together, these findings suggests that 
apoptotic cells contribute to a considerable extent to the generation of MPs in patients with LN. 
The degree of apoptotic histone modifications found in MPs declined during remission of LN and 
was much lower in SLE patients without LN. 
 
The presence of apoptotic cell-derived MPs in SLE patients with active LN has been linked to tissue 
damage induced by for example sun burns (41, 42). In addition,  apoptotic cell-derived MPs could 
also be a reflection of an ongoing state of inflammation and tissue damage elsewhere. We propose 
that the presence of apoptotic cell-derived MPs in the circulation also gives rise to a pathogenic 
feed forward loop by interacting with circulating neutrophils and triggering NET release. Aberrant 
NET release and the failure of endonucleases to degrade NETs have previously been linked to SLE 
and LN in particular (21, 43, 44). We show that SLE patients with either active or remissive LN fail 
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to degrade NET-derived chromatin, whereas SLE patients without LN are capable of degrading 
NETs. Thus, an impaired endonuclease activity is unique to SLE patients with LN. Undegraded NETs 
can ultimately deposit in the glomerular capillaries, where they may exacerbate renal 
inflammation by forming immune complexes or by directly damaging the glomerular endothelial 
lining with their cytotoxic histones and/or granule-derived cytotoxic enzymes (e.g. MPO, NE) (45-
48). This is in line with findings of circulating NET fragments as well as skin or renal NET depositions 
in lupus-prone mice and SLE patients (49), suggesting a pathogenic involvement of NETs in SLE. 
 
 
 
A key finding of our study is that the presence of acetylated histones within MPs is crucial for the 
induction of NETosis. Interestingly, the presence of acetylated histones within MPs inversely 
correlated with endonuclease activity in plasma, suggesting that endonucleases are not only 
involved in the degradation of NET-derived chromatin but also of chromatin present within 
apoptotic cell-derived MPs. Elegant studies recently indicated that the failure to digest chromatin 
in MPs leads to autoimmunity and the induction of SLE (36). Apoptosis-associated histone 
modifications increase the immunostimulatory potential of histones, and anti-histone antibodies 
in SLE patients show an increased reactivity with modified histones compared to their unmodified 
counterparts (5). Acetylated residues particularly increase the immunogenicity of histones. We 
previously described that hyperacetylated nucleosomes show an increased capacity to activate 
bone-marrow derived dendritic cells when compared to non-acetylated nucleosomes. Moreover, 
administration of an acetylated histone H4 peptide to lupus-prone mice enhanced proteinuria, 
skin lesions and mortality, whereas its non-acetylated counterpart had no such effects (13). 
Acetylated histones can be sensed via Toll-like receptors 2 and 4 (50), both of which are expressed 
by neutrophils. Since MPs containing more (modified) histones are more potent in inducing 
NETosis, it is tempting to speculate that TLR signaling is involved in MP-induced NETosis.  
 
 
We found that NETosis in response to hyperacetylated histones occurred rapidly and proceeded 
in a ROS-independent manner. Although many NET-inducing agents typically cause ROS-
dependent NETosis (51), a number of stimuli have been shown to promote NET formation without 
a requirement of ROS production (29, 35). Furthermore, lupus-prone mice deficient in ROS have 
markedly exacerbated lupus, including increased autoantibody profiles as well as renal disease, 
questioning the contribution of ROS-dependent NETosis to the pathogenesis of SLE (52). There-
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fore, we propose that circulating MPs are contributing to the pathogenesis of SLE by stimulating 
NET formation in a way that preceeds independent from the formation of ROS. 
 
Whether NET release after stimulation by apoptotic cell-derived MPs has a physiological meaning 
is unclear. NETosis was originally described as an antimicrobial defense strategy that is triggered 
by molecules derived from foreign (intruding) pathogens. However, many non-microbial and often 
host-derived molecules (e.g. HMGB1, uric acid) have been identified as NET-inducing stimuli (53, 
54). Therefore, NETosis may represent more than just antimicrobial defense. NETs can for instance 
also function as a transient barrier during tissue injury, a process in which debris released from 
dying cells triggers NETosis and the aggregation of NETs, thereby isolating injured tissue and 
limiting the spread of cell death-associated pro-inflammatory mediators (55, 56). The deleterious 
release of NETs in SLE in response to apoptotic cell-derived MPs with a hyperacetylated state may 
find its origin in this putative physiological function of NET release. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Proposed mechanism of MP-induced NETosis in patients with lupus nephritis. Cells undergoing 
apoptosis release MPs containing hyperacetylated histones (1). In patients with LN, MPs accumulate in 
the circulation and trigger neutrophils to go into NETosis (2). Since DNase activity is impaired in LN 
patients, NETs are not properly degraded (3). NETs deposit in the glomerular capillaries and induce 
tissue injury and inflammation, leading to nephritis and further cell death (4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In conclusion, we show that MPs induce the formation of NETs in SLE patients with LN (Figure 6). 
The degree of acetylated chromatin present in the MPs determines their potency to stimulate 
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neutrophils to go into NETosis. We propose that during active LN, apoptotic cell-derived MPs are 
formed. Without the proper functioning of endonucleases, MPs enriched in apoptosis-associated 
histone modifications persist within the circulation, thereby triggering NETosis and further kidney 
damage when the formed NETs deposit in the renal capillaries. This causes further release of 
apoptotic cell-derived MPs, thereby establishing a vicious pathogenic circle. 
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Supplementary Information                     Suppl. Table 1 
 Active Remission P-value 
Number 18 - 
Age (mean ± SD) 32.3 (10.6) - 
Gender female (n,%) 15 (83%) - 
Time to remission (weeks) 43 [18;90] - 
C3 (g/l) 0.525 [0.355;0.66] 0.755 [0.685;0.843] < 0.001 
Anti-dsDNA (IU/ml) 85.5 [20.5;637.5] 17.5 [7;60.75] < 0.05 
Creatinin (µmol/l) 108.5 [84.75;157.25] 79.5 [71;92.25] < 0.05 
Proteinuria (g/24h) 3.28 [1.85;4.79] 0.4 [0.28;0.5] < 0.0001 
SLEDAI 15 [12;21] 4 [2.25;6] < 0.0001 
 
 
 
 
Patient chacteristics. Data are given as median and interquartile ranges or as mean ± SD were indicated 
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1.  Abstract 
 
An excessive release and impaired degradation of neutrophil extracellular traps (NETs) leads to 
the continuous exposure of the endothelium to NETs in a variety of hematological and 
autoimmune disorders, including lupus nephritis (LN). This study aims to unravel the mechanisms 
through which NETs jeopardize vascular integrity. For this purpose, microvascular and macro-
vascular endothelial cells were exposed to NETs and subsequent effects on endothelial integrity 
and function were determined in vitro and in vivo. We found that endothelial cells have a limited 
capacity to internalize NETs via the receptor for advanced glycation endproducts (RAGE). An 
overflow of the phagocytic capacity of endothelial cells for NETs resulted in the persistent 
extracellular presence of NETs, which rapidly altered endothelial cell-cell contacts and induced 
vascular leakage and transendothelial albumin passage through elastase-mediated proteolysis of 
the intercellular junction protein VE-cadherin. Furthermore, NET-associated elastase promoted 
the nuclear translocation of junctional β-catenin and induced endothelial-to-mesenchymal 
transition (EndMT) in cultured endothelial cells. In vivo, NETs could be identified in kidney samples 
of diseased MRL/lpr mice and patients with LN, in whom the glomerular presence of NETs 
correlated with the severity of proteinuria and with glomerular EndMT. Together, these results 
indicate that an excess of NETs exceeds the phagocytic capacity of endothelial cells for NETs and 
promotes vascular leakage and EndMT through the degradation of VE-cadherin and the 
subsequent activation of β-catenin signaling. Our data designate NET-associated elastase as a 
potential therapeutic target in the prevention of endothelial alterations in diseases characterized 
by aberrant NET release. 
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2.  Introduction 
 
Neutrophil extracellular traps (NETs) are fibrillary networks of DNA, histones and antimicrobial 
peptides that are released from neutrophils during a highly complex cell death signaling pathway 
termed NETosis (1). NETosis was first described in 2004 as a novel defense mechanism of the 
innate immune system against intruding pathogens, but during the last years it has become 
increasingly clear that NETs can also exert deleterious effects on the host (2). An imbalance 
between the release and degradation of NETs has been linked to a variety of hematological 
disorders, such as transfusion-related acute lung injury (TRALI) (3, 4), sickle cell disease (5), 
thrombosis (6) and myeloproliferative neoplasms (6). Aberrant NETosis has also been associated 
with autoimmune conditions, such as ANCA-associated vasculitis (7) and systemic lupus 
erythematosus (SLE) (8, 9), in which NET-associated antigens may become targets of 
autoantibodies. In SLE, the failure to dismantle NETs has been linked to the development of lupus 
nephritis (LN), but the underlying mechanisms for this association are as yet still unresolved (10). 
 
NETs contain an arsenal of cytotoxic proteases, including cathepsin G, proteinase 3, neutrophil 
serine protease 4, matrix metalloproteinase 9 and neutrophil elastase (11). In addition, NETs are 
rich in cytotoxic (modified) histones (12). Although NET-associated histones and proteases exert a 
pivotal role in the elimination of pathogens, they may also injure surrounding tissues and 
bystander cells. The endothelium may be particularly at risk for NET-mediated damage, since 
endothelial cells are continuously exposed to NETs in NET-driven disorders (13-15). Especially the 
endothelial cells that line the renal glomeruli are thought to be heavily subjected to NETs, since 
circulatory NETs may deposit here in locally high amounts during blood filtration (16, 17).  
 
To date, the effects of NETs on endothelial cells still remain poorly characterized. In the present 
study, we investigated the effects of NETs on macrovascular human umbilical vein endothelial cells 
(HUVECs) and microvascular glomerular endothelial cells (ciGEnCs) both in vitro and in vivo. We 
observed that NETs alter endothelial cell-cell contacts through the proteolysis of the intercellular 
junction protein VE-cadherin by NET-associated elastase, thereby facilitating vascular leakage and 
the transendothelial passage of albumin. Additionally, cultured endothelial cells underwent 
endothelial-to-mesenchymal transition (EndMT) in response to NETs, which was also dependent 
on the proteolytic activity of elastase. The relevance of these in vitro findings was further 
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evaluated in vivo, where NET depositions could be demonstrated in renal biopsies of diseased 
MRL/lpr mice, as well as human LN subjects, in whom the glomerular presence of NETs correlated 
with the degree of proteinuria and with glomerular EndMT. Collectively, our data reveal that NETs 
play a crucial role in the induction of vascular leakage and EndMT. 
 
3.  Materials & Methods 
 
Chemicals, antibodies and primers. Reagents used in this study are listed in Suppl. Tables 1 – 3. 
 
Cell culture. Human umbilical vein endothelial cells (HUVECs), isolated from umbilical cords by 
perfusion and 20 min. incubation with trypsin at 37⁰C, and conditionally immortalized glomerular 
endothelial cells (ciGEnCs) were maintained in fibronectin-coated Corning cell culture flasks 
(Sigma-Aldrich) in EGM2-medium supplemented with 2% FCS and EGM-2 SingleQuots or EGM-2-
MV SingleQuots (Lonza), respectively. HUVECs and ciGEnCs were cultured with 5% CO2 at 37⁰C or 
33⁰C, respectively. CiGEnCs were allowed to differentiate at 37⁰C for 1 week as described 
previously (18). HUVECs between passages 3 and 8 were used for experiments. 
 
Isolation of neutrophils and induction of NETosis. Neutrophils were isolated from human whole 
blood by Ficoll density gradient centrifugation using Lymphoprep (Stemcell Technologies), as 
described previously (12). Isolated neutrophils (3x105 cells per cm2) were seeded in well plates in 
serum-free RPMI1640 medium (Sigma-Aldrich) supplemented with 100 nM PMA for 4 hours to 
form NETs. Adherent NETs were washed with pre-warmed PBS and isolated by partially digesting 
the NETs in fresh DMEM/F12 medium (Life Technologies) supplemented with 5U/mL micrococcal 
nuclease (MNase). Sytox Orange and N-Methoxysuccinyl-Ala-Ala-Pro-Val p-nitroanilide were used 
to quantify DNA content and elastase activity, respectively, in NET-containing supernatants. The 
induction of NETosis was confirmed with immunofluorescence microscopy (Suppl. Fig. 1). NETs 
were stored at -80⁰C until further use. 
 
Quantitative reverse-transcription PCR. Total RNA was extracted with TRIzol© reagent (Ambion). 
Reverse transcription was performed with RevertAid First Strand cDNA Synthesis Kit (Thermo 
Scientific), according to the manufacturer’s instructions. Quantitative reverse-transcription PCR 
was performed with FastStart Universal SYBR Green Master (Roche Diagnostics) on a CFX96 real-
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time PCR detection system (Bio-Rad). Experiments were performed in duplicate and the values 
were normalized to β2-microglobulin (β2M) or GAPDH using the delta-delta Ct method. Primer 
sequences are listed in Suppl. Table 3. 
 
Flow cytometry. All flow cytometry analyses were performed according to standard procedures 
(19). Briefly, endothelial cells were detached with 10 mM EDTA and stained with appropriate 
antibodies. For the assessment of cell death, endothelial cells were taken up in Annexin V-buffer 
and stained with FITC-conjugated Annexin V according to the manufacturer’s protocol (BioVision). 
All samples were analyzed on a FC500 flow cytometer with CXP software (Beckman Coulter). Data 
were analyzed with Kaluza Flow Analysis Software 1.3 (Beckman Coulter). 
 
 
Immunofluorescence imaging. Endothelial cells cultured on fibronectin-coated slideflasks were 
fixed with 4% paraformaldehyde and permeabilized with 0.3% Triton X-100. Slides were blocked 
with 1% BSA and stained with appropriate antibodies. Slides were embedded in VectaShield 
mounting medium with DAPI (Vector laboratories). For stainings on murine and human LN 
material, frozen kidney sections (2 µm) were fixed in ice-cold acetone for 10 min. and incubated 
with appropriate antibodies diluted in PBS containing 1% BSA and 0.05% sodium azide. All 
stainings were analyzed on a Zeiss Axioimager M1 immunofluorescence microscope using stan-
dard filter sets. 
 
 
Western blotting. Proteins were extracted with standard RIPA buffer and resolved by SDS-PAGE 
and transferred to nitrocellulose membranes. Blots were blocked with 1% BSA and incubated with 
primary antibodies overnight at 4⁰C. Proteins were detected with appropriate HRP-conjugated 
antibodies. Blots were developed using SuperSignal West Pico Chemiluminescent Substrate 
(Thermo Scientific), according to the provided protocol.  
 
 
Degradation assays. DNA degradation was assessed according to the protocol of Hakkim et al. (10) 
with modifications. Briefly, NET-associated DNA, calf thymus DNA or nucleosomal DNA from 
apoptotic cells was adjusted to a concentration of 500 ng/ml and incubated with 10% recalcified 
plasma. After 180 min. of incubation at 37⁰C, the remaining DNA was quantified with fluorometry 
using Sytox Orange. Nucleosomal DNA from apoptotic cells was obtained as described in (20). 
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Anti-NET antibodies ELISA. Polystyrene microplates were coated overnight with NET-containing 
supernatants (at a concentration of 2 µg/ml of NET-derived DNA) at 4⁰C. The next day, coated 
NETs were incubated with patient or healthy donor plasma (1:100 dilution) for 2 hours at room 
temperature followed by an 1 hour incubation with HRP-labeled anti-human IgG antibodies. 
Absorbance was measured at 450 nm after addition of TMB substrate and sulfuric acid. 
 
 
Transendothelial albumin passage. Endothelial cells seeded on polyester membranes (0.4 µm 
pore size) in tissue culture inserts (Corning Incorporated) were treated with a mixture of NETs and 
1 mg/ml FITC-labeled albumin (ratio 1:1) either in the presence or absence of the elastase inhibitor 
sivelestat. At the indicated time points, aliquots were removed from the well and fluorescence 
was determined by fluorometry. The amount of albumin passing the endothelial monolayer was 
determined by a set of standard dilutions, as described previously (21).  
 
Animal studies. Diseased MRL/lpr mice (n = 15) were sacrificed and classified into three groups 
based on their degree of proteinuria (22): no proteinuria (albustix < 300 µg/ml, n = 5), short-lived 
proteinuria (albustix > 1000 µg/ml, proteinuria < 7 days, n = 5) or long-lived proteinuria (albustix 
> 1000 µg/ml, proteinuria > 14 but < 21 days, n = 5). Age-matched CBA mice were included as 
control (n = 5). Kidney sections were stained for citrullinated histone H3 and Ly6G to detect NETs 
and RNA was isolated from kidney cortical tissue using TRIzol reagent.  
 
 
Human material. Renal biopsy samples were analyzed from 8 patients (22 – 41 years of age) with 
active LN, who were included in the Dutch SLE Nephritis Study (23). All patients fulfilled at least 4 
American College of Rheumatology criteria for SLE. Active signs of LN were defined as glomerular 
hematuria or proteinuria of ≥ 0.5 g/24 hours and confirmed by renal biopsy. Citrated plasma was 
collected at the time of biopsy retrieval. Two renal biopsies from healthy donor kidneys (not 
suitable for transplantation for anatomical reasons) were included as control. Clinical parameters, 
such as proteinuria and anti-dsDNA antibodies, were determined in our diagnostic facility.  
 
 
Statistics. Values are expressed as mean ± SEM. Statistical significance was determined by 
Student’s t-test or one-way ANOVA followed by Bonferroni correction using GraphPad Prism. P-
values less than 0.05 were considered as statistically significant.  
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Study approval. The local animal ethics committee of the Radboud University Nijmegen approved 
all animal experiments. All experiments with human material were approved by the institutional 
medical ethics committees. Written consent was obtained from all patients enrolled in this study. 
 
 
 
 
 
 
 
4.  Results 
 
Endothelial cells internalize NETs in a RAGE- and clathrin-dependent manner. Previously, 
macrophages were shown to play an important role in clearance of NETs (27). Endothelial cells are 
also capable to internalize a wide variety of cellular material, i.e. senescent neutrophils (28), 
apoptotic debris (29) and red blood cells (30). Since endothelial cells are continuously exposed to 
NETs in NET-driven disorders (13-17), we first evaluated whether endothelial cells have the 
capacity to internalize NETs. Such an endothelial phagocytic clearance may be crucial to avoid 
uncontrolled NET-mediated endothelial damage. To assess endothelial uptake of NETs, 
microvascular ciGEnCs or macrovascular HUVECs were incubated with NETs and the culture 
medium was analyzed for NETs at various time points with the cell-impermeable, DNA-binding dye 
Sytox Orange. A rapid (< 15 min) and time-dependent uptake of NETs by both ciGEnCs and HUVECs 
was observed (Figure 1a), which was more pronounced in ciGEnCs. To further validate 
internalization of NETs by endothelial cells, ciGEnCs were stained for neutrophil elastase, the most 
abundant protease within NETs (11). Indeed, NET-treated ciGEnCs showed an intracellular 
particulate staining for elastase, which was absent in control ciGEnCs (Suppl. Fig. 2a). Moreover, 
elastase co-localized with clathrin (Suppl. Fig. 2b), indicating a receptor-mediated pathway of 
endocytosis that leads to the formation of clathrin-coated NET-containing endosomes. Besides 
elastase, NET-derived histones were found in clathrin-coated endosomes after exposure of ciGECs 
or HUVECs to NETs (Figure 1b, middle panel; Suppl. Fig. 2c). Since NETs are primarily composed 
of DNA, we reasoned that the receptor for advanced glycation endproducts (RAGE), a 
transmembrane receptor of the immunoglobulin super family that was previously shown to 
promote the uptake of extracellular DNA into endosomes (31), could be the receptor responsible 
for the internalization of NETs into clathrin-coated endosomes. Indeed, the full digestion of NET-
derived DNA with DNase I prevented the uptake of NET-derived histones into clathrin-coated 
endosomes as observed by immunofluorescence imaging (Figure 1b, bottom panel). Furthermore, 
in the presence of FPS-ZM1, an antagonist of RAGE, both HUVECs and ciGEnCs were unable to 
internalize NETs (Figure 1c). The uptake of NETs by ciGEnCs or HUVECs did also not occur at 4⁰C, 
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indicating that the uptake of NETs is an active process (Figure 1c). In summary, NETs are rapidly 
internalized by endothelial cells during an active process involving both RAGE and clathrin.  
 
 
 
 
 
 
Figure 1. Endothelial cells rapidly internalize NETs through the receptor for advanced glycation 
endproducts (RAGE). (A) Endothelial cells rapidly internalize NETs, as determined by a decline in Sytox 
Orange signal after co-incubation of NETs with ciGEnCs (left) or HUVECs (right). The obtained value was 
related to the value obtained from NETs in the absence of endothelial cells (‘remaining NETs’). (B) 
Stimulation of ciGEnCs and HUVECs with NETs for 15 min results in a particulate cytosolic staining 
pattern for histones (stained with a PAN antibody against all core histones; see Materials & Methods), 
which co-localize with clathrin (middle panel). Degradation of NET-associated DNA with 5U/ml DNase I 
prior to co-incubation prevented the endothelial uptake of NET-associated histones (bottom panel). (C) 
Blockade of RAGE with 25 µg/ml FPS-ZM1 or co-incubation of NETs with ciGEnCs or HUVECs at 4°C 
abolishes NET uptake measured after 120 min. Scale bars: white = 10 µm; yellow = 5 µm. * p < 0.05, *** 
p < 0.001, compared to control.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NET-associated elastase promotes transendothelial albumin passage. Despite a rapid uptake of 
NETs, the phagocytic capacity of endothelial cells for NETs appeared to be limited. Addition of 
larger amounts of NETs (≥ 250 ng NET-derived DNA) to endothelial cells resulted in the saturation 
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of their phagocytic capacity, thereby causing a persistent extracellular presence of NETs (Figure 
2a). We used HUVECs as a model to study the extracellular effects of NETs on endothelium, since 
the phagocytic capacity of HUVECs for NETs was significantly lower than that of ciGEnCs (Figure 
1a). At high NET concentrations (2 µg DNA/ml), a rapid loss of endothelial cell-cell contacts and an  
 
 
Figure 2. NETs compromise endothelial monolayer integrity and promote transendothelial albumin 
passage. (A) The endothelial uptake of NETs is saturable, as the addition of > 250 ng NET-derived DNA 
overloads the phagocytic capacity of ciGEnCs (left) and HUVECs (right) for NETs. (B, C) The expression 
of CD31 and VE-cadherin on HUVECs is decreased after stimulation with NETs for 4 hours, as determined 
by immunofluorescence imaging (B) and flow cytometry (C; expression is indicated as mean 
fluorescence intensity, MFI). Immunofluorescence imaging clearly shows that endothelial cell-cell 
contacts are compromised in response to NETs (right panel in B, white arrows). (D) HUVECs acquire a 
mesenchymal-like phenotype (‘MC-like’; white arrows) after 24 hours of co-incubation with NETs. (E) 
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NETs promote transendothelial albumin passage in HUVECs after 2 hours of co-incubation, which can 
be prevented by the addition of 100 nM sivelestat, a specific inhibitor of elastase. (F, G) Inhibition of 
NET-associated elastase prevents VE-cadherin loss on HUVECs, as confirmed by flow cytometry (F) and 
Western blot (G). Scale bars: white = 10 µm; red = 20 µm. * p < 0.05, ** p < 0.01, *** p < 0.001, 
compared to control, where not specified.  
 
 
impaired endothelial monolayer integrity could be observed (Suppl. Fig. 3a), which was not the 
result of NET-mediated endothelial cell death as measured by Annexin V staining (Suppl. Fig. 3b). 
To further characterize endothelial integrity, the expression of the intercellular (junctional) 
proteins CD31 and VE-cadherin was analyzed, which revealed that both CD31 and VE-cadherin 
expression was significantly decreased on NET-treated HUVECs (Figures 2b and 2c). The loss of VE-
cadherin expression furthermore coincided with the gradual development of a spindle-shaped, 
mesenchymal-like phenotype, which was most prominent after 24 hours (Figure 2d). Treatment 
of ciGEnCs with NETs yielded similar results as obtained for HUVECs (Suppl. Fig. 3c). To assess 
alterations of the endothelial monolayer at a functional level, a transendothelial albumin passage 
assay was performed, which revealed that the transendothelial passage of albumin was signi-
ficantly increased in NET-treated HUVECs compared to control HUVECs (Figure 2e). Since VE-
cadherin and CD31 are known substrates of elastase (32) and matrix metalloproteinase 9 (MMP9) 
(33), respectively, we assessed whether we could prevent the loss of these junctional proteins and 
subsequent transendothelial albumin passage by inhibiting the activity of NET-associated elastase 
and MMP9. Pre-treatment of NETs with sivelestat, an inhibitor of elastase (34), abolished the NET-
induced loss of VE-cadherin (Figures 2f and 2g) and reduced transendothelial albumin passage 
(Figure 2e). The inhibition of MMP9 with anti-MMP9 antibodies could limit CD31 loss (Suppl. Fig. 
3d), but this did not alter endothelial monolayer integrity (data not shown). Taken together, the 
extracellular presence of NET-associated elastase promotes the proteolysis of VE-cadherin, which 
disturbs endothelial monolayer integrity and promotes transendothelial passage of albumin. 
 
 
 
 
 
 
 
 
 
 
NET-associated elastase promotes endothelial-to-mesenchymal transition. β-catenin, a dual 
function protein involved in cell-cell adhesion as well as gene transcription, is associated with the 
cytoplasmic tail of VE-cadherin in endothelial cells (35). It was previously shown that the loss of 
cadherin-mediated cell-cell adhesions can promote junctional β-catenin release and induce β-
catenin signaling (36, 37). Congruent with these reports, NETs promoted the nuclear translocation 
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of junctional β-catenin (Suppl. Fig. 4a and 4b), which was most prominent after 24 hours. The 
translocated β-catenin most likely is transcriptionally active within the nucleus as demonstrated 
by  immunofluorescence stainings  with an  antibody  specific for transcriptionally active β-catenin,  
 
 
Figure 3. NETs activate β-catenin signaling and promote endothelial-to-mesenchymal transition (EndMT). 
(A) NETs promote nuclear translocation of transcriptionally active β-catenin in ciGEnCs and HUVECs 
after 24 hours of incubation, which is prevented by inhibition of elastase with 100 nM sivelestat. (B, C) 
The nuclear presence (blue arrow) or absence (red arrow) of transcriptionally active β-catenin was 
scored (B) and 60 to 70% of ciGEnCs or HUVECs, respectively, were found to contain transcriptionally 
active β-catenin within their nuclei after exposure to NETs for 24 hours (C). (D) NETs induce the 
upregulation of EndMT markers Snail1 and MMP9 in both ciGEnCs (left) and HUVECs (right) in an 
elastase-dependent manner. Scale bars: 20 µm. *** p < 0.001, compared to control.  
 
 
 
 
 
 
i.e. recognizing dephosphorylated Ser37 and Thr41 epitopes (Figures 3a and 3b). Approximately 
60 and 70% of NET-treated ciGEnCs and HUVECs, respectively, contained transcriptionally active 
β-catenin within their nuclei (Figure 3c). To explain the mesenchymal-like phenotype of NET-
treated endothelial cells (Figure 2d), the expression of an important target gene of β-catenin, 
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Snail1, which fulfills a key role during endothelial-to-mesenchymal transition (EndMT) (38), was 
analyzed. Indeed, an increased expression of Snail1 was found in both NET-treated HUVECs as well 
as ciGEnCs (Figure 3d). Furthermore, the expression of matrix metalloproteinase 9 (MMP9) and 
the myofibroblast marker smooth muscle actin (SMA), which are in part regulated by Snail1 (39, 
40), were also upregulated in both endothelial cell types after exposure to NETs (Figure 3d; Suppl. 
Fig. 4c). Notably, elastase inhibition with sivelestat could completely block NET-induced Snail1, 
MMP9 and SMA expression (Figure 3d; Suppl. Fig. 4c). In conclusion, NETs induce EndMT in both 
HUVECs and ciGEnCs in an elastase-dependent manner. 
 
 
 
Glomerular NETs are associated with proteinuria and EndMT in murine LN. Next, we aimed to 
extend our in vitro findings to the in vivo situation. Since LN is perceived as a prototype NET-driven 
disease, we first studied renal biopsies from MRL/lpr mice for the presence of NETs and for 
markers of EndMT. For this purpose, MRL/lpr mice (22) were classified into three groups based on 
the degree and duration of proteinuria: (1) no proteinuria (NP), (2) short-lived proteinuria (SP) and 
(3) long-lived proteinuria (LP) (see Methods for concise definitions). The glomerular presence of 
citrullinated histone H3, a NET-specific marker frequently used in mice (41), was analyzed (Figure 
4a). In contrast to glomeruli of healthy CBA mice, it appeared that glomeruli of MRL/lpr mice in all 
3 groups contained NETs, whereby NETs were most prominently present in glomeruli of mice with 
LP (Figure 4b). The presence of glomerular NETs coincided with increased cortical Snail1 and 
MMP9 mRNA expression in MRL/lpr mice, particularly in those with LP (Figures 4c and 4d). Snail1 
protein expression was also specifically upregulated in the glomeruli of proteinuric MRL/lpr mice 
(Figure 4e), while being absent in tubular compartments (Suppl. Fig. 5a). Importantly, Snail1 
protein expression correlated with cortical Snail1 mRNA expression as well as with the amount of 
NET-positive glomeruli in these mice (Figures 4f and 4g). In addition to Snail1, MMP9 protein 
expression was assessed in glomeruli, whereby double stainings with CD31 confirmed the actual 
endothelial origin of MMP9 rather than neutrophil influx being the source of MMP9 (Suppl. Fig. 
5c). Taken together, the presence of NETs is associated with the glomerular upregulation of the 
EndMT markers Snail1 and MMP9 in proteinuric MRL/lpr mice. 
 
 
Glomerular NETs are associated with proteinuria and EndMT in human LN. We next analyzed 
renal biopsies from 8 patients with active LN for NET deposits and assessed whether the presence  
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Figure 4. Glomerular NETs associate with proteinuria and glomerular Snail1 expression in murine LN. (A) 
Kidney sections from MRL/lpr and control CBA mice were stained for citrullinated histone H3 (H3Cit) 
and Ly6G to detect NETs and neutrophils, respectively. (B) NETs are present in glomeruli of proteinuric 
MRL/lpr mice (SP; short-lived proteinuria, LP; long-lived proteinuria), but also in MRL/lpr mice without 
proteinuria (NP; no proteinuria). (C, D) Snail1 and MMP9 mRNA expression is increased in kidney cortical 
tissue of proteinuric MRL/lpr mice (SP and LP). (E) Snail1 protein expression is increased in glomeruli of 
proteinuric MRL/lpr mice (SP and LP). (F, G) Snail1 protein expression correlates to cortical Snail1 mRNA 
expression (F) and the amount of NET-positive glomeruli in MRL/lpr mice (G). Scale bar: 30 µm. * p < 
0.05, *** p < 0.001, compared to CBA; # p < 0.05, compared to MRL/lpr without proteinuria (NP).  
 
 
 
 
 
 
 
 
of renal NETs correlated with the degree of proteinuria and associated with glomerular EndMT. 
To identify NETs in these biopsies, kidney sections were stained for DNA and elastase (Figure 5a). 
Notably, in contrast to our experience in murine LN kidneys, a reliable staining of human LN 
biopsies for citrullinated histone H3 could not be obtained (data not shown). Stainings with 
monoclonal antibodies KM-2 (against tri-acetylated histone H4 (K8,12,16); (20)) or BT164 (against  
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tri-methylated histone H3 (K27); (26)) allowed further identification of NETs (Suppl. Fig. 6a and 
6b). Notably, these histone modifications were previously shown to be enriched in NETs when 
compared to unstimulated neutrophils (12). Taken all stainings together, the glomerular presence 
of NETs could be identified in 7 out of the 8 renal biopsies, ranging from 18 to 75% NET-positive 
glomeruli. Two human control kidneys were both negative for NETs (Figure 5a). There was a 
positive correlation between the percentage of NET-positive glomeruli and the level of proteinuria 
(Figure 5b). Since the impaired DNase I-mediated degradation of NETs was recently linked to the 
development of LN in patients with SLE (10), we ought to explore whether the impaired 
degradation of NETs by circulatory DNase I correlated to the glomerular presence of NETs. Plasma 
from 4 out of 8 LN patients degraded NETs poorly in vitro (Figure 5c and Suppl. Fig. 7). However, 
no statistical differences for anti-dsDNA titers, anti-NET antibody titers, the level of proteinuria or 
the percentage of NET-positive glomeruli was found when comparing poor degraders (PD) with 
good degraders (GD) of NETs (Figure 5d). To replicate the findings from LN mice, Snail1 protein 
expression was determined in renal biopsies of LN patients with severe proteinuria (> 10 g/day) 
and with minor proteinuria (< 1 g/day). It appeared that glomeruli of patients with severe 
proteinuria showed high glomerular expression of Snail1, whereas those with minor proteinuria 
showed no evident glomerular Snail1 expression (Figure 5e). Notably, peritubular endothelial cells 
were negative for Snail1 (Suppl. Fig. 5b). In summary, there is a correlation between the presence 
of glomerular NETs and proteinuria in LN, which in turn associated with glomerular Snail1 
expression. However, the NET-degrading capacity of plasma could not be correlated to the 
presence of NETs in the glomeruli of LN patients. 
 
 
 
 
 
 
 
5.  Discussion 
 
In the present study, we demonstrate a novel role for NETs in the transition of endothelial cells 
towards a mesenchymal phenotype, a process known as endothelial-to-mesenchymal transition 
(EndMT). EndMT is the process of cellular transdifferentiation in which endothelial cells lose their 
endothelial-specific markers and gain a mesenchymal phenotype (42, 43). EndMT is important 
during embryonic vascular development and also plays a role during vascular repair (44). However, 
EndMT has also been linked to various pathological conditions, including malignant (45) and 
fibrotic diseases (46). It has been suggested that during renal fibrogenesis, mesenchymal cells 
emerge predominantly via transdifferentiation of local endothelial (47) and/or epithelial cells (48). 
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Thus, NETs may facilitate the development of renal fibrosis in the progression of kidney disease 
by converting glomerular endothelial cells to a mesenchymal phenotype. Similarly, NETs may 
contribute to the pool of myofibroblasts that arise from lung capillary endothelial cells during the 
development of pulmonary fibrosis (49). The events that lead to pulmonary fibrosis still remain 
poorly understood, but the induction of EndMT by NETs may emerge as a potential pathway in 
diseases that are characterized by a high abundance of NETs within the lung capillaries, such as 
sickle cell disease (5) and TRALI (3). Elegant studies recently demonstrated that mice unable to 
form NETs are indeed protected from the development of fibrosis in the heart and lungs (50).  
 
 
 
 
 
 
Figure 5. Glomerular NETs associate with proteinuria and glomerular Snail1 expression in human LN. (A) 
Representative image of a glomerulus from a healthy donor (left; NHD) and a LN patient (right), the 
latter showing two NET-like structures composed of DNA and elastase (NE). Agrin was stained to 
visualize the glomerular basement membrane. (B) The percentage of NET-positive glomeruli correlate 
with the severity of proteinuria. (C) Plasma from 4 out of 8 LN patients fails to degrade NETs in vitro (PD; 
poor degraders, GD; good degraders). Plasmas from healthy donors (‘NHD’) and SLE patients without 
LN (‘SLE’) served as control. (D) The ability to degrade NETs is not related to anti-dsDNA levels, anti-NET 
antibodies (blue line represents the average OD value from 3 healthy donors plus 3 x the standard 
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deviation), proteinuria or the percentage of NET-positive glomeruli. (E) Two LN patients with severe 
proteinuria showed glomerular Snail1 protein expression, in contrast to two patients with minor 
proteinuria. Scale bars: white = 50 µm; yellow = 25 µm. 
 
 
We found that the predominant protease within NETs, neutrophil elastase, is key to the induction 
of EndMT by NETs. Its mode of action involved the proteolysis of endothelial VE-cadherin, a known 
substrate of elastase (32), and the subsequent activation of β-catenin signaling. β-catenin is a 
protein with a dual function that regulates the coordination of cadherin-mediated cell–cell 
adhesions as well as the transcription of genes involved in the differentiation of cells towards a 
mesenchymal phenotype, such as alpha smooth muscle actin, vimentin, matrix metalloproteinase 
9 and Snail1 (51). It was previously reported that the loss of cadherin-mediated cell-cell contacts 
can promote junctional β-catenin release and activate β-catenin signaling (36, 37). Therefore, the 
elastase-mediated loss of VE-cadherin appears to be an important initial event in the induction of 
EndMT through β-catenin signaling. Noteworthy, NET-mediated induction of EndMT is only 
observed when the concentrations of NETs are high and exceed the limited phagocytic capacity of 
endothelial cells for NETs. We indeed show that endothelial cells are endowed with a limited 
capacity to internalize NETs through the endothelial receptor for advanced glycation endproducts 
(RAGE), which specifically recognizes NET-associated DNA. Interestingly, in addition to its role in 
the internalization of NETs, RAGE activation is also a trigger for NETosis (52).  
 
In addition to its role in the induction of EndMT, the degradation of VE-cadherin by NET-associated 
elastase also caused a rapid phase of increased vascular permeability, as demonstrated by 
transendothelial albumin passage assays. Since the integrity of intercellular junctions, mediated 
particularly through VE-cadherin, is a prerequisite for maintaining a restrictive endothelial barrier 
(53, 54), NETs may thus play a role in the development of edema and/or proteinuria by increasing 
vascular permeability. Indeed, activated neutrophils have long been associated with vascular 
leakage and pulmonary edema in TRALI and sickle cell disease (55, 56). Similarly, elastase was 
previously shown to promote proteinuria in vivo (57, 58), and inhibition of elastase earlier 
successfully limited proteinuria in rats (59). More recently, Knight et al. found that proteinuria can 
be reduced in vivo in MRL/lpr mice through the systemic inhibition of NETosis with the 
peptidylarginine deiminase inhibitor Cl-amidine (41). In line with this, we found that the degree of 
proteinuria correlated with the percentage of NET-positive glomeruli in MRL/lpr mice and LN 
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patients, which was independent from the in vitro capacity of plasma to degrade NETs. The 
relationship between the in vitro capacity of plasma to degrade NETs and glomerular NET 
depositions therefore appears complex. This may be explained by the fact that the in vivo 
formation and deposition of NET-containing immune complexes may cause a drop in the level of 
antibodies that would normally prevent the degradation of in vitro generated NETs. Alternatively, 
our data may raise the question whether circulatory endonucleases are actually involved in the 
degradation of NETs present within the kidneys. Hence, more than 80% of the total endonuclease 
activity within the kidneys is attributed to locally synthesized DNase I (60). Importantly, an 
acquired, selective down-regulation of renal DNase I gene expression has been reported during 
the progression of both murine and human LN (61).  
 
 
 
 
 
 
 
 
 
Figure 6. Hypothetical model how NETs induce EndMT and vascular leakage. NETs are internalized by 
(glomerular) endothelial cells into clathrin-coated pits through RAGE (left side of the image). An excess 
of NETs, as occurs in SLE, overloads the phagocytic capacity of (glomerular) endothelial cells for NETs, 
resulting in a continous extracellular presence of NETs (right side of the image). Here, NETs promote 
vascular leakage through proteolysis of the extracellular domain of VE-cadherin, the latter resulting in 
the nuclear translocation of junctional β-catenin and the induction of EndMT. 
 
 
 
 
In sum, we propose a model in which excessive NETosis overloads the phagocytic capacity of 
endothelial cells for NETs, resulting in (i) proteolysis of VE-cadherin, (ii) the loss of endothelial cell-
cell contacts, (iii) the development of vascular leakage and (iv) the induction of EndMT through β-
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catenin signaling (Figure 6). Future research should be aimed at functional studies in NETosis-
deficient mice, or in mice treated with NETosis inhibitors, to functionally link NETosis to EndMT in 
vivo. Nevertheless, our data implicate that NET-associated elastase is potentially an attractive 
therapeutic target whose inhibition may limit vascular leakage and pro-fibrotic processes in a 
plethora of NET-driven inflammatory conditions.  
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Supplementary Information        Suppl. Table 1; chemicals 
Chemical From Catalog number 
FPS-ZM1 Merck Millipore 553030 
Sivelestat Sigma-Aldrich S7198 
Phorbol myristate acetate (PMA) Sigma-Aldrich P1585 
Micrococcal nuclease (MNase) Worthington  LS004798 
Sytox Orange Life Technologies S11368 
N-Methoxysuccinyl-Ala-Ala-Pro-Val p-nitroanilide Sigma Aldrich M4765 
Phalloidin-TRITC Sigma-Aldrich P1951 
Albumin-FITC Sigma-Aldrich A9771 
DNase I Roche 10104159001 
4-Nitroquinoline N-oxide (4-NQO) Sigma-Aldrich N8141 
Annexin V apoptosis kit BioVision 640914 
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Supplementary Information       Suppl. Table 2; antibodies 
Antibody From Catalog number 
Anti-CD31 (against human) BD Pharmingen 555446 
Anti-CD31 (against mouse) BD Pharmingen 553369 
Anti-VE-cadherin Santa Cruz sc-6458 
Anti-vimentin Dako M0725 
Anti-neutrophil elastase Abcam ab21595 
Anti-citrullinated H3 Abcam ab5103 
Anti-β-catenin  BD Pharmingen 610153 
Anti-β-catenin (active) EMD Millipore 05-665 
Anti-clathrin Santa Cruz sc-6579 
Anti-Ly6G Biolegend 108406 
Anti-β-actin Sigma-Aldrich A5441 
Anti-Snail1 Santa Cruz sc-28199 
Anti-MMP9 (blocking studies) Abcam ab38898 
Anti-MMP9 (mouse stainings) R&D Systems AF909 
Anti-agrin Lab collection Mouse (MI91): ref (24) 
Human (JM72): ref (25) 
Anti-histone Lab collection KM-2: ref (20) 
BT164: ref (26) 
Anti-histone (PAN) EMD Millipore MABE71 
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Supplementary Information           Suppl. Table 3; primers 
Gene Forward (5’ > 3’) Reverse (5’ > 3’) Species 
Snail1 CGAGTGGTTCTTCTGCGCTA CTGCTGGAAGGTAAACTCTGGA Human 
Snail1 CGTGTGTGGAGTTCACCTTCC  GGGTACCAGGAGAGAGTCCC  Mouse 
MMP9 GGACTCGGTCTTTGAGGAGC  CCTTCACGTCGAACCTCCAG  Human 
MMP9 GCCGACTTTTGTGGTCTTCC  GGTACAAGTATGCCTCTGCCA  Mouse 
SMA AAAGCAAGTCCTCCAGCGTT GCTTCACAGGATTCCCGTCT Human 
β2M ATGAGTATGCCTGCCGTGTG CCAAATGCGGCATCTTCAAAC Human 
GAPDH AGAAACCTGCCAAGTATGATGAC TCATTGTCATACCAGGAAATGAG Mouse 
 
Abbreviations: 
MMP9:  matrix metalloproteinase 9;  
SMA: smooth muscle actin; 
β2M:  beta-2 microglobulin;  
GAPDH:  glyceraldehyde 3-phosphate dehydrogenase. 
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Supplementary Information        Suppl. Fig. 1 
 
Figure S1. Induction and isolation of NETs. (A) The induction and isolation of NETs was routinely checked 
by immunofluorescence microscopy, where NETs were stained for elastase (NE; green) and DNA (red). 
NETs were induced with 100 nM PMA for 4 hours and isolated with 5U/ml micrococcal nuclease 
(MNase). (B) Neutrophils loose granularity after stimulation with PMA, as witnessed by conventional 
light microscopy. (C) DNA content (left) and elastase activity (right) in NET-containing supernatants was 
quantified by Sytox Orange or N-Methoxysuccinyl-Ala-Ala-Pro-Val p-nitroanilide, respectively. Scale bar: 
20 µm. * p < 0.05, *** p < 0.001, compared to control. 
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Supplementary Information        Suppl. Fig. 2 
 
Figure S2. NETs are internalized by endothelial cells into clathrin-coated pits. (A) ciGEnCs incubated with 
NETs for 15 min show a particulate cytosolic staining pattern for neutrophil elastase (NE), which is 
absent in ciGEnCs without NETs (control). (B) NE staining in ciGEnCs co-localizes with clathrin after 
exposure of ciGEnCs to NETs for 15 min. (C) Similar to NE, NET-associated histones are internalized into 
clathrin-coated pits as well by ciGEnCs after 15 min exposure to NETs (bottom row; magnification at the 
right). An isotype control staining was included (top row). Scale bars: white = 10 µm; green = 6 µm; 
yellow = 1 µm.  
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Supplementary Information        Suppl. Fig. 3 
 
Figure S3. Endothelial cell alterations in response to NETs are distinct from apoptosis or cellular activation. 
(A) After co-incubation with NETs for 4 hours, HUVECs lose their normal ‘cobblestone’ appearance and 
acquire a spindle-shaped morphology, being fundamentally different from HUVECs treated with 100 nM 
PMA (‘activation’) or 100 nM of the apoptosis-inducing agent 4-NQO (‘cell death’). (B) Flow cytometry 
analyses (Annexin V staining) confirmed that the morphological alterations in NET-treated HUVECs were 
not the result of endothelial cell death. (C) The loss of CD31 and VE-cadherin, and the reorganization of 
the vimentin cytoskeleton, in ciGEnCs (left) and HUVECs (right) occurs in response to NETs but does not 
occur upon endothelial cell activation with 100 nM PMA for 4 hours. (D) A subset of HUVECs loses CD31 
expression in response to NETs, which can be largely prevented by pre-incubation of NETs with 1 µg/ml 
polyclonal anti-MMP9 antibodies. Scale bars: black = 30 µm; white = 15 µm. 
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Supplementary Information        Suppl. Fig. 4 
 
Figure S4. Junctional β-catenin translocates to the nucleus in response to NETs. (A) HUVECs treated with 
NETs for 24 hours show an increased and decreased staining pattern of β-catenin in the nucleus or at 
the membrane, respectively (middle panel). These effects could be abolished by pre-treating NETs with 
100 nM sivelestat prior to co-incubation with HUVECs (bottom panel). (B) Quantification of the β-catenin 
staining intensity at the membrane (left) or in the nucleus (right) after treatment of HUVECs with NETs. 
(C) Similar to Snail1 and MMP9, smooth muscle actin (SMA) was found upregulated as well in both 
ciGEnCs (left) and HUVECs (right) in response to NETs. Scale bar: 20 µm. ** p < 0.01, *** p < 0.001, 
compared to control; ^ p < 0.05, compared to NETs.   
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Supplementary Information        Suppl. Fig. 5 
 
Figure S5. Snail1 and MMP9 protein expression in peritubular and glomerular endothelial cells. (A) Snail1 
protein expression is absent in peritubular endothelial cells in a proteinuric MRL/lpr mouse. (B) Snail1 
protein expression is absent in peritubular endothelial cells in a LN patient with severe proteinuria. (C) 
Similar to Snail1, MMP9 protein expression in MRL/lpr glomeruli was confirmed by immunofluorescence 
imaging. As neutrophils also highly express MMP9, we confirmed the endothelial origin of MMP9 in 
these glomeruli by double stainings with the endothelial marker CD31 and the neutrophil marker Ly6G; 
as depicted, MMP9 co-localized with the endothelial marker CD31 (yellow arrows; magnified at the 
bottom). CBA mice served as control. Scale bars: white = 30 µm; yellow = 100 µm; red = 30 µm.   
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Supplementary Information        Suppl. Fig. 6 
 
Figure S6. Glomerular NETs are positive for cell death-associated histone modifications. (A) NETs (white 
arrows; enlarged at the right panels) contain increased expression of tri-acetylated histone H4 
(K8,12,16), as recognized by the lupus-derived monoclonal antibody KM-2, when compared to intact 
neutrophils (yellow arrow; enlarged at the right panels). (B) Tri-methylated histone H3 (K27), recognized 
by the lupus-derived monoclonal antibody BT164, is also enriched in NETs (white arrows), when 
compared to intact neutrophils (yellow arrow). Note the increased size of NETs when compared to intact 
neutrophils (‘PMN’). Scale bars: white = 30 µm; yellow = 15 µm.  
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Supplementary Information        Suppl. Fig. 7 
 
Figure S7. A subset of LN patients fails to degrade DNA from three different sources. A subset of patients 
with LN fails to degrade (A) DNA from calf thymus, (B) DNA from apoptotic nucleosomes or (C) DNA from 
purified NETs. Plasmas from healthy donors (‘NHD’) and SLE patients without LN (‘SLE’) served as 
control.
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1. Abstract 
 
In addition to disturbances in apoptosis and an insufficient clearance of apoptotic cells, there is 
recent evidence for a role of neutrophils in the etiopathogenesis of systemic lupus erythematosus 
(SLE). In response to various stimuli, neutrophils can rapidly release DNA fibers decorated with 
citrullinated histones and antimicrobial peptides. These structures are referred to as neutrophil 
extracellular traps (NETs). In addition to apoptotic cell-derived microparticles, NETs may comprise 
a further source of autoantigens able to drive the autoimmune response in SLE. Our group recently 
identified specific histone modifications occurring during apoptosis that play an important role in 
the autoimmune response in SLE. In the current study, we evaluated the presence and immuno-
stimulatory potential of these previously identified histone modifications in NETs. Compared to 
NETs from healthy donors, the histones present in NETs formed by SLE-derived neutrophils 
contain increased amounts of acetylated and methylated residues, which we previously observed 
to be associated with apoptosis and SLE. Treatment of neutrophils with the histone deacetylase 
(HDAC) inhibitor Trichostatin A (TSA), prior to the induction of NETosis, induced NETs containing 
hyperacetylated histones, which were endowed with an increased capacity to activate macro-
phages in vitro. This implies that specific histone modifications, in particular acetylation, might 
enhance the immunostimulatory potential of NETs in SLE. 
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2. Introduction 
 
Systemic lupus erythematosus (SLE) is an autoimmune disease that mainly affects women in the 
childbearing age. SLE is a prototype type III hypersensitivity reaction in which immune complex 
depositions of chromatin and anti-chromatin autoantibodies cause a wide spectrum of clinical 
symptoms such as skin rashes, fever, alopecia, arthritis and nephritis. It is widely thought that 
abnormalities in apoptosis play an important role in SLE auto-immunization (1). Increased 
apoptosis as well as defects in the clearance of apoptotic material have both been implicated in 
the etiopathogenesis of SLE (2-9). During apoptosis, cellular constituents – in particular of nuclear 
nature – are susceptible to modifications and translocate into apoptotic blebs. When apoptotic 
cells or blebs are improperly cleared, they may progress into a state known as late apoptosis or 
secondary necrosis, thereby leaking their modified constituents into the cells’ vicinity. Uncleared 
apoptotic material may then be presented to antigen-presenting cells which subsequently instruct 
the adaptive immune system to produce the hallmark autoantibodies that characterize SLE. 
Autoantibodies found in SLE patients are mainly directed against nuclear components, i.e. 
nucleosomes, DNA, histones and ribonucleoproteins (10). In a substantial subset of SLE patients, 
autoantibodies also target proteins from the cytoplasm of neutrophils (11). The field of SLE 
research entered a new phase when a novel way of neutrophil cell death was described in 2004, 
involving the release of so-called neutrophil extracellular traps (NETs) in the extracellular milieu.  
 
 
 
 
 
 
NETs are extracellular DNA fibers decorated with citrullinated histones and neutrophil granule 
peptides such as elastase, cathepsin G and lactoferrin (12). NETs are formed by activated 
neutrophils in a process called NETosis that can be initiated by bacteria, viruses, fungi and 
parasites, but also by non-microbial mediators such as monosodium urate (MSU) crystals, IL-8, 
TNF-α or phorbol 12-myristate 13-acetate (PMA) (13). The formation of NETs has evolved as a 
strategy for killing extracellular pathogens. The sticky chromatin fibers of NETs immobilize and 
eliminate pathogens via antimicrobial peptides that decorate along the chromatin of NETs. Recent 
evidence suggests that NETs also prominently operate in various states of disease. In addition to 
a suspected involvement in tumor spreading (14) and thrombus formation (15), NETs are dis-
cussed to play a pivotal role in the etiopathogenesis of autoimmune diseases like SLE, since they 
contain many of the autoantigens that are targeted by SLE autoantibodies (16).  
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We have previously described that specific histone modifications are associated with both 
apoptosis and the autoimmune response in patients with SLE (17-20). In this report we 
investigated whether the same SLE-associated histone modifications are to be detected in NETs, 
since 70% of the proteins present within NETs are histones. 
 
 
 
 
 
3. Materials and Methods 
 
Patients and controls. In this study, seven consecutive patients who fulfilled the ACR classification 
criteria for SLE were included. Informed consent was obtained from all patients. The SLE patients 
(six female, one male) with a median age of 53 years (range 32 – 72 years) had a mean duration 
of disease of 14.3 years (range 9 – 26 years) and were in clinical remission (mean duration 10 
years; range 7 – 16 years). All patients were treated with hydroxychloroquine (mean 400 mg/day), 
except one who was treated with mycophenolate mofetil (750 mg/day). In addition to 
hydroxychloroquine, one patient received methotrexate (20 mg/day), one patient prednisone (5 
mg/day) and two patients azathioprine (50 and 150 mg/day). Three staff members (2 male, 1 
female) with a median age of 26 years (range 21 – 29 years) served as controls. 
 
 
 
 
Isolation of neutrophils. Neutrophils were isolated from heparinized (20 U/mL) blood by Ficoll 
density gradient centrifugation using Lymphoprep (Stemcell Technologies). Briefly, whole blood 
was diluted 1:1 in PBS to a volume of 30 mL and slowly layered on top of 15 mL Lymphoprep. The 
blood was then centrifuged at 800g for 20 minutes and neutrophils were collected from the lower 
cellular fraction. Erythrocytes were eliminated by hypotonic lysis until no erythrocytes were 
remaining. Viable neutrophils were counted by trypan blue exclusion in a Neubauer chamber. 
 
 
 
 
Visualization and quantification of histone modifications in NETs. Neutrophils at a density of 2 x 
106 per mL in 20 mM HEPES buffer (pH 7.5) supplemented with 5 mM CaCl2 were stimulated with 
20 nM PMA (Sigma-Aldrich) for 2 hours at 37°C to form NETs. After stimulation, neutrophils and 
NETs were suspended in paraformaldehyde (final concentration 1%) to a cell density of 1 x 106 per 
mL and then centrifuged at 800g for 10 minutes with a cytospin cuvette (Hettich Cyto System) on 
glass slides. DNA was stained for 30 min with 1 µg/ml 4,6-diamidino-2-phenylindole (DAPI) 
(Invitrogen) and histones were stained employing a panel of lupus-derived monoclonal antibodies 
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consisting of #34 (anti-H3, ref 17), KM-2 (anti-H4-K8,12,16ac, ref 18), LG11-2 (anti-H2B-K12ac, ref 
19) and BT164 (anti-H3-K27me3, ref 20). These antibodies were used at concentrations of 5 
µg/mL, 6 µg/mL, 0.1 µg/mL and 4 µg/mL, respectively. Purification of these monoclonal antibodies 
was performed as described before (17-20). The specificity for each batch of purified monoclonal 
antibody was validated by comparing the reactivity in ELISA with the respective modified histone 
peptide, H3(18-37) (#34) H4(1-22)-K8,12,16ac (KM-2), H2B(1-18)-K12ac (LG11-2) and H3(21-34)-
K27me3 (BT164) and its unmodified equivalent. Alexa Fluor 488-labeled goat anti-mouse IgG(H+L) 
(Invitrogen) was used for detection at 10 µg/mL. Slides were inspected by fluorescence 
microscopy using standard filter sets. Histone modifications in unstimulated viable neutrophils or 
in NETs were quantified with Adobe Photoshop CS5 as the mean Alexa488 signal intensity. 
 
 
 
Immunostimulatory potential of acetylated NET histones. For the respective production of 
hyperacetylated and hypoacetylated NETs, we pre-incubated neutrophils (5 x 106 per mL) from 3 
SLE patients for 3 hours in PBS supplemented with 100 ng/mL of the histone deacetylase (HDAC) 
inhibitor trichostatin A (TSA) (Sigma-Aldrich), or 10 µM of the histone acetyltransferase (HAT) 
inhibitor anacardic acid (AA) (Sigma-Aldrich), prior to stimulation of NETosis. For the isolation of 
NETs, we centrifuged neutrophils and NETs at 1000g for 5 minutes and washed the pellet in warm 
PBS. To subsequently separate NETs from neutrophils, the pellet of neutrophils and NETs was 
resuspended in 20 mM HEPES buffer (pH 7.5) supplemented with 5 mM CaCl2 and 500 mU/mL 
micrococcal nuclease (MNase) (Worthington Biochemical Corporation). After 20 minutes of 
incubation at 37°C, neutrophils were pelleted at 1000g for 5 minutes and the supernatants 
containing the NETs was mixed 1:1 with RPMI1640 medium supplemented with 20% autologous 
SLE plasma. Macrophages were differentiated from HL-60 cells with 20 nM PMA for 48 hours as 
described previously (21) and were kept in NET-containing media for 24 hours after which the 
expression of the activation marker CD71 was determined by flow cytometry, as stained with an 
anti-CD71 antibody (eBioscience; Cat. No. 11-0719). Addition of LPS to a final concentration of 100 
ng/mL served as positive control for the activation of in vitro generated macrophages. 
 
 
Statistical analyses. Results are represented as mean ± SEM of at least three independent 
experiments. For the analysis of variance for repeated measurements the Mann-Whitney U-test 
was used. The P value for significance was set at 0.05. 
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4. Results 
 
NETs contain apoptosis-associated histone modifications. Immunofluorescence imaging of NETs 
using our panel of monoclonal anti-histone antibodies revealed that histone modifications, that 
had previously been observed in chromatin of apoptotic cells, can also be observed in NETs (Figure 
1a). Extracellular DNA co-localized with modified histones and also with neutrophil elastase, there-
by confirming that the shown structures are indeed NETs (Figure 1b). Modified histones of NETs 
formed by neutrophils of patients with SLE and of healthy donors were compared. Our data show 
that unmodified H3 is equally present in both kinds of NETs, whereas acetylated H4-K8,12,16, 
acetylated H2B-K12 and tri-methylated H3-K27 is more abundant in NETs of SLE patients when 
compared to those of healthy donors (Figure 1a).  
 
 
 
Figure 1. NETs contain high amounts of apoptosis-associated histone modifications. (A) Modified histones 
co-localize with extracellular DNA from NETs. NETs from patients with SLE contain high amounts of tri-
acetylated H4-K8,12,16, acetylated H2B-K12 and tri-methylated H3-K27, whereas unmodified H3 is 
equally present in NETs of patients with SLE and of healthy donors (NHD). (B) Extracellular DNA also co-
localizes with neutrophil elastase (white arrows), confirming that the shown structures are indeed NETs. 
Scale bars: 50 µm. 
 
 
 
 
 
 
 
 
 
Histones from SLE patients are more susceptible to modifications upon NETosis. Next, we 
quantified histone modifications more precisely by analyzing a large cohort of single NETs and 
unstimulated viable neutrophils. In unstimulated viable SLE neutrophils, we observed hypo-
acetylation of H2B-K12 and H4-K8,12,16 as well as hypomethylation of H3-K27 when compared to 
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unstimulated viable healthy donor neutrophils (Figure 2a). In contrast, histones from NETs of SLE 
patients are 2-3 fold more acetylated on H2B-K12 and H4-K8,12,16 and methylated on H3-K27 
when compared to healthy donor NETs (Figure 2b). In addition to high reactivity with acetylated 
H4-K8,12,16, our monoclonal antibody KM-2 also reacts with a homologous (acetylated) epitope 
on histone H2A. From previous work, we know by using KM-2 that histone H2A becomes hyper-
acetylated during apoptosis (18). Interestingly, histone H2A appears to become hypoacetylated 
during NETosis. This hypoacetylation of histone H2A was to be seen in primary neutrophils as well 
as in granulocytes differentiated in vitro from the HL-60 cell line (Figure 2c). 
 
 
 
    
 
Figure 2. Quantification of apoptosis-associated histone modifications in viable neutrophils and NETs. (A) 
Histones from unstimulated viable SLE neutrophils are relatively hypoacetylated and hypomethylated 
(p < 0.05) when compared to neutrophils from healthy donors. (B) NETs from SLE patients contain higher 
amounts of H4-K8,12,16, acetylated H2B-K12 and tri-methylated H3-K27 (p < 0.05). (C) Histone H2A 
becomes hypoacetylated during NETosis in granulocytes differentiated from the HL-60 cell line and in 
primary neutrophils (black arrows), while H4 is hyperacetylated. Histones extracted from unstimulated 
viable cells (CE; cell extract) served as reference. 
 
 
 
 
 
 
Acetylated histones substantially contribute to the immunostimulatory potential of NETs. With 
the knowledge that NETs from SLE patients contain more acetylated H4-K8,12,16 and H2B-K12, 
we wanted to specifically evaluate whether these hyperacetylated histones contribute to the 
immunostimulatory potential of NETs. Therefore, we induced hyperacetylation, prior to NETosis, 
by incubating neutrophils for 3 hours with trichostatin A (TSA) or, alternatively, hypoacetylation 
with anacardic acid (AA). With TSA we were able to generate hyperacetylated H4-K8,12,16 in NETs, 
whereas the amount of unmodified H3 did not change (Figure 3a). Anacardic acid did not influence 
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the amount of acetylated H4-K8,12,16 in NETs (not shown). Finally, we cultured macrophages, 
derived from the HL-60 cell line, for 24 hours in the presence of normal and hyperacetylated NETs. 
Differentiation of HL-60 cells led to a typical increase in both side and forward scatter in flow 
cytometry and in corresponding morphological changes in light microscopy, thereby confirming a 
macrophage-like phenotype (not shown). Interestingly, the amount of macrophages that up-
regulated activation marker CD71 was significantly higher when cultured in the presence of 
hyperacetylated NETs compared to normal NETs (Figure 3b).     
 
 
 
 
5.  Discussion 
 
Over the past few years, several mechanisms have been proposed for a potential role of NETs in 
the etiopathogenesis of SLE. It is assumed that SLE patients extensively externalize NETs, since 
inflammatory cytokines and autoantibodies can initiate NETosis (13, 22). Moreover, Denny et al. 
described a distinct subset of SLE neutrophils, so called low-density granulocytes, with increased 
NET releasing capabilities (23). It has also been reported that SLE patients display a reduced NET 
clearance capacity due to a decreased DNase I activity and/or NET-bound C1q/autoantibodies 
preventing the accessibility to the NETs of DNase I (24, 25). Increased NETosis and reduced degra-
dation of NETs may both lead to an enduring exposure of NET antigens to the immune system, 
thereby evoking or amplifying an anti-nuclear autoimmune response. In addition, we describe in 
this report that NET-associated histones from SLE patients contain many methylated and 
acetylated residues that may increase the immunostimulatory potential of NETs. 
 
 
 
 
 
We show that when neutrophils undergo NETosis, histones are highly susceptible to acetylation 
and methylation of certain residues, that were reportedly associated with apoptosis (17-20). 
Whereas histones from unstimulated viable SLE neutrophils are relatively hypoacetylated at H4-
K8,12,16 and H2B-K12 and hypomethylated at H3-K27 (in concordance with earlier reported 
hypoacetylation and hypomethylation in splenocytes (26) and CD4+ T cells (27), respectively), they 
become hyperacetylated and hypermethylated upon NETosis. To test the hypothesis if NETs and 
the histone modifications they harbor might be capable to induce anti-histone autoantibodies, Liu 
et al. analyzed whether IgG autoantibodies from histone-reactive SLE patients react with targets 
present in NETs (28). They showed that SLE IgG autoantibodies preferentially recognize acetylated 
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H2B-K5, H2B-K12 and H2B-K20. However, they did not manage to identify these histone 
modifications within NETs formed by primary neutrophils due to significant proteolysis of the core 
histones during NETosis. Acetylated H2B-K5, H2B-K12 and H2B-K20 could also not be identified in 
NETs formed by the human HL-60 or murine EPRO cell line. It is therefore not surprising that EPRO-
derived NETs were weakly immunostimulatory in vivo, since there appears to be a discordance 
between the anti-histone autoantibodies found in SLE sera and the presence of their targets within  
 
           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Hyperacetylated NETs show an increased capacity to activate macrophages. (A) Pre-incubation 
with histone deacetylase inhibitor trichostatin A (TSA) prior to the induction of NETosis, renders NETs 
hyperacetylated at H4-K8,12,16, whereas the amount of unmodified H3 remains constant. (B) 
Hyperacetylated NETs (TSA NETs) activate more macrophages based on up-regulation of the activation 
marker CD71 (p < 0.05). Anacardic acid (AA NETs) did not affect the amount of acetylated histones in 
NETs and did not significantly differ in their macrophage-activating potential when compared with NETs 
obtained from untreated neutrophils (p < 0.05). LPS (100 ng/mL) served as positive control. Scale bars: 
white = 40 µm; yellow = 8 µm. 
 
 
 
NETs formed by murine EPRO cells. In contrast to Liu et al., we were able to identify acetylated 
H2B-K12 in NETs formed by primary neutrophils. NETs from primary neutrophils may therefore 
display a different immunostimulatory potential compared to HL-60 or EPRO-derived NETs, since 
they harbor different histone modifications. Liu et al. also not confirmed reactivity of anti-histone 
antibodies with acetylated H4-K8,12,16 and tri-methylated H3-K27 as we had described (18, 20). 
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Garcia-Romo et al. reported that NETs from SLE patients, in contrast to those of healthy donors, 
are highly capable in activating pDCs, a process accompanied by an increased secretion of the pro-
inflammatory cytokines IFN-α, IP-10, TNF-α and IL-6 (22). They furthermore showed that the 
antimicrobial peptides LL-37 and HMGB1 co-localize with the globular structures along NETs from 
SLE patients, whereas neutrophils from healthy donors tend to retain both proteins within 
cytoplasmic remnants upon NETosis. It was demonstrated by Lande et al. that the antimicrobial 
peptides in NETs are required for the ability of NETs to activate pDCs (29). It is speculated that 
histone modifications within NETs enhance the binding of antimicrobial peptides such as LL-37, 
HMGB1 and HNPs. The increased content of acetylated and methylated residues on histones from 
NETs of SLE patients may, therefore, indirectly increase the immunostimulatory potential of NETs 
via an enhanced binding of antimicrobial peptides to the NET. However, it appears that modified 
histones themselves are also highly immunostimulatory. In the past, our group demonstrated that 
hyperacetylated nucleosomes from apoptotic cells have a higher capacity to activate bone 
marrow-derived dendritic cells (DCs) in vitro compared to normal nucleosomes (18). Moreover, 
administration of hyperacetylated histone H4 peptides to lupus-prone mice enhanced mortality 
and aggravated disease symptoms, while nonacetylated H4 peptides had no pathogenic effect. 
We suggest that hyperacetylated chromatin of NETs may activate myeloid and plasmacytoid DCs 
and subsequently challenge self-tolerance in SLE. This causes the activation of autoreactive T and 
B cells to produce the plethora of autoantibodies that characterizes SLE. 
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1.  Abstract 
The release of neutrophil extracellular traps (NETs) during NETosis has been linked to a wide 
variety of infectious and autoimmune diseases. Although NETosis was originally described as a 
reactive oxygen species (ROS)-dependent cell death pathway (suicidal NETosis), it later became 
clear that there are also ROS- and cell death-independent ways through which NETs can be 
released (vital NETosis). Since the in vivo detection of vital and suicidal NETs in tissues and 
biological fluids has proven to be a major challenge, their relative contribution to disease 
conditions has not been established yet. Here, we report that neutrophil elastase, the most 
abundant protease within NETs, cleaves the N-terminal tails of core histones during suicidal 
NETosis, which does not occur during vital NETosis. As both vital and suicidal NETs contained equal 
amounts of myeloperoxidase (MPO), the detection of MPO - histone complexes with anti-histone 
antibodies directed against the N-terminal histones tails could discriminate between vital and 
suicidal NETs. In conclusion, the absence or presence of N-terminal tails in histones complexed 
with MPO could serve as potential markers to distinguish between ROS-dependent (suicidal) and 
ROS–independent (vital) pathways of NETosis, which can be used to further decipher the relative 
contribution of both NETosis pathways to NET-associated inflammatory diseases. 
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2.  Introduction 
Neutrophils are pivotal effector cells of the innate immune system. In addition to phagocytosis 
and degranulation, neutrophils can undergo a unique cell death pathway termed suicidal NETosis 
which involves the release of so-called neutrophil extracellular traps (NETs) into the extracellular 
space (1). NETs are web-like structures of chromatin and granule-derived proteases that serve to 
entrap and eliminate pathogens that are too large for phagocytic uptake or have evolved ways to 
circumvent phagocytosis (2). Despite its pivotal role in host defense, NET release has also been 
linked to a wide variety of infectious, hematological and autoimmune diseases (3, 4).  
 
The molecular events that lead to suicidal NETosis are not yet fully understood, but the activation 
of protein kinases, the generation of reactive oxygen species (ROS) and the deimination of 
histones by peptidyl arginine deiminase 4 (PAD4) appear to be essential for inducing suicidal 
NETosis (4). Stimulation of neutrophils with stimuli such as lipopolysaccharides (LPS), monosodium 
urate (MSU) crystals or phorbol myristate acetate (PMA) leads to the activation of protein kinases 
and the generation of ROS and resultantly triggers suicidal NETosis (5). In addition to suicidal 
NETosis, NETs can also be released during a ROS-independent pathway, which does not directly 
result in overt neutrophil cell death (6). This pathway has been termed vital NETosis and is thought 
to involve blebbing of the nuclear envelope and the vesicular exportation of NETs (7). In contrast 
to suicidal NETosis, the neutrophil’s outer membrane remains intact during vital NETosis, thereby 
allowing the neutrophil to continue cellular functions afterwards such as transmigration and 
phagocytosis. Activated platelets appear to be potent inducers of vital NET formation (8, 9). 
 
Several bioassays have been described to characterize and quantify NET release. The detection of 
cell-free DNA with DNA-binding dyes by spectrofluorometry or the detection of co-localization of 
DNA and neutrophil-specific proteins by immunofluorescence microscopy are currently the most 
frequently applied methods, despite the fact that both techniques are not specific for NETosis and 
fail to distinguish NET release from other forms of neutrophil cell death (10). The ELISA-based 
detection of complexes consisting of myeloperoxidase (MPO) and DNA appears more suitable for 
this purpose, and this assay is currently often employed when attempting to quantify NETosis in 
vivo in biological fluids (11-14). The detection of MPO – DNA complexes, however, fails to 
distinguish between NETs that have been generated through ROS-dependent suicidal or ROS-
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independent vital pathways, as both vital and suicidal NETs contain MPO and DNA (9). 
Discrimination between vital and suicidal NETs would be helpful, as both may have a different 
physiological function as well as a different pathological meaning (15). 
 
Since it has previously been demonstrated that histones are subjected to posttranscriptional 
modifications at their N-terminal regions during suicidal NETosis (16-18), we explored whether the 
use of anti-histone antibodies directed against N-terminal histone tails could be utilized in MPO-
based ELISAs in order to discriminate between suicidal or vital NETs. Here, we report a serological 
method that is able to discriminate between vital and suicidal NETs based on the presence or 
absence of N-terminal histone tails, respectively. 
 
3.  Materials & Methods 
 
Antibodies. In this study, a panel of mouse monoclonal antibodies consisting of #34 , KM-2, LG11-
2 and BT164 was used to detect N-terminal histone tails in suicidal and vital NETs. The lupus-
derived monoclonal antibody #36 was used for the detection of DNA. The epitopes of the applied 
antibodies are listed in Table 1. The production and purification of these antibodies was 
performed as previously described (19-22). In addition, a commercially available PAN antibody 
against the C-terminal regions of all core histones (Merck Millipore, MABE71) and a polyclonal 
antibody against citrullinated histone H3 (Abcam, ab5103) were used. 
 
Table 1. Properties of the mouse monoclonal antibodies used in this study. 
Antibody Epitope Isotype Origin Reference 
#36 DNA IgG2a (NZWxNZB)F1 (23) 
#34 H3(29-32); unmodified IgG2a (NZWxNZB)F1 (22) 
KM-2 H4(1-29); K8,12,16 acetylation IgG2a MRL/lpr (19) 
LG11-2 H2B(6-18); K12 acetylation IgG2a MRL/lpr (20) 
BT164 H3(21-34); K27 tri-methylation IgG2b MRL/lpr (21) 
 
 
 
 
 
 
 
 
 
 
 
Isolation of neutrophils and NETs. Neutrophils were isolated from human blood by Ficoll density 
gradient centrifugation using Lymphoprep (Stemcell Technologies), as described earlier (9). 
Briefly, isolated neutrophils (3x105 cells per cm2) were seeded in well plates in serum-free 
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DMEM/F12 medium and stimulated up to 4 hours with 50 nM phorbol myristate acetate (PMA) 
(Sigma-Aldrich) or 10 µg/ml of lipopolysaccharide (LPS) from Pseudomonas aeruginosa (serotype 
10) (Sigma-Aldrich) to generate suicidal NETs. For the generation of vital NETs, neutrophils were 
stimulated with activated platelets up to 4 hours. Platelets were isolated from whole blood and 
activated with LPS as described previously (9). Adherent NETs were washed with pre-warmed PBS 
and isolated after partial digestion for 20 min at 37°C in fresh DMEM/F12 medium supplemented 
with 5U/ml micrococcal nuclease (Worthington Biochemical Corporation). NETs were stored at a 
temperature of -80°C until further use. 
 
 
Inhibition assays. In selected experiments, isolated neutrophils were pre-treated for 1 hour and 
co-incubated during exposure to NET-inducing stimuli with one of the following inhibitors: 
diphenyleneiodonium (DPI) (Enzo Life Sciences; 40 µM; inhibitor of ROS), sivelestat (Sigma-Aldrich; 
100 nM; inhibitor of neutrophil elastase (NE)), alpha1-antitrypsin (Sigma-Aldrich, 100 µg/ml; 
inhibitor of NE), chymostatin (Enzo Life Sciences; 5 µg/ml; inhibitor of cathepsins), batimastat 
(Enzo Life Sciences; 5 µM; inhibitor of matrix metalloproteinases) and necrostatin-1 (Enzo Life 
Sciences; 50 µM; inhibitor of receptor-interacting serine/threonine-protein kinase 1 (RIPK1)).  
 
Immunofluorescence microscopy. Neutrophils were seeded on slide flasks and stimulated to form 
suicidal or vital NETs as described earlier. Slides were fixed with 4% paraformaldehyde for 20 min. 
and permeabilized with 0.3% Triton X-100 for 3 min at room temperature. Subsequently, slides 
were blocked in 1% BSA for 30 min. and stained with the appropriate antibodies for 1 hour. Slides 
were embedded in VectaShield mounting medium with DAPI (Vector laboratories) and analyzed 
on a Zeiss Axioimager M1 immunofluorescence microscope using standard filter sets. The 
reactivity of anti-histone antibodies with neutrophils and NETs was quantified with Adobe 
Photoshop CS6. For this purpose, the total fluorescent area was multiplied by the mean 
fluorescent intensity within the appropriate color channel.  
 
 
 
ELISA. Histones present within isolated NETs were characterized and quantified using two 
different ELISA approaches. In the first non-sandwich ELISA, NETs were coated for 2 hours on 
polystyrene microplates and subsequently blocked for 2 hours with 2% fish gelatin. After a 1 hour 
incubation with anti-histone antibodies (#34, KM-2, LG11-2 and BT164; see Table 1) or an anti-
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DNA antibody (#36) and subsequent washing, horseradish peroxidase (HRP)–conjugated goat anti-
mouse Ig (H+L) antibodies (Jackson Immuno Research, cat. no. #115-035-146, dilution 1:7,500) 
were added for 1 hour. The absorbance was measured at 450 nm after addition of TMB substrate 
and sulfuric acid. The presence of N-terminal histone tails in suicidal or vital NETs was expressed 
as the ratio between the reactivity of our panel of anti-histone antibodies and the reactivity of the 
antibody recognizing NET-associated DNA. In the second sandwich ELISA, polystyrene microplates 
were coated overnight at 4°C with 1 µg/ml of anti-histone or anti-DNA antibodies. The next day, 
plates were blocked for 2 hours with 2% fish gelatin and incubated with NET-containing 
supernatants for 2 hours. Subsequently, anti-myeloperoxidase (MPO) IgG1 antibodies (BioLegend, 
cat. no. #667802, dilution 1:2,000) were added for 1 hour. After washing, bound antibodies were 
detected by incubation with horseradish peroxidase (HRP)–conjugated goat anti-mouse IgG1 
antibodies for 1 hour (Southern Biotech, cat. no. #1070-05, dilution 1:5,000). The absorbance was 
measured at 450 nm after addition of TMB substrate and sulfuric acid. The presence of N-terminal 
histone tails in suicidal or vital NETs was expressed as the ratio between the reactivity of the anti-
histone - anti-MPO ELISAs versus the reactivity of the anti-DNA - anti-MPO ELISA. 
 
Statistical analyses. Values are expressed as mean ± SEM. Significance was either determined by 
Student’s t-test or one-way ANOVA followed by Bonferroni correction using GraphPad Prism 5.0. 
P-values less than 0.05 were considered as statistically significant. 
 
 
 
 
 
 
 
 
 
 
4.  Results 
 
 
 
N-terminal histone tails are lacking in suicidal NETs. It was recently described that neutrophil 
elastase exerts proteolytic activity on core histones during suicidal NETosis (24). As the N-terminal 
regions of histones appear to be particularly sensitive to degradation by proteases (25), we 
hypothesized that histones present within suicidal NETs may lack N-terminal tails as the result of 
proteolytic elastase activity. To test this hypothesis, we stimulated neutrophils with LPS or PMA 
to form suicidal NETs and subsequently analyzed these NETs by immunofluorescence microscopy 
for their reactivity with antibodies against the N-terminal histone tails. After 2 hours of  
stimulation,  reactivity  of  anti-histone  antibodies  against  N-terminal tails was maintained or 
enhanced in LPS- or PMA-exposed neutrophils, respectively (Figures 1a and 1b). Although the 
chromatin was clearly decondensed at this timepoint, NET-like structures were not observed yet. 
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Figure 1. Histones in suicidal NETs lack N-terminal histone tails. (A) Stimulation of neutrophils with PMA 
or LPS results in a time-dependent loss of N-terminal histone tails, as probed with our panel of mono-
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clonal antibodies against unmodified H3 (mAb #34), H4 Ac (K8,12,16) (mAb KM-2), H2B Ac (K12) (mAb 
LG11-2) and H3 Me (K27) (mAb BT164). (B) Reactivity of anti-histone antibodies with NETs was 
quantified with Photoshop (n = 3 random fields of view). (C) In contrast to the anti-histone antibodies 
recognizing N-terminal histone tails, a PAN anti-histone antibody recognizing the C-terminus of all core 
histones retained its reactivity with NET-associated histones.  Scale bars: 30 µm.  
 
 
 
 
 
 
 
At a later timepoint (4 hours), NET-like extracellular stretches of DNA could be clearly identified in 
response to both stimuli. However, at this timepoint the reactivity of NETs with our panel of 
monoclonal anti-histone antibodies against N-terminal histone tails was strongly reduced (Figures 
1a and 1b; Suppl. Figure S2). In contrast, a polyclonal PAN antibody against the C-terminal region 
of all core histones showed clear reactivity with NETs (Figure 1c). Altogether, these observations 
indicate that histones are present within suicidal NETs, but lack their N-terminal tails.  
 
 
The loss of N-terminal histone tails in suicidal NETs is mediated by neutrophil elastase. To assess 
whether neutrophil elastase is responsible for the loss of N-terminal histone tails, we co-incubated 
neutrophils with sivelestat or alpha1-antitrypsin, which both inhibit the proteolytic activity of 
neutrophil elastase, while stimulating them with LPS (Figure 2a) or PMA (Figure 2b) for 4 hours. 
Indeed, in the presence of both elastase inhibitors, reactivity of suicidal NETs with anti-histone 
antibodies against N-terminal tails could be maintained (Figures 2a and 2b; Suppl. Figures 3 and 
4). Inhibition of matrix metalloproteinases or cathepsins with batimastat or chymostatin, 
respectively, did not prevent loss of N-terminal histone tails (Suppl. Figure 5). Together, these data 
indicate that neutrophil elastase is responsible for the cleavage of N-terminal histone tails during 
suicidal NETosis. 
 
N-terminal histone tails remain present in vital NETs. Next, we explored whether histones 
present within vital NETs also lack their N-terminal tails. To evaluate this, we exposed neutrophils 
to activated platelets and analyzed these NETs by immunofluorescence microscopy for their 
reactivity with antibodies against the N-terminal histone tails. In contrast to suicidal NETs, vital 
NETs showed a strong reactivity with our panel of anti-histone antibodies against N-terminal tails 
(Figure 3a). Vital NETs appeared already 1 hour after stimulation with LPS-activated activated 
platelets. At this time point, stimulation of neutrophils with PMA or LPS had not yet resulted in 
chromatin decondensation or NET release, thereby confirming earlier reports that vital NETosis is 
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Figure 2. Neutrophil elastase cleaves N-terminal histone tails during suicidal NETosis. The loss of N-
terminal histone tails upon stimulation of neutrophils with LPS (A) or PMA (B) can be prevented by the 
inhibition of neutrophil elastase with sivelestat or alpha1-antitrypsin (hAAT). Reactivity of anti-histone 
antibodies with NETs was quantified with Photoshop (n = 3 random fields of view). Scale bars: 30 µm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a much faster process than suicidal NETosis (26). Reactivity of vital NETs with the anti-histone 
antibodies was maintained after 4 hours of stimulation with LPS-activated platelets (Suppl. Figure 
6). To more precisely quantify the differences in reactivity of anti-histone antibodies against N-
terminal tails with vital and suicidal NETs, we applied an ELISA in which NETs were coated as 
antigens after which the reactivity of our antibody panel was evaluated. This ELISA revealed the 
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low and high reactivity of our anti-histone antibody panel with suicidal and vital NETs, respectively 
(Figure 3b). In  summary,  vital NETs  contain  N-terminal  histone tails in  contrast to  suicidal NETs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. N-terminal histone tails are present in vital NETs. (A) Activated platelets stimulate neutrophils 
to release NETs as soon as 1 hour after stimulation, in contrast to stimulation with LPS or PMA for 1 
hour. Notably, our panel of monoclonal antibodies recognizing N-terminal histone tails shows strong 
reactivity against platelet-induced NETs. (B) The presence of N-terminal histone tails in isolated NETs 
(induced by either PMA (4h), LPS (4h) or activated platelets (1h), n = 5 per condition) was quantified by 
ELISA in which NETs were coated. The reactivity of our panel of anti-histone antibodies (mAbs #34 
against unmodified H3, KM-2 against H4 Ac (K8,12,16), LG11-2 against H2B Ac (K12) and BT164 against 
H3 Me (K27)) was plotted as a ratio to the reactivity of a monoclonal antibody recognizing NET-
associated DNA (mAb #36). The dashed red lines (positive controls) represent reactivity of our antibody 
panel with 1 µg/ml of apoptotic chromatin, which was obtained as described in (19). *** p < 0.001, ** 
p < 0.01 compared to PMA and LPS. Scale bars: 30 µm. 
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Vital NETs are detected in sandwich ELISAs employing anti-MPO and anti-histone antibodies 
directed against N-terminal tails. In order to allow discrimination between vital and suicidal NETs 
in biological fluids, we aimed to establish a sandwich ELISA employing anti-MPO and anti-histone 
antibodies directed against N-terminal tails. For this purpose, we first validated the presence of 
MPO within both suicidal and vital NETs. Immunofluorescence microscopy confirmed that MPO 
was present within both suicidal and vital NETs (Figure 4a; Suppl. Figure 7), with NET-associated 
MPO being equally present in suicidal and vital NETs when corrected for the total amount of NET-
associated DNA (Figure 4b). To confirm that the observed NETs were derived from either ROS-
dependent or ROS-independent pathways, we also stimulated neutrophils in the presence of the 
ROS inhibitor diphenyleneiodonium (DPI), which confirmed that activated platelets induced ROS-
independent vital NETosis whereas both PMA and LPS triggered ROS-dependent suicidal NETosis 
(Figure 4a). Next, we employed sandwich ELISAs using our panel of anti-histone antibodies against 
N-terminal tails or a commercially available PAN anti-histone antibody against the C-terminal 
regions of all core histones as capturing antibodies and anti-MPO as detecting antibody. 
Complexes consisting of MPO and histones with intact N-terminal tails could only be detected in 
case of vital NETs (Figure 4c). In contrast, the PAN antibody against C-terminal histone regions 
showed similar reactivity for both suicidal and vital NETs. In conclusion, the detection of MPO - 
histone complexes with anti-histone antibodies directed against the N-terminal histones tails as 
capturing antibodies in a sandwich ELISA allows measurement of vital but not suicidal NETs. 
 
 
 
 
 
Citrullinated histones are absent in both suicidal and vital NETs. Citrullination of histones has 
gained considerable attention in the context of suicidal NETosis, particularly in the setting of 
rheumatoid arthritis, where citrullinated NET-associated histones could be the origin of anti-
citrullinated protein antibodies (ACPAs) (27-29). Indeed, suicidal NETosis is dependent on the 
activity of PAD4, the enzyme that is responsible for histone citrullination (30). However, seemingly 
contradicting data exist concerning the presence of citrullinated histones within suicidal NETs (31). 
Since the antibodies used for detecting citrullinated histones are (mainly) directed against N-
terminal tails, we evaluated whether the proteolytic activity of neutrophil elastase also influenced 
the reactivity of anti-citrulline antibodies with NETs. For this purpose, we assessed the reactivity 
of a commonly used antibody against citrullinated histone H3 (H3Cit; Abcam, ab5103) with suicidal 
NETs in  the  absence  or  presence of the elastase  inhibitor  sivelestat. After 4 hours of  stimulation,  
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Figure 4. Vital NETs can be measured in sandwich ELISAs employing anti-MPO and anti-histone antibodies 
directed against N-terminal tails. (A) Stimulation of neutrophils with PMA, LPS or activated platelets 
yields NETs containing myeloperoxidase (MPO). Inhibition of reactive oxygen species (ROS) with 
diphenyleneiodonium (DPI) prevents NET release by PMA or LPS, but not by activated platelets. (B) The 
presence of MPO in isolated NETs (induced by either PMA, LPS or activated platelets, n = 4 per condition) 
was quantified by utilizing an ELISA in which NETs were coated and probed with either an anti-MPO or 
anti-DNA (mAb #36) antibody. The ratio between the anti-MPO and anti-DNA reactivity was plotted. (C) 
The presence of N-terminal histone tails in PMA- or LPS-induced suicidal NETs and platelet-induced vital 
NETs (n = 4 per condition) was measured in a sandwich ELISA employing one of the following capturing 
antibodies: #34 (against unmodified H3), BT164 (against H3 Me (K27)), KM-2 (against H4 Ac (K8,12,16)), 
LG11-2 (against H2B Ac (K12)) and a PAN antibody against all core histones. Anti-MPO was used as 
detection antibody. The obtained reactivity of these ELISAs was plotted as a ratio compared to the 
reactivity of an ELISA with anti-DNA (mAb #36) as capturing antibody. * p < 0.05 compared to PMA and 
LPS. Scale bars: 30 µm. 
 
 
 
both PMA- and LPS-induced suicidal NETs did not show reactivity with the anti-H3Cit antibody, 
while the co-presence of sivelestat enhanced the reactivity to some extent (Figure 5a). 
Importantly, platelet-induced vital NETs also showed no reactivity with the anti-H3Cit antibody, 
indicating  that  citrullinated  H3  cannot  serve  to  discriminate  between  vital  and  suicidal  NETs  
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Figure 5. Citrullinated histone H3 is not present in suicidal and vital NETs. (A) An antibody against 
citrullinated histone H3 (anti-H3Cit) only reacts with suicidal NETs (induced by PMA or LPS) when 
elastase activity is inhibited with sivelestat. (B) Different neutrophil morphologies during the induction 
of suicidal NETosis with LPS; the anti-H3Cit antibody only reacts with neutrophils during early-stage 
NETosis when the chromatin is decondensing (yellow box). (C) Neutrophils with decondensing 
chromatin (H3Cit positive neutrophils; yellow bars) are not permeable, since treatment with 
micrococcal nuclease (MNase) did not affect the number of H3Cit positive cells per field of view (FOV). 
In contrast, NETs are significantly degraded by MNase (green bars). (D) Co-incubation of LPS-exposed 
neutrophils with the RIPK1 inhibitor necrostatin-1 (Nec-1) prevents suicidal NETosis and arrests 
neutrophils at the stage of chromatin decondensation. *** p < 0.001 compared to NETs not treated 
with MNase. Scale bars: yellow and black = 30 µm; white = 10 µm. 
 
 
 
 
 
 
 
 
 
 
 
(Figure 5a). Although suicidal NETs do not appear to contain citrullinated H3, neutrophils clearly 
showed an enhanced reactivity with the anti-H3Cit antibody during earlier stages of NETosis when 
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the chromatin was decondensing and spreading across the cytosol (Figure 5b). At this stage, the 
neutrophil’s outer membrane seems intact, since treatment with the chromatin-degrading 
enzyme micrococcal nuclease (MNase) did not influence the amount of neutrophils positive for 
citrullinated chromatin (Figure 5c). Together, these findings suggest that citrullination of H3 may 
play a role during early-stage NETosis, but that citrullinated N-terminal histone H3 tails are lost 
when the chromatin is extracellularly released and exposed to neutrophil elastase. To get 
additional proof that citrullination of histones is mainly present on intracellular histones during 
suicidal NETosis, we stimulated neutrophils with LPS in the presence of necrostatin-1, a molecule 
that prevents the extracellular release of suicidal NETs by preventing neutrophil lysis through the 
inhibition of mixed lineage kinase domain-like protein (MLKL) pore formation (32). Importantly, 
necrostatin-1 does not affect the upstream signaling events of MLKL pore formation, such as ROS 
formation  (33). Indeed, NET release in response to LPS was prevented by necrostatin-1 and 
neutrophils were arrested at the stage in which the chromatin was fully decondensed and spread 
across the cytosol (Figure 5d; Suppl. Figure 8). At this stage, almost all neutrophils showed a strong 
reactivity with the anti-H3Cit antibody (Figure 5d). In summary, these findings indicate that anti-
H3Cit antibodies do not react with suicidal NETs due to the loss of N-terminal tails at the stage 
when the chromatin becomes extracellularly released. At the same time, citrullinated histones are 
also not present in vital NETs, indicating that anti-citrulline antibodies are not able to discriminate 
between NETs generated through ROS-dependent or –independent pathways.  
 
5.  Discussion 
 
This study shows that the predominant protease within NETs, neutrophil elastase, is able to cleave 
N-terminal histone tails during ROS-dependent (suicidal) NETosis, which does not occur during 
ROS-independent (vital) NETosis. The original view that there is only one form of NETosis (i.e. ROS-
dependent suicidal NETosis) appears to be too simplistic, as proven by ROS-independent vital 
NETosis (6-8, 26). Although it can be debated whether the terminology vital versus suicidal is 
appropriate (10), there is consensus that there are ROS-dependent and ROS-independent forms 
of NETosis. However, the relative contribution of these two forms of NETosis to disease conditions 
has not been addressed in vivo yet, since a proper assay that can discriminate between vital and 
suicidal NETs has been lacking. In this study, we have developed and evaluated a method that 
allows discrimination between vital and suicidal NETs, which is based on the detection of 
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complexes consisting of MPO and histones with intact N-terminal tails. As the detection of MPO – 
histone complexes with intact N-terminal histone tails is unique to ROS-independent vital NETosis, 
this assay can thus be exploited to assess the contribution of vital NETosis to NET-associated 
disease conditions, such as SLE. Although ‘classical’ NETosis (i.e. ROS-dependent) has long been 
associated with the pathogenesis of SLE, this contribution was recently questioned due to the 
observation that ROS-deficient MRL/lpr mice actually develop a markedly exacerbated form of 
disease (34). Similarly, the fact that individuals with chronic granulomatous disease (i.e. who fail 
to produce ROS) have a propensity of developing SLE may question the involvement of ROS-
dependent NETosis in SLE (35-37). Nevertheless, MPO – DNA complexes are frequently identified 
in the circulation of SLE patients and NETs have extensively been described in skin and renal 
biopsies both in SLE mouse models and in SLE patients (38-40). Altogether, these observations 
suggest that in SLE NETs are generated through a different pathway than ROS-dependent suicidal 
NETosis. Indeed, an increasing plethora of disease-relevant stimuli appear to trigger ROS-
independent vital NETosis in vitro (26, 41-43). Evidence that vital NETosis is occurring in vivo 
remains to be established, but this assay can serve that purpose. 
 
 
We have previously shown that neutrophil elastase has proteolytic activity in suicidal NETs, but 
not in vital NETs (9), which possibly explains the differences in the presence of N-terminal histone 
tails between suicidal and vital NETs. Why the proteolytic activity of elastase differs between 
suicidal and vital NETs is not completely clear, but there may be a relation with the differential 
requirement of ROS during both NETosis pathways, as it was previously demonstrated that 
antioxidants prevent elastase activity upon exposure of neutrophils to PMA (44). 
 
 
 
The degradation of core histones during suicidal NETosis has been described previously by 
Papayannopoulos et al. (24). This group showed that the degradation of histones by elastase was 
mediated by ROS, which in turn appeared essential for suicidal NETosis to occur. However, in our 
hands, suicidal NET release was not prevented with the cell-permeable elastase inhibitor 
sivelestat, which is a different inhibitor of elastase than the one used by Papayannopoulos et al. 
Accordingly, an indispensable role for elastase during suicidal NET release is also not evident from 
the work of others (45). As the elastase-mediated degradation of N-terminal histone tails seems 
to occur outside the cell, i.e. after suicidal NETs have been released, we propose that elastase may 
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function to increase the antimicrobial activity of NET-associated histones (46), reduce their 
cytotoxicity to host cells (47) or facilitate the timely removal of NETs by endonucleases (48).  
 
 
 
 
 
 
 
Figure 6. Proposed model how antibodies recognizing N-terminal histone tails could serve as potential 
probes to distinguish between NETs generated through ROS-dependent (suicidal) or -independent (vital)  
pathways of NETosis. The formation of ROS during suicidal NETosis leads to the activation of neutrophil 
elastase which subsequently degrades N-terminal histone tails within NETs. In contrast to antibodies 
against N-terminal histone tails, anti-histone antibodies against the C-terminal histone regions maintain 
reactivity with suicidal NETs. During ROS-independent vital NETosis, neutrophil elastase remains 
proteolytically inactive, thereby yielding NETs which react with antibodies directed against N-terminal 
histone tails.  
 
 
The observation that N-terminal histone tails are cleaved during suicidal NETosis may also provide 
an explanation for the discrepancies that have arisen regarding the presence of citrullinated 
histones within suicidal NETs (31). Whereas multiple groups have reported the presence of 
citrullinated histones in suicidal NETs (30, 49, 50), others have not been able to confirm these 
findings (31, 51-53). As an explanation for these discrepancies, it has been proposed that histone 
citrullination during suicidal NETosis may be stimulus-dependent (31) or that the use of different 
commercially available anti-citrulline antibodies may bias outcomes (54). We propose that these 
discrepancies may also arise from variations in the time points that are being used for the 
assessment of suicidal NETosis, which typically varies amongst laboratories between 2 – 6h. 
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Although (intracellular) histones become citrullinated early during suicidal NETosis, thereby 
facilitating processes like chromatin decondensation (17, 30, 48), citrullinated N-terminal histones 
tails ultimately do not end up in suicidal NETs due to their (extracellular) degradation by elastase. 
Thus, the reactivity of anti-citrulline antibodies with neutrophils undergoing suicidal NETosis 
decreases in time. The same holds true for antibodies recognizing acetylated and/or methylated 
N-terminal histone tails (17, 18), which show an increased reactivity with neutrophils during early-
stage suicidal NETosis but ultimately fail to react with extracellular NETs. Altogether, after the 
suicidal NETosis program has been completed, N-terminal histone tails thus appear to be released 
from the NETs in the extracellular space. We speculate that this may generate neoantigens/danger 
signals, which can play a role in autoimmune diseases such as SLE where immunological tolerance 
to chromatin is breached (55).  
 
 
 
 
In summary, we conclude that N-terminal histone tails are lacking in suicidal but not in vital NETs 
due to a different activity of neutrophil elastase in both conditions. Therefore, we propose that 
the use of antibodies recognizing N-terminal histone tails in MPO-based ELISAs can help to 
distinguish between NETs that have been generated through suicidal or vital NETosis pathways 
(Figure 6). Our findings will aid future investigations into the (patho)physiological roles of these 
two distinct NETosis pathways in health and disease. 
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Supplementary Information        Suppl. Fig. 1 
 
Figure S1. Supplementary images to Figure 1A. Reactivity of the commercially available PAN antibody 
against the C-terminus of all core histones (PAN mAb; left) and the lupus-derived mAb #34 (right) against 
the unmodified N-terminal histone H3 tail in unstimulated neutrophils.  
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Supplementary Information        Suppl. Fig. 2 
 
Figure S2. Supplementary images to Figure 1A.  Reactivity of the commercially available PAN antibody 
against the C-terminus of all core histones (PAN mAb; left) and the lupus-derived mAb #34 (right) against 
the unmodified N-terminal histone H3 tail in LPS-stimulated neutrophils (suicidal NETs).  
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Supplementary Information        Suppl. Fig. 3 
 
Figure S3. Supplementary images to Figure 2A.  Reactivity of the lupus-derived mAb #34 against the 
unmodified N-terminal histone H3 tail in LPS-stimulated neutrophils (suicidal NETs), either in absence 
(left) or presence (right) of alpha1-antitrypsin (hAAT).  
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Supplementary Information        Suppl. Fig. 4 
 
Figure S4. Supplementary images to Figure 2A.  Reactivity of the lupus-derived mAb #34 against the 
unmodified N-terminal histone H3 tail in LPS-stimulated neutrophils (suicidal NETs), either in the 
absence (left) or presence (right) of sivelestat.  
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Supplementary Information        Suppl. Fig. 5 
 
Figure S5. Supplementary images to Figure 2.  Reactivity of the lupus-derived mAb #34 against the 
unmodified N-terminal histone H3 tail in PMA-stimulated neutrophils (suicidal NETs), in the presence of 
batimastat (left) or chymostatin (right). In contrast to sivelestat and hAAT, these inhibitors do not 
prevent the cleavage of the N-terminal histone H3 tail during suicidal NETosis.  
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Supplementary Information        Suppl. Fig. 6 
 
Figure S6. Supplementary images to Figure 3A.  Reactivity of the lupus-derived mAb #34 against the 
unmodified N-terminal histone H3 tail in platelet-stimulated neutrophils (vital NETs; left) or LPS-
stimulated neutrophils (suicidal NETs; right).   
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Supplementary Information        Suppl. Fig. 7 
 
Figure S7. Supplementary images to Figure 4A.  PMA-stimulated neutrophils (suicidal NETs; left) and 
platelet-stimulated neutrophils (vital NETs; right) both contain myeloperoxidase (MPO).  
  
 
 
 
Cleaved N-terminal histone tails upon suicidal NETosis 
206 
 
Supplementary Information        Suppl. Fig. 8 
 
Figure S8. Supplementary images to Figure 5D.  Reactivity of the anti-H3Cit antibody with LPS-stimulated 
neutrophils, either in the absence (left) or presence (right) of necrostatin-1 (Nec-1).  
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1.  Introduction 
 
After years of intensive research, the pathogenesis of the autoimmune disease systemic lupus 
erythematosus (SLE) is still not resolved. An increased rate of apoptosis and an impaired clearance 
of apoptotic material appear to be key processes that drive the autoimmune response in SLE (1, 
2). Over the last decade, several lines of evidence have indicated that neutrophils play an impor-
tant role in the pathogenesis of SLE as well (3). By releasing neutrophil extracellular traps (NETs) 
in a process known as NETosis, neutrophils attempt to capture and eliminate pathogens extra-
cellularly independent from phagocytic uptake. Although NETosis is an important antimicrobial 
defense mechanism of neutrophils, NETs can become dangerous to the host when the body fails 
to adequately dismantle and clear these structures. In that case, the enduring exposure of the 
immune system to NETs may evoke autoimmune responses against the (modified) constituents of 
NETs, such as chromatin. Moreover, the presence of cytotoxic enzymes within NETs may directly 
cause damage to host tissues.  
 
As outlined in chapter 1, this thesis addresses the pathogenic role of NETosis in the autoimmune 
response as well as the development of renal damage in patients with SLE. As a better under-
standing of NETosis in a physiological context may also provide more insights into the pathogenic 
role of NETs, factors that determine whether neutrophils go into NETosis were studied as well. In 
this final chapter, the most important findings of this thesis are summarized and the possible 
implications of the findings for future research and the management of SLE are discussed.  
 
2.  Factors that drive NETosis 
 
The discovery of NETosis in 2004 led to great excitement among scientists, as this antimicrobial 
strategy could help explain the pathogenesis of a plethora of inflammatory diseases, including that 
of SLE. However, the identification of NETosis has also led to a certain extent of confusion. One of 
the major questions that has arisen concerns the reciprocal relationship between the neutrophil’s 
main antimicrobial strategy, i.e. phagocytosis, and NETosis. In other words, how is it determined 
whether neutrophils internalize pathogens through phagocytosis or eliminate them through 
NETosis? By studying NETosis in the context of hyperuricemia and Gram-negative infection, this 
thesis sought to identify factors that drive the neutrophil to go into NETosis.  
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2.1.  Size matters 
 
A variety of conditions, including SLE, can lead to elevated levels of uric acid in the blood 
(hyperuricemia). When the concentration of uric acid exceeds its solubility limit, uric acid can 
crystallize to form monosodium urate crystals (cMSU). Such cMSU initially appear as round-shaped 
bifringent urate microaggregates (UMA; ≤ 1 µm in size), which can subsequently grow in a bipolar 
manner to form needle-shaped monosodium urate crystals (nsMSU; up to 100 µm in size). In 
chapter 2, the response of neutrophils toward UMA and nsMSU was studied and it appeared that 
neutrophils respond differently to both structures: whereas small UMA become readily ingested 
by neutrophils, nsMSU are too large to be adequately removed through phagocytosis and, as a 
result, trigger the formation of NETs. Thus, neutrophils are capable to selectively release NETs in 
response to structures that are too large to be phagocytosed (4).  
 
2.2.  Recognition of lipopolysaccharides 
 
Chapter 3 describes that, in addition to the sensing of large (pro-inflammatory) structures, 
neutrophils have the capacity to selectively release NETs after recognition of specific 
lipopolysaccharides (LPS) provided by certain Gram-negative bacteria. By studying the response 
of neutrophils toward LPS derived from different bacterial sources, it was found that neutrophils 
release NETs only in response to specific LPS structures, of which LPS derived from Pseudomonas 
aeruginosa appeared to be the most potent NET-inducing stimulus (5). Since Pseudomonas 
aeruginosa is notorious for its ability to circumvent phagocytosis, for example through biofilm 
formation (6), these data suggest that NETosis is executed when the intruding pathogen has 
evolved strategies to circumvent phagocytic killing. Indeed, many other pathogens known for their 
potential to evade phagocytosis, such as Streptococcus pneumoniae (7), Haemophilus influenzae 
(8), and Klebsiella pneumoniae (9), are potent stimuli for NETosis. 
 
2.3.  NETosis when phagocytosis is hampered 
 
Altogether, based on the findings from chapters 2 and 3, it can be proposed that phagocytosis and 
NETosis may have complementary roles, whereby the failure to phagocytose may elicit NET 
release and vice versa. Thus, when neutrophils are not capable of phagocytosis, either because 
the size of the pathogen is too large or the pathogen has evolved ways to circumvent phagocytosis, 
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NETosis may be brought into play. This implies the existence of regulatory mechanisms that can 
minimize undesired NET-associated immunopathology. The identification of these regulatory me-
chanisms may be exploited to further study and identify disease-relevant stimuli, such as immune 
complexes, infectious agents and/or apoptotic cell remnants, that could enhance NETosis and 
drive autoimmunity in SLE. 
 
 
3.  NETosis in response to dying cells: implications for SLE 
 
In addition to antimicrobial defense, the formation of NETs may have other functions as well. 
Indeed, many factors other than microbial products have been identified as NET-inducing stimuli; 
e.g. several cytokines (10), high-mobility group box 1 (HMGB1) protein (11), an alkaline pH (12), 
activated endothelial cells (13) and autoantibodies (14). One postulated function of NETs is to act 
as a transient barrier during tissue injury. This can occur when debris released from dying cells 
initiates the formation of NET-based barriers that spatially shield inflamed sites from viable tissue 
and thereby limit the spread of pro-inflammatory mediators from the inflamed area (12, 15, 16).  
 
3.1.  Apoptotic microparticles trigger NETosis 
 
As outlined, disturbances in apoptosis and NETosis are both linked to the pathogenesis of SLE. In 
chapter 4, the available literature on the roles of both these cell death modalities in breaking 
immunological tolerance in SLE was reviewed, with a specific focus on the role of histone modi-
fications that are linked to (apoptotic) cell death and the development of autoimmunity (3). 
 
Although NETosis and apoptosis are two self-contained entities in the pathogenesis of SLE, a 
possible connection between both cell death pathways was investigated in chapter 5. Arising from 
the putative barrier function of NETs described above, the capacity of apoptotic cell-derived 
microparticles to directly stimulate NETosis or prime neutrophils for NETosis was assessed, which 
could create a feedforward loop between apoptosis and NETosis in driving the autoimmune 
response in SLE. Microparticles rich in apoptosis-modified chromatin could be identified in the 
plasma of SLE patients. The expression of CD31 and absence of CD45 on their surface indicated 
that these microparticles predominantly originated from endothelial cells. Similar microparticles 
were not present in healthy subjects or patients suffering from other rheumatic diseases (i.e. 
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rheumatoid arthritis or scleroderma). In functional assays, these apoptotic cell-derived micro-
particles were not only capable of activating blood-derived plasmacytoid and myeloid dendritic 
cells but were indeed also potent stimuli of NETosis (17). 
 
3.2.  NETosis in response to acetylated histones 
 
In chapter 6, the mechanisms of NETosis induction by apoptotic cell-derived microparticles were 
further explored and the association of this putative feedforward loop between apoptosis and 
NETosis with renal involvement in SLE patients was assessed. For this purpose, apoptotic cell-
derived microparticles in SLE patients with and without active signs of lupus nephritis were 
characterized. It appeared that in patients with active lupus nephritis, the population of micro-
particles fundamentally differed compared to those from patients without lupus nephritis. 
Although the total number of microparticles was similar in both groups, microparticles in patients 
with active lupus nephritis were larger in size and contained more apoptosis-associated acetylated 
histones. By generating apoptotic cell-derived microparticles enriched in hyperacetylated 
histones, it could be demonstrated that the NETosis-inducing capacity of apoptotic cell-derived 
microparticles is related to the presence of acetylated histones within these microparticles (18). 
 
As the (rapid) degradation of NETs is important for the prevention of autoantigen presentation 
and NET-mediated tissue damage, the activity of the NET-degrading enzyme DNase I in the plasma 
of SLE patients with and without active signs of lupus nephritis was also assesed. In accordance 
with earlier reports, the activity of DNase I was reduced in patients with active lupus nephritis. 
Importantly, DNase I activity was also reduced in SLE patients without actual lupus nephritis but 
who had presented with one or more episodes of renal involvement in the past. In contrast, in SLE 
patients who never had signs of lupus nephritis during the course of their disease, DNase I activity 
was comparable to that of healthy controls. Thus, patients with lupus nephritis (either with active 
or remissive disease) have an impaired ability to degrade NETs. The acquired inability of lupus 
nephritis patients to degrade NETs is likely to only manifest when NETosis truly occurs, for instance 
during an infection or when an increased bulk of apoptotic cell-derived microparticles enters the 
circulation. In that case, the imbalance between the formation and degradation of NETs will result 
in the deposition of NETs within the glomeruli; such depositions may then incite renal inflam-
mation and cause damage to the kidney, giving rise to the clinical features of lupus nephritis. 
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4.  The role of NETosis in lupus nephritis 
 
As an imbalance between the formation and degradation of NETs may ultimately lead to the 
exposure of NETs to the glomerular endothelium, chapter 7 investigated the effects of NETs on 
(glomerular) endothelial cells. It appeared that the exposure of the endothelium to NETs rapidly 
altered endothelial monolayer integrity and induced vascular leakage and transendothelial 
albumin passage, which was due to the proteolysis of the intercellular junction protein VE-
cadherin (19). The loss of VE-cadherin furthermore coincided with the nuclear translocation of 
junctional β-catenin, which induced endothelial-to-mesenchymal transition (EndMT) in cultured 
endothelial cells. EndMT is the process of cellular transdifferentiation in which endothelial cells 
lose their endothelial-specific markers and gain a mesenchymal phenotype (20, 21). Although this 
process is important during embryonic vascular development and vascular repair, it has also been 
linked to various pathological conditions, including fibrotic disease (22). It has been suggested that 
during renal fibrogenesis, mesenchymal cells emerge predominantly via transdifferentiation of 
local endothelial and/or epithelial cells (23); thus, NETs may facilitate the development of renal 
fibrosis in the progression of kidney disease by converting glomerular endothelial cells to a 
mesenchymal phenotype. The disturbed endothelial monolayer integrity and the induction of 
EndMT were both dependent on the proteolytic activity of NET-associated neutrophil elastase, as 
the presence of elastase-specific inhibitors prevented vascular leakage and the upregulation of 
EndMT markers. The relevance of these in vitro findings was further evaluated in vivo, where NET 
depositions could be demonstrated in renal biopsies of diseased MRL/lpr mice and patients with 
lupus nephritis, in whom the glomerular presence of NETs correlated with the degree of 
proteinuria and with glomerular EndMT. Collectively, these data reveal that NETs play a crucial 
role in the induction of proteinuria and EndMT in lupus nephritis, and designate NET-associated 
neutrophil elastase as a potential therapeutic target in the prevention of endothelial alterations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.  Histone modifications in SLE 
 
Specific posttranslational histone modifications can give rise to neoantigens, which have been 
designated a putative pathogenic role in breaching immunological tolerance in SLE. Previous 
research from our laboratory has identified multiple histone modifications occurring during 
apoptotic cell death which are specifically recognized by lupus-derived anti-histone antibodies 
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(24-27). In this thesis, a panel of lupus-derived monoclonal antibodies was employed to characte-
rize histone modifications that occur during NETosis and that are present or absent within NETs. 
 
 
5.1.  NETs as a source of modified histones 
 
In chapter 8, the presence of modified histones within NETs was evaluated. It appeared that 
histones become heavily acetylated and methylated at their N-terminal tails during the process of 
reactive oxygen species (ROS)-dependent NETosis (28). By utilizing our panel of lupus-derived 
monoclonal antibodies, it could be demonstrated that histones present in NETs formed by SLE-
derived neutrophils contained increased amounts of acetylated and methylated residues 
compared to NETs generated by neutrophils from healthy donors. By inducing NETosis in the 
presence of a histone deacetylase inhibitor, NETs enriched in hyperacetylated histones were 
generated. As hyperacetylated NETs displayed an increased capacity to activate macrophages, a 
putative pathogenic role for modified histones within SLE-derived NETs could be postulated. 
 
 
5.2.  Modified histones in ‘vital’ and ‘suicidal’ NETs 
 
Although NETosis was originally described as a ROS-dependent cell death pathway (‘suicidal’ 
NETosis) (29), an increasing body of evidence has indicated that there are also ROS- and cell death-
independent ways of NET formation (‘vital’ NETosis) (30). It is important to carefully distinguish 
between ‘vital’ and ‘suicidal’ NETosis, as they may have a different physiological function as well 
as a different pathological meaning. However, since the discrimination between ‘vital’ and 
‘suicidal’ NETs appears complex, the individual contribution of both forms of NETosis to disease 
conditions has not been investigated until now. Since histones are subjected to modifications at 
their N-terminal regions during ROS-dependent NETosis, the presence of modified histones as a 
marker to discriminate between ‘vital’ and ‘suicidal’ NETs was explored. Chapter 9 shows that 
neutrophil elastase, the most abundant protease within NETs, time-dependently cleaves the N-
terminal tails of core histones that are present within ‘suicidal’ NETs; a phenomenon that does 
not occur during ‘vital’ NETosis (31). In line with the findings from chapter 8, an increased 
reactivity of our panel of anti-histone antibodies with neutrophils that had been stimulated in vitro 
with NET-inducing agents for 2 hours could be observed; however, this reactivity was completetely 
lost at later timepoints as the result of the proteolytic activity of neutrophil elastase. Thus, 
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although modifications at the N-terminal histone tails occur during early-stage ‘suicidal’ NETosis, 
it appears that these modified tails ultimately do not end up in ‘suicidal’ NETs but instead are 
extracellularly released. It can be speculated that the cleavage and release of highly modified N-
terminal histone tails during ‘suicidal’ NETosis may elicit or enhance autoimmune responses 
against chromatin, as seen in SLE. Importantly, as both ‘vital’ and ‘suicidal’ NETs contained equal 
amounts of myeloperoxidase (MPO), the detection of MPO - histone complexes with enzyme-
linked immunosorbent assays (ELISAs) employing anti-MPO and anti-histone antibodies directed 
against the N-terminal histones tails appeared suitable for measuring ‘vital’ but not ‘suicidal’ NETs. 
Thus, it can be postulated that the use of antibodies recognizing N-terminal histone tails in MPO-
based ELISAs can help to discriminate between NETs that have been generated through ‘suicidal’ 
or ‘vital’ NETosis pathways, which will aid future investigations into the roles of these two distinct 
NETosis pathways in both health and disease. 
 
 
 
 
 
6.  Future perspectives 
 
In this thesis, fundamental aspects and pathological implications of NETosis particularly in the 
context of SLE and its renal manifestation lupus nephritis have been studied, and the findings are 
integrated in Figure 1.  
 
 
6.1.  A link between apoptosis and NETosis 
 
Apoptosis and NETosis are well known as important cell death modalities that can independently 
from each other provide autoantigens and break immunological tolerance in SLE. However, a 
possible pathogenic connection between these cell death modalities has never been set out. The 
work described in this thesis revealed an important feedforward mechanism between apoptosis 
and NETosis, since apoptotic cell-derived microparticles isolated from blood plasma of SLE 
patients were identified as potent triggers of NETosis. Together with the impaired degradation of 
NETs, as was observed in SLE patients with lupus nephritis, it can be proposed that an increased 
bulk of NETs ultimately deposit in the glomerular capillaries and thereby alter the integrity of the 
glomerular filtration barrier. Indeed, glomeruli of patients with lupus nephritis, but not those from 
healthy donors, were found to contain NETs. There are several mechanisms through which NETs 
could alter the glomerular filtration barrier, including the disruption of the glomerular endothelial 
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monolayer by NET-derived elastase and the subsequent induction of EndMT, as described in this 
thesis. Alternatively, the binding of autoantibodies, for instance anti-DNA antibodies, to antigens 
in glomerular deposited NETs could trigger complement-mediated kidney damage, but whether 
this indeed occurs in vivo remains to be established. The observed glomerular EndMT in response 
to NETs is interesting because this transition can potentially be targeted to reverse already 
established disease (32). Although this remains speculative for now, it will definitely be an exciting 
topic for future studies that attempt to find a remedy for this serious manifestation of SLE. 
 
 
 
 
 
 
 
Figure 1. Schematic overview integrating the main findings from this thesis. Apoptotic cell-derived 
microparticles (MPs; chapters 5 and 6), specific lipopolysaccharides (LPS; chapter 3) and needle-shaped 
monosodium urate (nsMSU) crystals (chapter 2) stimulate neutrophils to form NETs. In the process of 
(ROS-dependent) NETosis, histones become modified (chapter 8) and ultimately cleaved and released 
(chapter 9). In lupus nephritis, the impaired degradation of NETs (chapter 6) results in the renal 
deposition of NETs, which causes proteinuria and endothelial-to-mesenchymal transition (EndMT) as 
the result of glomerular endothelial alterations by NET-associated neutrophil elastase (NE; chapter 7). 
The black numbered circles represent the corresponding chapters of this thesis.  
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6.2.  Inhibition of NETosis 
 
Based on the observations described in this thesis and those described by others, it is now 
generally accepted that an imbalance between the release and degradation of NETs is a potential 
threat for the kidneys in SLE. Thus, in order to avoid or minimize kidney damage in SLE patients, 
therapeutic interventions should focus on restoring the balance between the formation and 
degradation of NETs. Obviously, this balance can be restored either by inhibiting NETosis or by 
improving the clearance of NETs. Interestingly, it has already been shown that inhibition of NETosis 
with Cl-amidine, an inhibitor of protein arginine deiminase 4 (PAD4), improves renal function and 
lowers mortality and morbidity in lupus mice (33). As NETosis is largely driven by ROS, ROS 
scavengers may also serve as therapeutical options to avoid uncontrolled NETosis in SLE. However, 
the efficacy of this approach can be questioned as the number of known SLE-relevant stimuli that 
can trigger NETosis independent from ROS is expanding; the (relative) contribution of ROS-
independent and ROS-dependent NETosis to the pathogenesis of SLE should therefore be an 
important subject of future investigation in order to identify the appropriate molecular targets for 
adequate NETosis inhibition. The assay described in chapter 9 could serve this purpose. 
Nevertheless, as apoptotis-modified chromatin within microparticles represents an important 
trigger of ROS-independent NETosis in SLE, the endonuclease DNase 1L3 may represent a 
promising candidate for the inhibition of NETosis in SLE. Null mutations and hypomorphic variants 
of DNase 1L3 are linked to familial and sporadic SLE, respectively, and DNase 1L3 levels inversely 
correlate with anti-dsDNA antibodies in SLE (34, 35). It was recently demonstrated that circulating 
DNase 1L3, produced by dendritic cells and macrophages, is uniquely capable of digesting 
chromatin in microparticles released from apoptotic cells (36). Therefore, in addition to decreasing 
the availability of autoantigens in apoptotic cell-derived microparticles, DNase 1L3 may also be 
capable of preventing NETosis in response to apoptotic cell-derived microparticles. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.3.  Restoring the capacity to degrade NETs 
 
As NETosis comprises an important line of defense against intruding microorganisms, the 
inhibition of NETosis may ultimately come at the cost of adequate antimicrobial defense. An 
alternative approach would therefore be to restore the capacity to degrade NETs, which would 
potentially leave antimicrobial defense unaffected. It is to date still not fully elucidated why NET 
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degradation is impaired in patients with lupus nephritis, but a growing body of evidence suggests 
that anti-NET autoantibodies (i.e. anti-histone and anti-DNA) prevent the accessability for 
endonucleases like DNase I to the NET (37). This could explain why the administration of DNase I 
to lupus mice fails to improve clinical outcomes (38). The fact that NET degradation is impaired by 
anti-NET antibodies implies that an impaired NET degradation only occurs after immunological 
tolerance toward nuclear antigens has already been broken. Thus, NETs may exacerbate or 
perpetuate existing pathology but are unlikely to be responsible for the development of SLE.  
 
 
 
 
 
 
 
 
 
6.4.  Reinforcing apoptotic cell clearance 
 
Disturbances in apoptosis and the clearance of apoptotic material are considered as the initial 
driving force for breaking immunological tolerance in SLE. As outlined in chapter 1, the impaired 
clearance of apoptotic cell remnants leads to the formation of apoptosis-modified antigens, such 
as acetylated or methylated histones, which may no longer be perceived as being ‘self’ but rather 
as ‘danger signals’ by T- and B-cells, thereby resulting in an autoimmune response. Enhancing the 
clearance of apoptotic cell remnants therefore seems the key in preventing the development of 
SLE. As intrinsic phagocyte defects appear to be the predominant cause for the impaired clearance 
of apoptotic cell remnants, this will presumably be difficult to restore (39, 40). However, several 
serum proteins also play an important role in the clearance of apoptotic cells. Adequate removal 
of apoptotic waste requires a clear recognition of apoptotic cells, which is, in addition to the 
exposure of phosphatidylserine on the outer leaflet of their plasma membrane, strongly 
dependent on opsonizing proteins such as immunoglobulin M (IgM), mannose-binding lectin 
(MBL), serum amyloid P (SAP), C-reactive protein (CRP), and C1q. Numerous studies ascribe an 
association between altered levels of these opsonins and defective clearance of apoptotic material 
in SLE. For instance, it has been shown that decreased IgM levels correlate with an increased 
disease activity in SLE (41) whereas C1q-deficient mice rapidly develop autoantibodies against 
nuclear autoantigens (42). In addition, administration of SAP (43) and/or CRP (44) significantly 
delays disease onset and alleviates symptoms of SLE in mice. Thus, the therapeutic administration 
of such opsonins may avoid autoimmunity against apoptosis-modified antigens and thus 
simultaneously restore the balance between the generation and degradation of NETs. Finally, an 
alternative exciting approach to prevent the development of autoantibodies against nuclear 
antigens would encompass neutralizing or tolerizing strategies using specific modified antigens. In 
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such an approach, the immune system could be repeatedly exposed to low doses of apoptosis- or 
NETosis-related (modified) antigens in order to induce epigenetic (re)programming in immune 
cells that will result in tolerance toward these antigens and thus prevent autoimmune responses. 
An example of this approach comes from the relatively new drug lupuzor, a phosphorylated 
peptide derived from the ribonucleoprotein U1-70K, which has already shown promising results 
in randomized clinical trials (45). 
 
6.5.  NETs as biomarker  
 
In addition to the aforementioned therapeutical opportunities, future research efforts should 
address the question whether circulatory NETs or NET-specific proteins could serve diagnostic 
purposes in SLE.  NETs can nowadays be reliably measured in biological fluids, but whether their 
detection in the blood or urine of SLE patients can actually act as a measure of disease activity or 
as a predictor of kidney involvement remains to be demonstrated. 
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1.  Introductie 
 
Systemische lupus erythematosus (SLE) is een auto-immuunziekte waarbij het lichaam een 
aanhoudende afweerreactie voert tegen lichaamseigen eiwitten (zie ook hoofdstuk 1). Bij SLE 
worden onderdelen van het chromatine (zoals DNA, histonen en nucleosomen) onterecht gezien 
als lichaamsvreemd, hetgeen resulteert in de productie van autoantistoffen tegen het chromatine. 
Na binding aan hun doeleiwit zorgen deze autoantistoffen voor lokale weefselschade, bijvoor-
beeld in de huid, het hart, de longen, de gewrichten of de nieren. Als de nieren betrokken raken 
bij het ziekteproces spreekt men van lupus nefritis, wat door een hoge morbiditeit en mortaliteit 
gezien wordt als een van de meest ernstige klinische manifestaties van SLE.  
 
 
 
 
 
Het is na jarenlang onderzoek nog steeds niet volledig opgehelderd waarom er bij SLE patiënten 
een auto-immuunreactie plaatsvindt tegen het chromatine. Omdat het chromatine zich in de 
celkernen van onze lichaamscellen bevindt en daarmee door een kern- en plasmamembraan is 
afgegrensd van cellen van het immuunsysteem, komt het chromatine normaliter niet in aanraking 
met het immuunsysteem. Hoe komt het dan dat er toch een afweerreactie optreedt tegen het 
chromatine bij SLE patiënten? Er is concensus dat een toegenomen frequentie van geprogram-
meerde celdood (apoptose) en een verminderde capaciteit tot opruiming van apoptotische cellen 
bijdragen aan de auto-immuunreactie die bij SLE plaatsvindt (1, 2).  
 
 
 
 
Een recent beschreven antimicrobiële strategie door neutrofielen, de meest voorkomende witte 
bloedcellen van het lichaam, biedt mogelijk een aanvullend antwoord op de vraag waarom er een 
afweerreactie optreedt tegen het chromatine bij SLE patiënten (3). Als reactie op ziektever-
wekkers kunnen neutrofielen namelijk een vorm van geprogrammeerde celdood ondergaan, 
waarbij hun chromatine in de vorm van een web naar buiten wordt ‘geschoten’ met als doel de 
ziekteverwekker te vangen en uiteindelijk ook te doden. Deze antimicrobiële strategie draagt de 
naam NETose en impliceert de formatie van zogenaamde Neutrophil Extracellular Traps (NETs).  
Ieder mens maakt NETs bij blootstelling aan ziekteverwekkers. NETose is een fysiologisch proces. 
NETs worden echter pas gevaarlijk als neutrofielen teveel NETs aanmaken, of als de afbraak van 
NETs door gespecialiseerde bloedeiwitten (endonucleases) niet adequaat verloopt. Een onbalans 
in de formatie en afbraak van NETs leidt er in dat geval toe dat NETs in aanraking komen met cellen 
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van het afweersysteem wat kan leiden tot een auto-immuunreactie. Een onbalans in de formatie 
en afbraak van NETs kan uiteindelijk ook resulteren in de depositie van NETs in de nieren tijdens 
het proces van bloedfiltratie, hetgeen de nierfilters kan beschadigen doordat NETs een uitgebreid 
arsenaal aan ‘toxische’ eiwitten bevatten. 
 
In dit proefschrift is de rol van NETose in de context van SLE en lupus nefritis bestudeerd. Omdat 
een beter begrip van de fysiologische context van NETose ook meer inzicht verschaft in de 
pathogene rol van NETs bij SLE, werden ook de factoren bestudeerd die de neutrofiel aanzetten 
tot het maken van NETs. In dit laatste hoofdstuk wordt een overzicht verschaft van de belang-
rijkste bevindingen van dit proefschrift en worden de implicaties ervan, zowel voor toekomstig 
onderzoek als voor de diagnostiek en behandeling van SLE, bediscussieerd.   
 
 
2.  Factoren die tot NETose aanzetten 
 
In het eerste deel van dit proefschrift werden de factoren die de neutrofiel aanzetten tot NETose 
onderzocht. Omdat neutrofielen decennia lang met name gezien werden als fagocyten (cellen die 
het letterlijk opeten van ziekteverwekkers als belangrijkste antimicrobiële strategie hanteren), 
ontstond er na de eerste beschrijving van NETose in de literatuur veel onduidelijkheid omtrent de 
onderlinge relatie tussen fagocytose en NETose. Met andere woorden, welke factoren zorgen 
ervoor dat een neutrofiel een ziekteverwekker opeet of elimineert middels NETose? Deze vraag 
stond centraal in de hoofdstukken 2 en 3, waarin NETose werd bestudeerd in de context van 
hyperurikemie en infectie met Gram-negatieve bacteriën.  
 
2.1. Grootte doet er toe! 
 
Verschillende ziekteprocessen, waaronder SLE, kunnen leiden tot verhoogde concentraties aan 
urinezuur in het bloed (hyperurikemie). Als de concentratie van het urinezuur sterk verhoogd is, 
kan het urinezuur veelal niet meer oplosbaar gehouden worden. In een dergelijk geval zullen er 
uraatkristallen gevormd worden. Hoofdstuk 2 laat zien dat het kristallisatieproces van urinezuur 
begint met het ontstaan van kleine microaggregaten (UMA) die na verloop van tijd uitgroeien tot 
de karakteristieke naaldvormige uraatkristallen (nsMSU) die onder andere in de gewrichten van 
jichtpatiënten gevonden worden. Door neutrofielen bloot te stellen aan UMA of nsMSU, werd 
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gevonden dat neutrofielen in staat zijn hun ‘vechtstrategie’ aan te passen aan de grootte van het 
urinezuurkristal. Daar waar UMA klein genoeg waren om verwijderd te worden middels fago-
cytose, zorgden de grote nsMSU ervoor dat de neutrofiel aangezet werd tot NETose. NETose lijkt 
hiermee dus een antimicrobiële strategie te zijn die pas gehanteerd wordt als de ziekteverwekker 
te groot is om opgegeten te worden (4). 
 
2.2. Herkenning van specifieke lipopolysacchariden 
 
Lipopolysacchariden (LPS) zijn moleculen die voorkomen in de buitenmembranen van Gram-
negatieve bacteriën en die een sterke immuunrespons bij mensen veroorzaken. Het repertoire 
aan Gram-negatieve bacteriën is enorm en al deze bacteriën beschikken over unieke LPS 
structuren. In hoofdstuk 3 werden neutrofielen blootgesteld aan verschillende LPS structuren, 
waarbij bleek dat neutrofielen in staat zijn om selectief NETs te maken als reactie op specifieke 
LPS structuren. Met name de LPS van Pseudomonas aeruginosa bleek in staat de neutrofiel aan te 
zetten tot NETose (5). Aangezien Pseudomonas aeruginosa berucht is voor zijn vermogen om 
fagocytose te omzeilen (6), suggereren deze bevindingen dat NETose plaatsvindt wanneer de 
ziekteverwekker het vermogen heeft ontwikkeld om zijn ondergang middels fagocytose te 
voorkomen. Verschillende andere Gram-negatieve bacteriën die bekend zijn om hun capaciteiten 
fagocytose te vermijden, zoals Streptococcus pneumoniae (7), Haemophilus influenzae (8) en 
Klebsiella pneumoniae (9), zijn tevens krachtige stimuli gebleken voor NETose.  
 
2.3. NETose als strategie wanneer fagocytose faalt 
 
Op basis van de bevindingen uit hoofdstuk 2 en 3 kan geconcludeerd worden dat fagocytose en 
NETose complementaire rollen vervullen. Als fagocytose niet mogelijk is, bijvoorbeeld omdat een 
ziekteverwekker te groot is of als deze in staat is gebleken fagocytose te omzeilen, kan de neutro-
fiel overgaan tot NETose en hetzelfde geldt mogelijk ook vice versa. Door de relatie tussen fago-
cytose en NETose beter te begrijpen, kan het optreden van NETose in een pathologische context 
zoals die van SLE uiteindelijk ook beter worden begrepen.  
 
3.  NETose in reactie op celdood: implicaties voor SLE 
 
Een toenemend aantal publicaties doet vermoeden dat NETose meer is dan enkel een antimicro- 
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biële strategie. Naast microbiële producten zijn er namelijk verschillende stimuli, zoals cytokines 
(10), high-mobility group box 1 (HMGB1) (11), een alkalische pH (12), geactiveerde endotheel-
cellen (13) en autoantistoffen (14), die de neutrofiel kunnen aanzetten tot NETose. Eén van de 
gepostuleerde functies van NETs is dat ze als een barrière kunnen fungeren tijdens weefselschade, 
waarbij (componenten van) de dode cellen die tijdens weefselschade ontstaan de neutrofiel 
stimuleren NETs te maken. Deze NETs schermen vervolgens het ontstoken weefsel af van het 
gezonde weefsel en voorkomen daarmee dat pro-inflammatoire componenten van het ontstoken 
gebied zich kunnen gaan verspreiden (12, 15, 16).  
 
 
 
 
 
 
3.1.  Apoptotische microparticles zetten aan tot NETose 
 
 
 
Zoals reeds uiteengezet, worden verstoringen in apoptose en NETose beide in verband gebracht 
met de pathogenese van SLE. Hoofdstuk 4 biedt een overzicht van de rol van apoptose en NETose 
in de pathogenese van SLE, waarbij er in het bijzonder wordt ingegaan op histonmodificaties die 
optreden tijdens celdood en die geassocieerd worden met het ontstaan van auto-immuniteit.  
 
 
 
 
 
Hoewel NETose en apoptose twee entiteiten zijn die onafhankelijk van elkaar de pathogenese van 
SLE zouden kunnen verklaren, werd een mogelijke connectie tussen beide modaliteiten van cel-
dood onderzocht in hoofdstuk 5. Voortkomend vanuit de vermeende barrièrefunctie van NETs 
tijdens weefselschade werd de hypothese, dat apoptotische microparticles bij SLE patiënten in 
staat zijn om NETose te induceren, onderzocht. In het bloed van SLE patiënten werden 
microparticles geïdentificeerd die apoptose-gemodificeerd chromatine bevatten en die afkomstig 
bleken te zijn van endotheelcellen gezien de aan- en afwezigheid van respectievelijk CD31 en CD45 
op deze microparticles. De aanwezigheid van deze microparticles is naar alle waarschijnlijkheid 
een uiting van het verstoorde opruimingsproces van apoptotische cellen bij SLE. Vergelijkbare 
microparticles konden niet worden geidentificeerd in het bloed van gezonde proefpersonen en 
ook niet in het bloed van patiënten met reumatoïde arthritis of sclerodermie. Microparticles van 
SLE patiënten bleken in functionele experimenten in staat te zijn om dendritische cellen te 
activeren en ook neutrofielen aan te zetten tot het maken van NETs (17). Met andere woorden, 
de verminderde opruiming van apoptotische cellen bij SLE resulteert in een toegenomen formatie 
van NETs, wat het auto-immuunproces mogelijk in stand houdt danwel doet toenemen. 
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3.2. Geacetyleerde histonen als stimuli voor NETose 
 
In hoofdstuk 6 wordt antwoord gegeven op de vraag waarom apoptotische microparticles de 
neutrofiel aanzetten tot NETose, waarbij er ook is gekeken of er een associatie bestaat tussen dit 
fenomeen en het ontstaan van lupus nefritis bij SLE. Voor dit doel werden apoptotische micro-
particles in het bloed van SLE patiënten met en zonder (actieve tekenen van) lupus nefritis 
gekarakteriseerd. Hoewel het totale aantal microparticles in beide groepen gelijk was, bleken de 
microparticles bij patiënten met actieve lupus nefritis groter te zijn en meer apoptose-
gemodificeerd chromatine te bevatten. In het bijzonder waren geacetyleerde histonen rijkelijk 
aanwezig in microparticles afkomstig van patiënten met actieve lupus nefritis. In functionele 
experimenten werd aangetoond dat de capaciteit van microparticles om NETose te induceren 
afhankelijk is van de hoeveelheid  geacetyleerde histonen in de microparticles (18). De inductie 
van NETose door microparticles lijkt daarmee dus met name een rol te spelen bij SLE patiënten 
van wie de nieren betrokken zijn in het ziekteproces.  
 
Omdat de afbraak van NETs medebepalend is of aangemaakte NETs daadwerkelijk schade 
veroorzaken, werd ook de capaciteit van het NET-afbrekende enzym DNase I bij SLE patiënten met 
en zonder (actieve) lupus nefritis bepaald. Het bleek dat patiënten met lupus nefritis over een 
verminderd vermogen beschikken NETs af te breken in vergelijking met patiënten zonder lupus 
nefritis of gezonde proefpersonen. Al met al is er bij lupus nefritis dus sprake van een verstoorde 
balans tussen de aanmaak en afbraak van NETs, wat kan leiden tot nierschade zodra de NETs 
vastlopen in de nierfilters (glomeruli) tijdens het proces van bloedfiltratie. 
 
 
4.  NETose in de context van lupus nefritis 
 
Zoals hierboven beschreven kan de onbalans tussen de aanmaak en afbraak van NETs leiden tot 
de depositie van NETs in de glomeruli. Maar wat zijn hier de gevolgen van? In hoofdstuk 7 wordt 
deze vraag beantwoord. Door de interactie tussen NETs en het glomerulaire endotheel te 
bestuderen werd aangetoond dat elastase, een eiwit dat rijkelijk aanwezig is in NETs, niet alleen 
schadelijk is voor ziekteverwekkers maar ook voor het endotheel van de glomeruli (19). Elastase 
verstoort de barrièrefunctie van het endotheel en draagt daarmee mogelijk bij aan het 
ontwikkelen van proteinurie, waarbij belangrijke bloedeiwitten via de urine verloren raken. Ook 
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leidt de blootstelling van het endotheel aan elastase tot een transformatie van het endotheel in 
cellen die bindweefselgroei bevorderen, een proces dat doorgaans wordt aangeduid met de term 
endothelial-to-mesenchymal transition (EndMT) (20, 21). Ondanks het feit dat EndMT een 
belangrijk fenomeen is tijdens de aanmaak en het herstel van bloedvaten, wordt het ook 
geassocieerd met pathologische processen zoals fibrose (22). Verschillende (recente) publicaties 
tonen aan dat EndMT en ook het vergelijkbare proces van epithelial-to-mesenchymal transition 
(EMT) een belangrijke rol vervullen tijdens het ontstaan van nierfibrose (23). De renale depositie 
van NETs bij SLE lijkt daarmee dus geassocieerd te zijn met het ontwikkelen van nierfibrose, 
hetgeen doorgaans gezien wordt als een eindstadium van nierschade. Gebaseerd op de bevin-
dingen uit dit hoofdstuk biedt de remming van elastase dus mogelijk een interessant thera-
peutisch aanknopingspunt voor patiënten met lupus nefritis.  
 
5.  Histonmodificaties tijdens NETose 
 
Tijdens apoptose wordt het chromatine (met name histonen) van de cel gemodificeerd om de 
processen die leiden tot de uiteindelijke celdood te faciliteren. Doordat er bij SLE patiënten een 
stoornis is in de opruiming van apoptotisch materiaal kan het gemodificeerde chromatine door 
het immuunsysteem als lichaamsvreemd gezien gaan worden. Er zijn reeds meerdere posttrans-
lationale histonmodificaties geidentificeerd die zich voordoen tijdens apoptose en die specifiek 
herkend worden door anti-histon antilichamen die aanwezig zijn bij SLE (24-27). In de hoofd-
stukken 8 en 9 werd een panel van anti-histon antilichamen gebruikt om histonmodificaties te 
identificeren die optreden tijdens NETose. 
 
5.1. NETs als een bron van gemodificeerde histonen 
 
Uit hoofdstuk 8 blijkt dat histonen onderhevig zijn aan acetylering en methylering tijdens het 
proces van NETose (28). De hoeveelheid histonmodificaties tijdens NETose werd hierbij 
vergeleken tussen neutrofielen van SLE patiënten en die van gezonde proefpersonen. Hieruit 
bleek dat de histonen van SLE neutrofielen tijdens NETose meer onderhevig zijn aan modificaties 
dan de histonen van ‘gezonde’ neutrofielen. Door NETose te induceren in de aanwezigheid van 
een histon-deacetylaseremmer kon worden aangetoond dat geacetyleerde histonen in NETs bij-
dragen aan het activeren van immuuncellen, zoals macrofagen. Hiermee is een pathogene rol voor 
geacetyleerde histonen in NETs van SLE patiënten aannemelijk gemaakt. 
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5.2. Gemodificeerde histonen in ‘suicidal’ en ‘vital’ NETs 
 
De oorspronkelijke gedachte dat er één vorm van NETose zou zijn gaat niet meer op. Er wordt 
tegenwoordig onderscheid gemaakt tussen ‘vital’ en ‘suicidal’ NETose, waarbij het proces van 
‘vital’ NETose onafhankelijk van de generatie van vrije zuurstofradicalen (ROS) verloopt terwijl 
‘suicidal’ NETose wel degelijk afhankelijk is van ROS (29, 30). De fysiologische en pathologische 
implicaties van beide vormen van NETose zijn vooralsnog echter onduidelijk, waardoor een ‘tool’ 
om onderscheid te maken tussen beide vormen van NETose dus van belang kan zijn voor 
toekomstige onderzoeken. Voortkomend uit de bevindingen van hoofdstuk 8 dat histonen 
gemodificeerd worden tijdens ‘suicidal’ NETose, werd in hoofdstuk 9 onderzocht of de aan-
wezigheid van gemodificeerde histonen in NETs kan fungeren als een marker om onderscheid te 
maken tussen ‘vital’ en ‘suicidal’ NETs. Het blijkt dat histonmodificaties zowel optreden tijdens 
‘vital’ als ‘suicidal’ NETose, maar dat deze histonmodificaties na verloop van tijd niet meer 
aanwezig zijn in ‘suicidal’ NETs (31). Onder invloed van ROS zorgt het enzym elastase er namelijk 
voor dat de N-terminale (gemodificeerde) staarten van histonen gedegradeerd worden in 
‘suicidal’ NETs, een fenomeen dat niet optreedt tijdens de ROS-onafhankelijke ‘vital’ NETose. Door 
gebruik te maken van anti-histon antilichamen gericht tegen de N-terminale staarten van 
histonen, werd een assay ontwikkeld waarmee onderscheid gemaakt kan worden tussen ‘vital’ en 
‘suicidal’ NETs. Deze ‘tool’ kan derhalve toegepast worden in toekomstige onderzoeken naar de 
fysiologische en pathologische rol van beide vormen van NETose. 
 
 
 
 
6.  Toekomstperspectieven 
 
In dit proefschrift werden fundamentele aspecten en pathologische implicaties van NETose be-
studeerd in de context van SLE en in het bijzonder lupus nefritis. De belangrijkste bevindingen die 
dit heeft opgeleverd zijn op een integrale manier weergegeven in Figuur 1. 
 
 
 
 
 
 
6.1. Een link tussen apoptose en NETose 
 
Hoewel NETose en apoptose twee entiteiten zijn die onafhankelijk van elkaar in de pathogenese 
van SLE betrokken kunnen zijn, heeft dit proefschrift een connectie tussen beide modaliteiten van 
celdood aangetoond. Het blijkt dat apoptotische microparticles belangrijke stimuli zijn voor 
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NETose in patiënten met lupus nefritis. Samen met de verminderde capaciteit om NETs af te 
breken lijkt daarmee in patiënten met lupus nefritis dus een onbalans te bestaan tussen de 
aanmaak en afbraak van NETs, waarbij NETs uiteindelijk in de glomeruli kunnen vastlopen tijdens 
bloedfiltratie en aldaar de integriteit van het nierfilter kunnen bedreigen. Er zijn verschillende ma- 
 
 
 
 
 
 
 
 
 
 
Figuur 1. Schematisch overzicht met de belangrijkste bevindingen van dit proefschrift. Apoptotische 
microparticles (MPs; hoofdstuk 5 en 6), specifieke lipopolysacchariden (LPS; hoofdstuk 3) en naald-
vormige uraatkristallen (nsMSU; hoofdstuk 2) stimuleren neutrofielen tot NETose, hetgeen leidt tot (het 
vrijkomen van) histonmodificaties (hoofdstuk 8 en 9). In lupus nefritis zorgt de verminderde afbraak van 
NETs (hoofdstuk 6) ervoor dat het glomerulaire endotheel wordt blootgesteld aan NETs, wat door de 
aanwezigheid van elastase (NE) in NETs leidt tot het ontwikkelen van proteinurie en endothelial-to-
mesenchymal transition (EndMT; hoofdstuk 7). De genummerde zwarte cirkels vertegenwoordigen de 
corresponderende hoofdstukken in dit proefschrift.  
 
 
 
 
 
 
 
nieren mogelijk waarop NETs het nierfilter zouden kunnen beschadigen, waaronder het elastase-
afhankelijke mechanisme zoals beschreven staat in hoofdstuk 7. De binding van autoantistoffen 
aan NETs en de daaruitvolgende activering van het complementsysteem kan ook een mechanisme 
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zijn waarmee NETs schade aan de nieren veroorzaken, maar of dit in vivo ook daadwerkelijk 
gebeurt is vooralsnog niet aangetoond. De observatie dat NETs leiden tot EndMT van het 
glomerulaire endotheel is interessant omdat er gesuggereerd is dat een dergelijke transformatie 
(en dus ook reeds aanwezige nierschade) teruggedraaid kan worden (32). Hoewel dit voorlopig 
nog speculatief blijft, zal het zeker een spannend onderwerp zijn voor toekomstige studies die 
proberen een oplossing te vinden voor deze verwoestende manifestatie van SLE.  
 
6.2. Remming van NETose 
 
Mede door de onderzoeken beschreven in dit proefschrift is een pathogene rol voor NETose in de 
context van SLE en in het bijzonder lupus nefritis zeer aannemelijk. Om nierschade bij SLE te 
voorkomen of te verminderden, dienen therapeutische interventies zich derhalve te richten op 
het herstellen van het evenwicht tussen de vorming en de afbraak van NETs. Dit evenwicht kan 
hersteld worden door enerzijds NETose te remmen en anderzijds de afbraak van NETs te 
bevorderen. Het is reeds aangetoond dat remming van NETose met Cl-amidine, een remmer van 
protein arginine deiminase 4 (PAD4), de mortaliteit en morbiditeit in lupus muizen verlaagt (33).  
Aangezien NETose grotendeels afhankelijk is van ROS, kunnen ROS scavengers ook mogelijk 
fungeren als therapie om NETose te remmen. De effectiviteit van dergelijke ROS scavengers kan 
echter betwist worden, aangezien het repertoire aan SLE-relevante stimuli waarvan is aangetoond 
dat ze kunnen aanzetten tot ROS-onafhankelijke NETose blijft toenemen. De (relatieve) bijdrage 
van ROS-onafhankelijke en ROS-afhankelijke NETose aan de pathogenese van SLE zou daarom een 
belangrijk onderwerp moeten zijn van toekomstig onderzoek, waarmee de juiste moleculaire 
doelwitten kunnen worden geidentificeerd voor de optimale remming van NETose in SLE. De assay 
die is ontwikkeld in hoofdstuk 9 zou dit doel kunnen dienen. Gebaseerd op de bevinding dat 
apoptose-gemodificeerd chromatine uit apoptotische microparticles een belangrijke trigger is 
voor ROS-onafhankelijke NETose (hoofdstukken 5 en 6), zou de endonuclease DNase 1L3 een 
veelbelovende therapeutische kandidaat kunnen zijn voor de remming van NETose bij SLE. 
Nulmutaties en hypomorfe varianten van DNase 1L3 zijn geassocieerd met respectievelijk 
familiaire en sporadische SLE en DNase 1L3 concentraties zijn negatief gecorreleerd met de titers 
van anti-dsDNA antilichamen bij SLE (34, 35). Recent werd aangetoond dat circulerend DNase 1L3, 
dat geproduceerd wordt door dendritische cellen en macrofagen, uniek is in zijn capaciteiten om 
chromatine uit apoptotische microparticles te degraderen (36). Naast het feit dat DNase 1L3 de 
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hoeveelheid autoantigenen in apoptotische microparticles vermindert, lijkt DNase 1L3 dus ook in 
staat om NETose als reactie op chromatine in apoptotische microparticles te voorkomen. 
 
6.3. Het herstellen van de afbraak van NETs 
 
Aangezien NETose een belangrijke verdedigingslinie tegen indringende micro-organismen 
vertegenwoordigt, kan de remming van NETose uiteindelijk ten koste gaan van adequate 
antimicrobiële verdediging. Het herstellen van de capaciteit om NETs af te breken lijkt derhalve 
een betere aanpak om de balans tussen de aanmaak en afbraak van NETs bij SLE te herstellen. Het 
is tot op heden nog niet volledig opgehelderd waarom de afbraak van NETs bij patiënten met lupus 
nefritis is verstoord. Een recente publicatie suggereert echter dat autoantistoffen gericht tegen 
onderdelen van NETs de toegankelijkheid van NETs voor endonucleases, zoals DNase I, vermin-
deren (37). Dit kan verklaren waarom de toediening van DNase I aan lupus muizen niet tot 
klinische verbetering leidde (38). Het gegeven dat de verminderde afbraak van NETs lijkt voort te 
komen uit de aanwezigheid van autoantistoffen impliceert dat NETs niet de initiele trigger zijn 
voor het ontwikkelen van een auto-immuunreactie tegen het chromatine. Dit neemt niet weg dat 
NETs pre-existente (auto-immuun) pathologie kunnen versterken.  
 
6.4. Het verbeteren van de opruiming van apoptotische cellen 
 
Verstoringen in apoptose worden nog altijd gezien als de initiele trigger voor het ontwikkelen van 
auto-immuniteit bij SLE. De verminderde opruiming van apoptotisch materiaal leidt tot het 
vrijkomen van gemodificeerde antigenen, zoals geacetyleerde/gemethyleerde histonen, die door 
dendritische cellen als ‘danger signals’ gezien worden en de bron vormen van lichaamsvreemde 
antigenen. Het verbeteren van het opruimingsproces van apoptotische cellen zou daardoor 
mogelijk de ontwikkeling van SLE kunnen voorkomen. Decennia lang is onderzoek gedaan naar de 
verstoorde opruiming van apoptotische cellen bij SLE maar het is vooralsnog onmogelijk gebleken 
dit proces te verbeteren. De verstoorde opruiming van apoptotische cellen berust namelijk gro-
tendeels op intrinsieke defecten van fagocyten, hetgeen moeilijk te corrigeren valt (39, 40).  
 
 
 
 
 
 
 
 
 
 
 
 
Verschillende serumeiwitten spelen echter ook een belangrijke rol bij de opruiming van apopto-
tische cellen. Naast de expressie van fosfatidylserine op de plasmamembraan van de apoptotische 
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cel, is de opruiming van apoptotisch cellen sterk afhankelijk van opsoniserende eiwitten zoals 
immunoglobuline M (IgM), mannose-bindend lectine (MBL), serum amyloïd P (SAP), C-reactive 
protein (CRP) en C1q. Verschillende studies hebben een associatie gerapporteerd tussen 
veranderde niveaus van deze opsoninen en de verminderde opruiming van apoptotisch materiaal 
bij SLE. Zo is bijvoorbeeld aangetoond dat verlaagde IgM niveaus correleren met een verhoogde 
ziekteactiviteit van SLE (41), en dat C1q-deficiënte muizen spontaan autoantistoffen tegen 
nucleaire autoantigenen ontwikkelen (42). Daarnaast vertraagt de toediening van SAP (43) en/of 
CRP (44) het ontstaan van SLE en vermindert het de symptomatologie bij lupus muizen. De 
therapeutische toediening van bovengenoemde opsoninen zou dus mogelijk de autoimmuun-
reactie tegen apoptotisch materiaal kunnen verminderen of voorkomen. Tegelijkertijd zou hier-
mee ook de afbraak van NETs verbeterd kunnen worden. 
 
 
 
Ongeacht de afbraak van NETs of de opruiming van apoptotische cellen, zou het een alternatieve 
strategie kunnen zijn om het immuunsysteem ‘tolerant’ te maken tegen de gemodificeerde 
eiwitten van apoptotische cellen of NETs. Dergelijke strategieën zouden kunnen bestaan uit het 
herhaaldelijk blootstellen van het afweersysteem aan lage doses gemodificeerde eiwitten om zo 
uiteindelijk tolerantie tegen deze modificaties te ontwikkelen. Een lichtend voorbeeld is het 
medicament lupuzor, een gefosforyleerd peptide afkomstig van het ribonucleoprotein U1-70K, 
wat reeds zeer positieve resultaten heeft laten zien in gerandomiseerde klinische studies (45).   
 
 
 
6.5.  NETs als biomarker 
 
Naast bovengenoemde therapeutische mogelijkheden, zouden circulerende NETs of fragmenten 
daarvan mogelijk ook gebruikt kunnen worden in de diagnostiek van SLE. Tegenwoordig kunnen 
NETs in biologische vloeistoffen betrouwbaar gemeten worden, maar of de detectie van NETs in 
het bloed of de urine van SLE patiënten daadwerkelijk kan fungeren als een maat voor ziekte-
activiteit of als een voorspeller van nierbetrokkenheid blijft vooralsnog een open vraag. 
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Dat was het dan. Mijn promotie zit erop en het boek is af. Rest mij iedereen te bedanken die op 
welke wijze dan ook heeft bijgedragen aan de totstandkoming van het werk beschreven in dit 
proefschrift. Zonder de steun en hulp van supervisoren, collega’s, vrienden en familie was het niet 
gelukt dit voor elkaar te krijgen.  
 
 
 
 
 
Beste Johan, als mijn co-promotor ben jij de persoon geweest die het meest betrokken was bij 
mijn promotie. Ik heb veel van je geleerd, niet alleen als onderzoeker maar ook als mens. Het was 
onwijs plezierig om met je samen te werken. Het enthousiasme en de bezieling waarmee je mij 
hebt begeleid voelde erg prettig. Jij creëerde voor mij het ideale leerklimaat toen ik als ‘onervaren’ 
geneeskunde student op het lab kwam, waardoor ik met veel plezier en enthousiasme het funda-
mentele onderzoek ‘leerde kennen’. Na afronding van mijn Honours stage stak jij je handen voor 
me in het vuur en opperde jij het idee om het reeds begonnen onderzoek voort te zetten als een 
promotietraject, wat we uiteindelijk hebben kunnen afronden in een relatief kort tijdsbestek. Je 
hebt me veel vrijheid gegeven binnen het project. Je wist me te motiveren en stuurde bij op die 
momenten dat het nodig was. Voortkomend uit mijn eigen enthousiasme had ik de neiging veel 
‘zijpaden’ te bewandelen waarbij ik het originele onderzoeksplan en -doel wel eens uit het oog 
kon verliezen. Dankzij jouw begeleiding bleef ik echter op het juiste pad en ik hoop dan ook dat 
we in de toekomst nog vele ‘onderzoekspaden’ samen mogen bewandelen.  
 
 
 
Beste Luuk, mede dankzij jouw inspirerende colleges over het immuunsysteem ontstond al vroeg 
tijdens mijn studie de interesse voor de immunologie. Toen de kans zich voordeed om een stage 
te doen over een immunologisch onderwerp was de keuze dan ook snel gemaakt. Ik dank je voor 
de plezierige samenwerking en de kansen die je mij hebt geboden gedurende dit traject. Omdat 
deze promotie op een ongebruikelijke manier tot stand is gekomen, was er in beginsel geen 
subsidiegeld beschikbaar voor dit project. Dankzij de inzet van jou en alle andere stafleden kwam 
er echter ondersteuning vanuit de afdeling om dit traject mogelijk te maken, waarvoor dank! 
 
 
Geachte leden van de manuscriptcommissie, ik wil jullie bedanken voor het beoordelen van mijn 
proefschrift en jullie bereidheid om zitting te nemen in de promotiecommissie. 
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Beste (oud-)collega’s van het lab, dank voor de gezelligheid, hulp en samenwerking gedurende 
mijn promotie. Uit angst iemand te vergeten weet ik niet of ik er verstandig aan doe om iedereen 
bij naam te noemen, maar ik wil bij deze toch een poging wagen. Beste Jürgen, Wim, Wilco, 
Ramon, Mathijs, Markus, Dirk, Mark, Nils, Niels, Jasper, Marjolein, Nuria, Shagun, Marinka, 
Margreet en Angelique, nogmaals dank voor de gezelligheid, hulp en samenwerking gedurende 
mijn promotie! Het was ongetwijfeld niet makkelijk voor jullie om mij als collega te hebben. Onder 
het mom van ‘pipetteren is ook maar pipetteren’ moesten jullie veel flauwe grappen en slechte 
songteksten aanhoren, waarvoor ik me bij deze wil verontschuldigen. Tevens bied ik mijn excuses 
aan voor alle pipetten en pipetdoosjes die ‘spontaan’ van jullie benches verdwenen bleken te zijn, 
en voor de troep die ik regelmatig liet slingeren. Maar hé, gezellig was het wel toch?  
 
 
 
 
 
 
Beste Jürgen, ik wil jou in het bijzonder bedanken. Je was mijn directe begeleider tijdens mijn 
Honours stage, wat een hele klus voor je geweest moet zijn. Je leerde me in een rap tempo de 
nodige onderzoekstechnieken, waarvoor dank. Maar hé, dat western blotten doe ik nooit meer.  
 
 
 
 
 
Veel dank gaat ook uit naar al mijn co-auteurs, in het bijzonder dr. J Hofstra en prof. J. Berden. 
Julia en Jo, dank voor de prettige samenwerking en in het bijzonder voor het aanleveren van 
onderzoeksmateriaal uit de kliniek, hetgeen veel nieuwe (onderzoeks)inzichten heeft opgeleverd 
en een onmisbare bijdrage heeft geleverd aan de manuscripten beschreven in dit proefschrift. 
Nils, dank voor de bijdrages die je hebt geleverd aan de manuscripten uit dit boek. Het was 
plezierig om met je samen te werken aan het SLE project, en ik wens je veel succes met de 
voortzetting van je eigen promotietraject. Ook wil ik Jelle en Cansu bedanken voor het 
enthousiasme en de inzet tijdens jullie stages op het SLE project. Ik wens jullie een goede 
(wetenschappelijke) toekomst toe, en hopelijk dragen jullie (toekomstige) co-auteursschappen 
daar een steentje aan bij. 
 
 
 
 
 
 
I would also like to thank all my friends and colleagues from Erlangen who made my six months in 
Erlangen definitely a period to remember. Mona, Baschti, Christian, Dana, Christine, Ricardo, 
Markus, Luis, Ivica and Yi, thanks for your collegiality, help and glee both in- and outside the lab. 
The memories of ‘Berch’ and the frequent visits to ‘KW’ truly put a big smile on my face.  Prof. M. 
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Herrmann, dear Martin, and of course your amazing secretary Irmgard, thank you for the 
hospitality and all the energy and effort you put into hosting me. Erlangen, until we meet again! 
 
 
Ik wil al mijn goede vrienden en vriendinnen ook heel erg bedanken voor alle steun en afleiding. 
Door de drukte van de co-schappen en het onderzoek had ik niet altijd de tijd en energie meer om 
flinke nachten door te halen, maar na afronding van dit proefschrift vind ik wel dat het weer eens 
tijd wordt voor een ouderwetse ‘Tequila’ avond?! Bas, ik wil jou in deze paragraaf nog even in het 
bijzonder noemen. Sinds ‘groepje 10’ zijn we gedurende onze studietijd altijd goede vrienden 
geweest, hetgeen herinneringen heeft opgeleverd die ik de rest van mijn leven niet zal vergeten. 
Ik hoop dan ook van harte dat onze vriendschap na afronding van onze studies nog heel veel 
nieuwe herinneringen zal opleveren. 
 
Pap en mam, jullie hebben me door dik en dun gesteund in alles wat ik heb gedaan. Ik wil jullie 
danken voor al het vertrouwen dat jullie mij in voor- en tegenspoed hebben gegeven. Ik kon altijd 
rekenen op jullie interesse, ook al was het niet altijd even duidelijk waar ik me nou precies mee 
bezig hield. Jullie hebben mij altijd gestimuleerd eruit te halen wat erin zit en zonder jullie had ik 
absoluut nooit gestaan waar ik nu sta. Enorm bedankt voor alles.  
 
Jesse en Stef, ik heb veel bewondering voor jullie beide en ik hoop dat jullie (mede door afronding 
van dit proefschrift) ook een beetje trots zijn op jullie kleine broertje. Dank voor al jullie steun en 
interesse in alles wat ik de afgelopen jaren ‘uitspookte’ hier in Nijmegen. En Jesse, ik hoop dat het 
jou als filmliefhebber deugd doet dat dit proefschrift toch wel evident voorzien is van een ‘spider-
man’ thema. Ik hoop dan ook dat ik, bij een aankomend weekendje Enschede, dit proefschrift kan 
terugvinden in de blu-ray kast tussen de overige Marvel collectie. 
 
 
 
Tot slot, Susan, bedankt voor je onvoorwaardelijke steun en liefde de afgelopen tijd. Dat ik jou als 
vriendin heb overgehouden aan mijn tijd in Erlangen is zonder enige twijfel het beste ‘resultaat’ 
van mijn onderzoeksperiode aldaar. Ik ben dan ook onwijs blij dat je mee bent gekomen naar 
Nederland, waar je inmiddels goed je draai hebt gevonden en hard aan je eigen (academische) 
onderzoekscarriere werkt. Ik ben er van overtuigd dat we samen een geweldige toekomst tege-
moet gaan. Rakastan sinua kultaseni. 
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